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Infectious disease is an important issue for animal breeders, farmers and 
governments. Solutions to control infectious disease are needed and research focused 
on the genetic loci determining variation in immune-related traits has the potential to 
deliver solutions. The primary aim of this thesis is to discover regions of the bovine 
genome which influence the immune response post immunisation. To accomplish 
this two types of immunising agents, a Foot-and-Mouth Disease Virus (FMDV) 
peptide (FMDV15) and a commercial vaccine for Bovine Respiratory Syncytial 
Virus (BRSV), were used to immunise the second generation (F2 and backcrosses) of 
the Roslin Bovine Genome (RoBoGen) herd, a Charolais Holstein cross population. 
The FMDV15 peptide consisted of two sections of the VP1 protein located on the 
FMDV capsid, together encompassing the major neutralising antibody sites that are 
known to be immunogenic. Protection against FMDV is generally believed to relate 
to the levels of neutralising antibody and has been correlated with IgG1 and IgG2 
levels as well as interferon-. In addition it has been shown that T cell responses also 
play a role in protection against FMDV. Thus all of these were used as phenotypic 
measurements post immunisation to the FMDV15 peptide. The BRSV vaccine used 
was an attenuated live vaccine. Protective mechanisms against BRSV infection 
include IgA, IgG1, IgG2 and IgM BRSV-specific antibodies and antibody titres 
particularly those of the IgG isotypes are considered to be correlates of protection. 
Thus, IgG1 and IgG2 antibody levels were measured post vaccination with the 
BRSV vaccine. All phenotypes were measured across time, and allowed analysis of 
the primary and secondary adaptive immune responses. 
 
Both agents caused considerable variation in the phenotypes measured post 
immunisation, with significant responses detected two weeks post immunisation. 
REstricted Maximum Likelihood (REML) analysis attributed much of this variation 
to sire, highlighting the heritable component, and environmental effects. Significant 
positive correlations were detected across time within each trait for both the FMDV 
and BRSV responses. The FMDV and BRSV antibody levels also correlated with 
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each other at later time points, suggesting that there may be animals which are 
genetically predisposed to be high or low responders in general. Initially a linkage 
mappingapproach was followed using 165 microsatellite markers, which detected 77 
QTL in response to the FMDV peptide and 27 QTL in response to the BRSV 
vaccine. There were some overlapping QTL, for example QTL which spanned the 
Major Histocompatibility Complex. Further analysis was conducted by developing a 
Perl scripted program which genotyped the RoBoGen herd in two ways; 1) Single 
Nucleotide Polymorphism(s) (SNP) were genotyped within the confidence intervals 
of the previously discovered QTL and 2) SNP were genotyped via a candidate gene 
approach. Association study methodology, accounting for relationship stratification 
via principal components of the genetic relationship matrix, was used to detect 
significant SNP, in response to both the FMDV peptide and the BRSV vaccine. 
Twenty significant SNP associations were discovered across 19 traits, with some 
SNP located in genes with known biological relevance to an immune response, such 
as the Toll-Like Receptors (TLR), TLR4 and TLR8. 
 
This thesis has detected regions of the genome which are significantly associated 
with the immune responses elicited by two different agents, suggesting similar 
pathway(s)/gene(s) may be used in defence of multiple pathogens. Once regions of 
significance were detected, further analysis using SNP markers identified significant, 
non-synonymous SNP that were associated with the immunising agents. The novel 
markers discovered in this study may aid breeding for resistance to disease via 
marker assisted selection. In addition, they may also have highlighted new targets for 
vaccinologists to develop ‘next generation’ vaccines. 
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Infectious disease of livestock continues to be a cause of substantial economic loss 
and has adverse welfare consequences, even in well managed agricultural systems 
[1].  In addition, even with stringent bio-security, there are incursions of “exotic” 
diseases e.g. the recent Foot-and-Mouth Disease (FMD) outbreaks within the E.U. 
[2].  Current interventions against infectious disease include anthelminthics, 
antibiotics and other chemicals as well as vaccination, although for many endemic 
and exotic diseases there are limited appropriate and effective controls. Thus 
alternative solutions for disease control are needed.  Breeding for disease resistance 
together with more effective vaccines have the potential to deliver solutions. 
 
There is considerable variation among individuals in the response to infectious 
disease and vaccination, a significant proportion of which can be shown to be genetic 
[1].  It is clear that the wide range in immune responsiveness and disease resistance 
found within livestock population is controlled by many genes [3].  Many candidates 
genes have been identified that may influence the immune response, including the 
Major Histocompatibility Complex (MHC), however, the relative contribution of the 
MHC and non-MHC loci to the wide variation in immune-related traits is only 
beginning to be explored. Identifying and understanding the role of different 
polymorphic loci in immune-related traits may lead to the identification of selectable 
markers for disease resistance, and may also suggest new host targets to improve 
vaccine efficacy. 
 
Identifying the causal genes involved in disease resistance and vaccine response is 
not straightforward. Most studies in livestock mammals have used field data, with 
the inherent problem of variation caused by considerable environmental influences, 
and where the phenotypes are generally based on morbidity and mortality as 
determined by veterinary observation. An example of veterinary observation is 
shown by Casas et al [4], where a veterinarian defined the presence bovine 
keratoconjunctivitis infection as a phenotype. These forms of classification fail to 
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realise the whole spectrum of the immune response, which can also be viewed as a 
quantitative response. Thus much of the variance from the immune response is 
ignored, making statistically significant associations with fixed or random effects 
more difficult to detect. However, the actual correlates of protection are often 
unknown and likely to be a complex combination of innate and acquired immunity. 
Many diseases, such as mastitis can be caused by distinct pathogens which result in 
different responses that are likely to be under different genetic controls [5]. The 
causal pathogen is often not identified in field studies. In addition, field data consists 
of single time points and cannot account for variation in the kinetics of immune 
responses. 
 
1.1.1 Genetics of Vaccination  
Genetic variation has not been explored thoroughly in terms of response to 
vaccination [6], even in humans [7]. It is clear that there is variability in host 
response to vaccination, but many factors account for this. In order to concentrate on 
the genetic factors involved in the immune response post immunisation, most studies 
have attempted to reduce or separate out the other factors which affect the 
phenotypic traits. In practice this either means reducing environmental variables as 
much as possible and/or conducting large scale studies in a population with a 
complete pedigree.  
 
Although this project is focused on cattle, it is important to take account of other 
research to gain a full insight of the current issues in the field of vaccination, in 
particular the genetics behind vaccination. Initially most studies investigated the role 
of the highly polymorphic MHC region, due to its known role during an immune 
response. However it is becoming clear that non MHC genes control a large 
proportion of the genetic variability in immune responses to vaccination [6, 8-9]. 
 
In the human field, typical examples of variation in the immune response post 
vaccination include responses to measles and hepatitis B. Measles is still causing 
significant world health problems for the young. Currently there is a two dose 
vaccine which maintains protection from measles in vaccinated populations but there 
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is variability in the response. Non responders to the vaccination have been associated 
with dysfunction of Th1 and specific B cells [10-11], which indicates the likely 
polygenic nature of the underlying genetic causes. These results also highlight that 
protection relies on several immune pathways, thus a vaccine which effectively 
induces protection by stimulating appropriate immune pathways is needed. One 
method to make vaccines more efficacious is to understand the genetics of responder 
individuals. Discovering the genetics associated with the response to measles 
vaccination has begun [7, 12-15],  and it is apparent that responders to the measles 
vaccine appear to lack the ‘non responder’ alleles rather than having specific 
responder alleles [12]. In addition, the recently available recombinant vaccine against 
hepatitis B is also an example of a vaccine resulting in variation in response, as 5-
10% of people vaccinated are complete non responders [16]. The research compiled 
on hepatitis B vaccination and infection to date shows similar conclusions to that of 
the research on measles vaccination; there is a large genetic component to the 
response to infection or vaccination with hepatitis B [8, 10, 16-20].  
 
Genome wide association studies in humans are also providing targets for treatment 
of infectious diseases. Hepatitis C virus (HCV), for example, infects 170 million 
people a year (http://www.who.int/), and infection carries the risk of liver fibrosis 
and subsequent cirrhosis and hepatocellular carcinoma [21]. Recently, genome wide 
association studies associated HCV infection with IL28B [22-24]. This finding has 
led to the implementation of clinical trials [25], potentially discovering a novel 
treatment for HCV infection. This is an encouraging example of the potential of what 
whole genome scans could contribute to the cattle industry, possibly improving 
vaccine efficacy by detecting pivotal genes. One possibility for improving vaccines 
is the potential to develop analogues of pivotal gene products. Thus, if a non 
responder allele confers poor production of protein, these individuals could have 
vaccines tailored to include the protein analogues. 
 
Vaccination of cattle also elicits a highly variable immune response [6], which 
indicates that a genetic component plays a role in the variation. However, studies 
investigating the variation post vaccination often do not investigate the genetic loci 
Chapter One – General Introduction  
 17 
associated with the variation (examples include, [26-27]). Studies investigating post 
infection phenotypes have shown associations with genetic loci that account for a 
proportion of the variability in the immune response (section 1.2.2), strongly 




1.2 Relevant Phenotypes 
1.2.1 The Immune system 
To detect regions of the bovine genome which influence the immune response 
following immunisation, a detailed phenotype is required which is able to capture the 
variation of the immune response in a herd. In addition, as the immune response is a 
qualitative response which constantly changes, measuring the response over several 
time points, will allow analysis of how the immune response reacts to an 
immunogen. However, an understanding of the immune response is required to 
collect appropriate immune related phenotypes and measure the phenotypes at 
relevant time points. 
 
The immune system consists of highly complex components that detect and defend 
against foreign bodies (pathogens) from infecting the host [28] and causing disease 
(However, in certain cases the immune response itself can also cause disease [28]). 
To fight infection the immune system orchestrates innate and adaptive immune 
divisions. The innate immune system is the first line of host defence [29] and reacts 
to a wide range of pathogens [30]. If the innate immune system fails to eliminate a 
pathogen then vertebrates have a secondary defence, the adaptive immune response 
[31-32]. Once alerted to a pathogen via the innate immune response the adaptive 
response is antigen specific and involves the generation of immunological memory 
(Figure 1.1) [33]. 





1.2.1.1 Innate immunity 
As the innate immune system communicates and directs with the adaptive immune 
system [34], which ultimately confers immunity [33], the genes and pathways which 
the innate immune response uses are of great interest to vaccinologists and animal 
breeders as they may enable a higher percentage of animals to elicit appropriate 
responses to disease. Understanding the mechanisms which elicit an adaptive 
immune response may also explain some of the variance detected in the immune 
response post vaccination. 
 
Innate immunity is one of the first barriers to infection. It detects pathogens in many 
different ways, for example: using Pathogen Recognition Receptors (PRR) [30, 35], 
Figure 1.1: An adaptive immune response. When the adaptive immune system initially 
encounters an antigen, the primary response is elicited after a lag phase. If the adaptive 
immune system encounters the antigen again a swift and stronger secondary response is 
elicited. Based on an illustration within Janeway et al [10]. 
Chapter One – General Introduction  
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such as Toll-Like Receptors (TLRs) [30] and Nod Like Receptors (NLR) [35]  which 
are located on Antigen Presenting Cells (APC) such as Macrophages (M) and 
Dendritic Cells (DC) [28]. PRR are coded into the germline and are able to detect 
conserved regions of bacteria, viruses and fungi [30], called Pathogen-Associated 
Molecular Patterns (PAMP). Once a PRR is stimulated by a PAMP multiple distinct 
signalling pathways become activated. Both immunogens investigated in this thesis 
are derived from viral pathogens. In the case of viral infection, key molecules are 
transcription factors such as Interferon Regulatory Factor (IRF) 3, 7 and Nuclear 
Factor B (NF- B) [36]. These transcription factors cause the secretion of cytokines 
such as interferons (IFN) [36], which are critical in coordinating the innate and 
adaptive responses [34] against viral infection. Thus variations in the innate immune 
response can vastly affect how it communicates with, and elicits, the adaptive 
immune response [34]. 
 
1.2.1.2  Adaptive immunity 
The adaptive immune response is initiated within the lymphatic organs, which have 
evolved to provide an ideal environment for DCs to present antigen to naïve B cells 
and T cells [34]. During  a virus elicited response, type II IFN and other cytokines 
such as interleukins 12 and 18 produced by the innate immune response cause CD4+ 
T cells to polarize into Th1 cells [37]. Indeed, IFN-, a type II IFN mainly produced 
by Natural Killer (NK) cells [38], has been shown to play a key role during viral 
infections [36] and has been used as a phenotype to measure the immune response to 
different pathogens [39-40]. In addition, during activation of differing subsets of T 
cells [41], CD8+ T cells will differentiate to Cytotoxic T Cells (CTL), enabling them 
to kill virus infected cells [41], via communication with Major Histocompatibility 
Complex (MHC) class I molecules [42]. Further, activation of B cells, during a viral 
infection means that antibody production can be elicited [34]. Thus, antigen specific 
antibody levels and T cell levels can be used as phenotypes to follow the adaptive 
immune response. 
 
The MHC is an essential link between an innate and adaptive immune response as it 
used to communicate between T cells and antigen presenting cells (APC). In cattle 
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the MHC region is named the Bovine Leukocyte Antigen (BoLA) and consists of 
three classes: I, II and III [43]. The MHC class I molecules bind to peptides derived 
from a cell's expressed proteins and presents them on the cell surface [44]. Thus if 
the cell is infected by a virus, peptides from the virus will be expressed on the cell 
surface and be detected by CTL [41]. Class I MHC has been shown to play a role in 
the clearance of viral infections in cattle, for example, against foot and mouth disease 
virus (FMDV) [45]. MHC class II molecules bind peptides which have originated 
from pathogens that have been phagocytised by APC, such as M and DC, and are 
expressed on their cell surface [34]. Class II MHC polymorphisms have been 
associated with variation in antibody responses and cell mediated responses to a 
number of viral infections such as bovine leukaemia virus [46] and FMDV [47]. 
MHC class III molecules encode many gene products with functions from cell 
cytotoxicity to enzymatic activity [43, 48]. The MHC genes are highly polymorphic 
to enable it to bind to many pathogen types. However, genetic variations from animal 
to animal may mean that some processed peptides may not bind or only bind at low 
affinity [6]. Thus variations in the MHC may also have large impacts on an immune 
response. 
 
Once a virus has been eliminated or become latent [49] within the host, specific T 
cell and B cell populations will significantly decrease [34]. However, T memory and 
B memory cells remain to protect against re-challenge with the same or an 
antigenically related pathogen [33]. 
 
1.2.2 Immunity and resistance 
The adaptive immune response is very important in generating immunity within 
animals, thus both cell mediated and humoral responses are measured as phenotypes 
in cattle to quantify the immune response to many pathogen types, examples include 
fungal [50], parasitic [26], bacterial [51] and viral [52] pathogens. Antibody levels, 
which is the simplest measure of an adaptive response to a pathogen [3], can be 
correlated with protection [53]. A proportion of the variation in the immune 
responses across herds [51-52], appears to be genetic, with breed and sire effects 
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detected [27, 54-55]. As a heritable genetic component exists, breeding animals for a 
more disease resistant herd is possible [56].  
 
Cell mediated and humoral immune responses have been also been measured post 
vaccination in cattle, as phenotypes and attributed a proportion of the observed 
variation to genetics [26-27, 57]. Detecting and locating the genes underlying this 
genetic component has the potential to turn non or low responders to vaccination into 
responders. By targeting the genes causing the high/low response, it may be possible 
to improve vaccine components to better target the low-responders. 
 
Many genes, pathways and physical barriers make up the immune system. In 
chapters 2, 3 and 4 of this thesis, regions of the genome are shown to be significantly 
associated with the immune response post immunisation. Few of these regions have 
known immune function, thus only the major genes and pathways of the immune 
response have been studied, and where appropriate, more detailed explanations of the 
immune response will follow in later chapters. 
 
 
1.3 Genotypes  
1.3.1 The Bovine Genome Sequence 
The bovine genome is an excellent resource and can be used in many ways. For 
example, finding a marker that is associated to the immune response is the basis of 
Marker Assisted Selection (section 1.3.4). Further, placing a significant marker into 
the genome to discover where it is positioned is a different process involving 
bioinformatics. Once a marker is placed, further analysis of the biological context is 
possible, for example, the marker may exist within a gene of known immunological 
relevance, highlighting possible pathways which have an effect on a phenotype. 
However a highly detailed and annotated genome sequence is required.  
  
The bovine genome (http://www.hgsc.bcm.tmc.edu/projects/bovine/) contains 30 
chromosomes (2n=60, XY). In recent years, sequencing of the bovine genome has 
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increased rapidly [58]. The initial genetic map of the bovine genome in 1986 [59], 
had enough resolution to detect synteny between species and their genetic locations 
within the genome. The resolution of this map steadily increased [60-61] and 
expanded [62-63] throughout the 1990’s. The next big jump came in the form of 
radiation hybrid maps which provided much more detail of the genome [64].  The 
current bovine genome sequence was released in 2007 with a 7.1 times coverage of 
the Bos taurus genome. For assembly of the sequenced genome in 2007, two 
methods were utilised. The first method used whole genome shotgun (WGS) 
sequencing, following the example of the rat genome construction [65]. The other 
method followed the human genome approach [66], which used Bacterial Artificial 
Chromosomes (BAC) for construction [67].  
 
Following the sequencing, a large international effort was made to annotate the 
genome [68]. This was led by National Institutes of Health (NIH) and the United 
States Department of Agriculture (USDA), and was successful in bringing the 
international scientific community together to annotate all aspects of the genome, of 
which, I contributed to the annotation of immune related genes [68]. Although the 
annotation effort was a great achievement in itself much work is still needed to 
confirm the ordering of some scaffolds and to further annotate the genome to a 
higher standard, as many genes within the bovine genome are still currently either 
un-annotated or annotated predictions (computer annotations), with no known gene 
functions (http://www.ensembl.org).  
 
1.3.2 Detection of Quantitative Trait Loci 
A Quantitative Trait Locus (QTL) is a region of the genome which is significantly 
associated with phenotypic variation. To detect QTL, a region of the genome must 
contain a genetic marker that is either in Linkage Disequilibrium (LD) with a causal 
polymorphism, or be the causal polymorphism [69]. During the early 1980s the 
development of molecular technologies to genotype markers began [70], which has 
led to the production of panels with hundreds of thousands of markers upon them ( 
e.g. http://www.affymetrix.com), greatly increasing the chance of discovering QTL. 
However it was Lander and Botstein [71] who revolutionised QTL detection via 
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interval mapping using a maximum likelihood (ML) approach to map QTL lying 
within a chromosome region surrounded by two markers. With the constant addition 
of more markers though, these methods became computationally intensive. Haley 
and Knott [72] addressed this issue using a regression approach, which approximated 
the interval mapping method, thus needing far less computational demand. Following 
this, refinements were made [73-74], as well as variations in methodology, with: ML 
[71], regression [72] and Bayesian [75] methodologies all being implemented. 
However, there is little difference between the final results of ML and regression 
[76].  
 
The two methods for QTL detection used in this thesis are Linkage Mapping (LM), 
implementing the Haley and Knott [72] methodology which uses a general linear 
model to detect QTL and Association Study (AS) methodology using REsidual 
Maximum Likelihood (REML) [77], using the package nlme within R 
(http://127.0.0.1:14665/library/nlme/html/nlme.html). Both methods of QTL 
detection rely on the co-inheritance of adjacent DNA variants, with linkage mapping 
capitalizing on this by identifying haplotypes that are inherited intact over several 
generations, and the association study methodology relying on the retention of 
adjacent DNA variants over many generations [78]. However, differences occur in 
the principles used by these methods to detect QTL. 
 
1.3.2.1 Linkage Mapping 
Linkage mapping [72], tracks within-family segregation of linked markers, thus it 
focuses on recent ancestry, in which there have been relatively few opportunities for 
recombination to occur. As a result disease associated regions of the genome that are 
identified by linkage mapping will often be large, and can encompass hundreds of 
possible genes across many megabases of DNA [79]. 
 
To detect QTL, LM uses pedigree information in combination with a linkage map 
and the genotypes of the animals to infer the Identity By Descent (IBD) of 
chromosome segments for each animal at specified distances along the genome [80]. 
During this thesis the genotype probability of each locus at 1 centiMorgan (cM) 
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intervals on each chromosome was calculated. For each locus position a general 
linear model is fitted against the phenotype [81], using an F-Statistic as a measure of 




LM is credited as a good technique to detect the correct position of a QTL [69], In 
addition, due to the use of within-family LD, LM studies are better suited to detect 
low penetrance genes, compared with an association study [82]. However, as the 
RoBoGen herd was not very large and had few founders, few recombination events 
will have occurred in the herd, thus large haplotype blocks will be present, making 
precise detection of QTL difficult using LM methodology. This will result in large 
confidence intervals for QTL. The confidence intervals of QTL also reflect the QTL 
effect size, and the density of the markers used [83]. 
 
1.3.2.2 Association Study  
The second approach used to detect QTL in this thesis is Association. The basic 
principle underlying the identification of QTL using AS methodology is simple: 
every animal phenotyped is also genotyped. If a difference exists in the mean 
Figure 1.2. The graph depicts a hypothetic QTL. The X-axis is the length along a chromosome; 
the black squares along the X-axis are the locations of markers on the chromosome. The Y-axis is 
the measure of significance (F-Statistic). The plotted red line shows the significance of the QTL at 
each point of the chromosome. In this case the QTL is most significant at 21cM. 
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phenotype among the different genotype classes of a marker, then that marker is in 
LD with a QTL.  
 
In small populations, the amount of LD between tightly linked markers generated by 
random drift or admixture may be sufficient to allow fine mapping of major genes 
using a random population sample [69]. As a result, AS relies upon a QTL being in 
population-wide LD with a casual mutation. As this approach relies on LD at the 
population level, rather than at the family level which LM relies upon, it does not 
track within family segregation, and thus it has benefits in unstructured populations 
or populations with unknown pedigrees as only one generation needs to be 
genotyped.  
 
For this approach I used a REML model to calculate the significance of marker 
effects, as it is able to simultaneously account for multiple factors affecting the trait. 
The REML model associated each marker, one by one, with a phenotype. Single 
Nucleotide Polymorphisms (SNPs) are generally used as markers in AS [84] as they 
are plentiful across the genome (thus specific SNP can be chosen for candidate gene 
studies, or whole panels of SNPs can be used in GWAS) and relatively cheap [85]. 
SNP have 3 possible genotypes, which the REML model uses to estimate the effect 
for each marker in a study (Figure 1.3).  
 
As a pedigree does exist in the current study it was accounted for within the REML 
model using a genetic relationship matrix. Both the AS and the LM methods will 
provide similar estimates of QTL effect [86-87].Further, both methods (LM and AS) 
allow the addition of covariates (all covariates are linear in the current study) and 
fixed effects to obtain the most appropriate model to detect QTL. Thus highly similar 
models were used in both approaches. Furthermore both models are able to detect 2 
QTL upon the same chromosome. 






Both forms of QTL (LM and AS) detection have the potential to improve when extra 
markers are added. However, as the number of markers increase, more statistical 
tests are made, and these need to be accounted for in the analysis [88] (this is 
discussed further in section 1.3.3.). 
 
Association studies are well suited to detect large and medium genetic effects. In 
addition, due to the expansion of SNP chip technology and the decrease in the price 
of genotyping [85], AS have become a common and successful method of QTL 
Figure 1.3 The three genotypes of a hypothetical marker are represented along the X-axis. The 
phenotype (weight gain) is shown on the Y-axis. The regressed line in the graph shows the effect 
of this marker (assuming an additive model). Thus the animals with the A allele weigh more than 
those with a B allele. 
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detection. However, much of the heritability is left unexplained during the analysis 
complex traits [89]. Below I have highlighted some of the technical issues that cause 
AS to miss, or simply not detect, heritable genetic variants that may be associated 
with complex traits: 
 
Alleles with small effect size 
A strength of AS is that it can test many thousands of SNPs across a genome 
for a significant association with a trait. However, this is also a drawback. As 
many tests are completed the true causal variants in LD with a SNP are 
‘swamped’ with statistical noise from the other markers that aren't associated 
with a complex trait, causing positive findings to be disregarded as 
insignificant. This is discussed further in section 1.3.3. It has been recently 
suggested that much of the missing heritability in AS is due to marker effects 
being too small to pass stringent significance tests [90]. 
 
SNP selection 
SNP chip designs have been optimised to capture the maximum amount of 
genetic variation in a genome. In addition the assumption of ‘common disease 
common variant’ (CDCV) [91], argues that common variants may underlie 
many common diseases, and that common variants would be more easily found 
using population-based LD rather than family-based LD (such as LM), even if 
this required testing every gene in the genome. Thus only high-frequency 
variants that capture the largest proportion of genetic variation are included in 
the majority of studies and commercially available SNP chips. However, rare 
variants are thought to, at least contribute, to complex traits [92]. Thus by not 
including rare variants in an investigation, phenotypic variance and heritability 
that could be attributed to the rare variants is lost. 
 
Genetic architecture  
There are forms of genetic architecture within the genome that will play a role 
in the expression of a phenotype. Some of these, such as epigenetic inheritance 
[93], can not be modelled or tracked by DNA based markers as they are 
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chemical alterations of the DNA which cause differential expression to occur. 
However, others such as: epistasis (discussed further in section 5.2.1.1), 
pleiotrophy and copy number variation (CNV) can be discovered by using 
similar models as used in the AS section of this thesis. The latter, CNV, will be 
the most difficult as modern SNP chips and SNP genotyping technologies can 
only detect a small proportion of CNVs indirectly (by looking for distortions of 
signal intensity or inheritance patterns), thus the majority CNVs remain 
invisible to AS. All of the different forms of genetic architecture mentioned in 
this section may contribute to the expression of a complex trait, yet to date they 
have not been analysed sufficiently to highlight the possible variance they may 
account for. 
 
Linkage Disequilibrium Linkage Association (LDLA) is a two step method used to 
extract the maximum information from a pedigreed population to detect QTL. 
Initially an LM approach is conducted to discover broad regions of significance that 
are inherited throughout a pedigree. These regions are then fine mapped using AS 
methodology which relies on population LD, enabling the discovery of markers that 
are closer to a causal variant. This method (LDLA), has been previously shown to be 
successful in refining confidence intervals (for example: [94-95]) and even 
discovering casual polymorphisms (for example: [96-97]). Chapter 4 of this thesis 
follows the same logic. Initially an LM approach is used, which detects broad regions 
of the genome that are significantly associated the immune traits measured. 
Following this, further markers are genotyped within these regions (and other regions 
which were suspected to play a role in the immune response) and an AS conducted in 
an attempt to fine map the regions of the genome previously shown to be significant. 
 
1.3.3 Quantitative Trait Loci Significance 
Due to the nature of both the techniques of QTL detection used in this thesis, 
multiple testing becomes an issue. In statistical terms, multiple testing becomes a 
problem when a set of statistical tests (of markers in this case) are calculated 
simultaneously [69]. For example, if a p-value of 0.05% is used for 1 test (or marker 
in this example), then the chance of wrongfully rejecting the null hypothesis (type I 
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error/false positive) is 5%. Thus, if 100 tests are done simultaneously, again with a p-
value of 0.05%, then 5 type I errors are expected. To reduce the type I error rate, 
many multiple testing techniques exist, which all have different attributes [98]. Many 
are also tailored to be beneficial for certain experimental designs with certain 
expectations (e.g. normal underlying distributions) [98].    
 
In both the LM and AS methods used in this thesis over 165 markers are tested 
simultaneously. To correct for this, two methods for multiple testing were used. The 
initial method was a standard Bonferroni correction [99], which was only used for 
the AS. The second, permutation testing [100], was used when calculating empirical 
thresholds during the LM and AS studies. 
 
1.3.3.1 Bonferroni Correction 
The Bonferroni correction is a swift multiple correction method designed to obtain 
an overall significance level [69]. Below is the equation used to calculate the 
significance threshold when adjusting for multiple testing using the Bonferroni 
formula: 
 
 = 1-(1- )1/n   /n 
 
Where:  is the significance level applied to each of the individual tests (n) and  is 
significance level for the entire experiment. 
 
This method of correction is highly conservative when large numbers of tests are 
used. For example, to achieve an experiment-wide significant marker with a p-value 
() of 0.05, with the number of tests (n) at 100,000 markers, requires a p-value () of 
5.00E-07. Thus this has the effect of increasing the frequency of type II errors (false 
negatives), which can be equally as erroneous as type I errors. As the Bonferroni 
correction has the expectation that all the markers are not linked. If markers are 
consistently in LD with each other, then other methods of multiple correction should 
be used [69]. 
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1.3.3.2 Permutation Testing 
Permutation testing is far more robust [69, 100] than the Bonferroni correction 
method. Using this approach the original analysis is repeated n times, each time 
shuffling the phenotypic and genotypic data and retaining the highest test statistic. As 
the link between the phenotypes and the genotypes is destroyed, the retained test 
statistics can be used to calculate 5% and 1% levels significance thresholds. 
 
For example, if 1000 tests were performed and all the test statistics are ordered from 
lowest to highest, the 10th test statistic would represent the experiment wide () of 
1% threshold and the 50th test statistic would represent the experiment wide () of 
5% threshold. 
 
This method, however, depending on the complexity of statistical models used, is 
extremely computationally extensive. For example, Churchill and Doerge [100] 
suggest 10,000 permutations are required to estimate 1% experiment wide 
significance levels. The time taken to calculate 10,000 permutations in the AS 
component of this thesis was prohibitively long, thus the Bonferroni correction was 
chosen for the publication of results. 
 
1.3.4 Marker Assisted Selection 
Marker Assisted Selection (MAS) has been used in the cattle industry for at least a 
decade [101]. MAS is process where a trait of interest is selected, not based upon 
phenotype alone, but by using a marker that is in linkage with a favourable 
phenotype [102]. The animals with the favourable allele of the marker are then 
‘selected’ to produce the next generation. This method of selection needs no 
understanding of the biology and simply uses marker information to select animals 
based on perceived genetic potential [103]. The SNP markers discovered to be 
significantly associated to different disease traits, throughout this thesis, could be 
used, post validation in separate herds measuring the same phenotypes, in large SNP 
chip arrays in the cattle industry to select animals for better disease resistance. 
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1.4 Experimental Design  
The experimental design undertaken in this thesis, attempted to reduce environmental 
factors with the aim of maximising detection of genetic affects. Thus the same farm, 
management team and animal husbandry were used.  
 
1.4.1 The Roslin Bovine Genome (RoBoGen) Herd 
The objectives of the RoBoGen project were to map major genes controlling 
commercially important traits in cattle.  The strategy for breeding was to source F1 
heifers and bull calves which were progeny of Holsteins mated to one of four pure bred 
Charolais bulls. From the F1 population, 13 sires were used to create the F2 population 
and two backcross populations (Charolais backcross (CB1) and Holstein backcross 
(HB1)) were created (Figure 1.4). Traits were measured on an F2 population of 500 
animals; all were originally genotyped for 165 microsatellite markers covering the 29 
autosomes of cattle. Successful mapping of QTL, using this herd, to production traits 
has already been shown [104-106]. In relation to this thesis, the F2 animals were 
immunised with a peptide derived from Foot and Mouth Disease Virus (FMDV) and 
vaccinated with a Bovine Respiratory Syncytial Virus (BRSV) vaccine.  
 
1.4.2 The data sets  
The FMDV and the BRSV studies were performed on the same animals to minimise 
the environmental and genetic variance between the two studies. When the animals 
were vaccinated with the BRSV vaccine IgG1 and IgG2 levels were measured pre 
and post vaccination. At a later date, the animals were also immunised with a 40-mer 
FMDV peptide (FMDV15). Once immunised IgG1, IgG2, T cell and Interferon  
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1.5 Project Overview 
The aims of this thesis were to locate and define the genetic component to the 
observed variability in immune responses pre and post immunisation, identifying 
markers which are associated with the immune response following immunisation. 
The markers discovered have the potential to be used in breeding for enhanced 
disease resistance and may also be used to address poor vaccine efficacy by 
highlighting potential targets for improving vaccine response, thus aiding 
vaccinologists to develop next generation vaccines. 
  
The RoBoGen herd was immunised with a FMDV15 peptide and a BRSV vaccine 
and immune responses were measured over a time course post immunisation. 
Immune phenotypes and environmental parameters were measured, such as: year of 
birth (cohort), age at vaccination, weight at vaccination and sex. These parameters 
enabled detailed statistical analysis of which factors played a significant role post 
immunisation. The herd was also genotyped to discover the regions of the bovine 
genome that have a significant effect on the immune response post immunisation.  
 
Aims include: 
• Analysing the kinetics of the immune response post immunisation with an 
FMDV peptide (chapter 2) 
• Discovery of QTL (via a linkage approach) associated with the immune 
response post immunisation with an FMDV peptide and BRSV vaccine 
(chapters 2 and 3) 
• Discovery of QTL (via a linkage approach) associated with the immune 
response pre immunisation with the BRSV vaccine. (Chapter 3) 
• Comparisons of the immune responses post immunisation to the FMDV 
peptide and BRSV vaccine (chapter 3) 
• Genotyping of the RoBoGen herd “under the QTL” previously detected 
whilst simultaneously using a candidate gene approach (chapter 4) 
• Further discovery of QTL and genes (via an association approach) associated 
with the immune response post immunisation with an FMDV peptide and 
BRSV vaccine (chapter 4) 
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1.5.1 Hypothesis 
There is a genetic component to the observed variability in the response to 
immunisation in cattle. During this thesis I plan to locate and define some of the 
genetic component, within the RoBoGen population, to the observed variability in 
response to the immunisations used in this thesis. Furthermore, I will be able to 
construct a list of regions and genes which are associated with the immune response 
post immunisation. 













Chapter 2  
 
____________________________________________________________________ 
Quantitative trait loci for variation 
in immune response to a Foot-and-
Mouth Disease virus peptide 
____________________________________________________________________ 
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2.1 Background  
As stated in chapter one, variation in the immune response has a genetic component. 
In this chapter I aim to discover the genetic loci which are associated with an 
immune response elicited to a Foot and Mouth Disease Virus (FMDV) peptide over a 
time course. In addition, the kinetics of the immune response will be analysed to 
detect significant effectors of the immune response. 
 
FMDV is extremely contagious to cloven 
hoofed animals, posing a particular 
problem to those on farms due to the close 
proximity of other cloven hoofed animals. 
Infection of cattle generally occurs via the 
respiratory route [107], with the infected 
animals exhaling the virus in aerosol form 
[2]. Once the clinical signs which include 
visible lesions, fever and lameness, are 
present, viral presence is obvious. 
However animals are highly infectious 
before they develop these signs [2], thus in the later stages it is too late to quarantine 
individual animals. The mortality rate to FMDV is low, generally affecting young 
animals, where the virus can affect the heart [2]. Due to the effect of the disease it is 
economically (due to trade restrictions), and on welfare grounds, important to protect 
animals and farms from outbreaks, such as the 2001 U.K outbreak which cost 
approximately $13 billion  [2]. 
 
FMDV is endemic in large parts of the world, though not in the U.K, E.U, U.S.A or 
Australia. Many countries where FMDV is endemic, routinely vaccinate using 
inactivated viral vaccines [2]. In contrast, if outbreaks occur in non-endemic 
countries quarantine and slaughter are the policies used (http://www.oie.int). This 
however, leaves these countries vulnerable to incursions of exotic pathogens such as 
FMDV which have occurred in the U.K. Since the 2001 UK outbreak, considerably 
 
 
Figure 2.1: A cartoon of the Foot 
and mouth Disease Virus. Showing 
the capsid made up of the envelope 
proteins: VP1 is red, VP2 is green 
and VP3 is blue. (VP4 is internal). 
Chapter Two – QTL associated with FMDV  
 37 
more research around the world is directed to developing safer, more efficacious 
vaccines and other methods of control [108]. In order to achieve this it is clear that 
greater knowledge of the host response to, and interaction with FMDV is also 
required. Considerable animal to animal variation has been reported in the context of 
FMDV challenge and immunisation with a variety of vaccine constructs including 
peptides. However the role of host genetics in variation of the response to 
immunisation has not been generally considered: there has only been one study 
which suggested that host genetic factors might play a role in response to vaccination 
with inactivated FMDV vaccines [109]. 
 
Foot and mouth disease virus is a member of the picornaviridae family [110]. The 
virus has a single stranded RNA genome which is non-enveloped. The capsid has 
icosahedral symmetry with 60 copies of four proteins [2], Vp1-Vp4 (Figure 2.1). 
Currently, there are seven distinct serotypes of the virus: O, A, C, SAT 1-3 and Asia 
1 [111] making vaccination difficult as all vaccines against FMDV, to date, are 
serotype specific. The FMDV peptide (FMDV15) used in this chapter, to elicit an 
immune response, consists of two sections of the VP1 protein, together 
encompassing the major neutralising antibody sites [112].  
 
Protection against FMD is generally believed to relate to the levels of neutralising 
antibody and has been correlated with IgG1 and IgG2 levels [113-114] as well as 
interferon- [115]. In addition, T cell responses play a role in protection against 
FMDV [116]. The Glass group have shown that there is considerable variation in the 
immune response to this and related peptides as well as variation in the protection 
against viral challenge [117-118]. Although previous studies have revealed that 
polymorphisms in loci within the bovine MHC (BoLA), particularly the class II 
DRB3 gene, accounted for some of the variation in immune response [117-119], it 
seems likely that other genetic factors are also important.  
 
To explore the contribution of the MHC and other loci to variation in immune 
responses, the work reported in this chapter analyses the variability in the kinetics of 
FMDV15 specific IgG1, IgG2 and T cell responses during a primary and secondary 
Chapter Two – QTL associated with FMDV  
 38 
response following immunisation with the FMDV15 peptide. The second generation 
of the RoBoGen herd were also genotyped with 165 microsatellite markers 
distributed across the bovine genome. The variation in response to the peptide was 
also correlated with the markers to identify QTL controlling variation in the immune 
response across a time course.  
 
 
2.2 Materials and Methods  
2.2.1 Acknowledgements 
All statistical analysis, within this chapter, was conducted by Richard Leach. The 
FMDV15 peptide was synthesised by Alistair Douglas, Department of Agriculture 
for Northern Ireland. All the lab based assays, in this chapter, were completed by 
Susan Craigmile, the Roslin Institute. Immunisations were done by the Roslin 
Institute farm staff. John Williams’ group at the Roslin Institute completed the 
genotyping of the RoBoGen herd with the microsatellite markers. 
 
2.2.2 Animals  
Immune response measurements were collected from 195 second generation cross 
heifers (121 from the F2, 43 from the HB1 and 31 from CB1). All female calves 
were weaned by 36h, segregated from the rest of the herd and raised indoors, initially 
on milk-replacer then weaned early onto a propriety compound diet. The age of the 
first immunisation with the FMDV15 peptide ranged from 469-609 days. 
 
2.2.3 Immunisation and sampling  
The FMDV15 peptide was chemically synthesized using an ABI 431A peptide 
synthesiser with FMOC chemistry.  Following deprotection and cleavage, it was 
purified by preparative reverse phase HPLC (Beckman Coulter System Gold HPLC 
using a Phenomenex Luna C18 column).  The peptide consisted of two separate 
regions (residues 141 to 158 and 200 to 213) of the virus coat protein (VP1) from the 
O1 Kaufbeuren strain of foot-and-mouth disease virus [112]. The female F2 and 
backcross heifers were immunised subcutaneously with 1mg FMDV15 
Chapter Two – QTL associated with FMDV  
 39 
peptide/animal emulsified in Freund’s incomplete adjuvant at week 0, followed by a 
boost of 100µg FMDV15 peptide/animal at week 6. Whole blood samples were 
collected by jugular venipuncture from all of the female F2 and backcross heifers at 
weeks 0, 1, 2, 4, 8 and 10, post immunisation for IgG analysis (see below) and at 
weeks 0, 4, 8 and 10 post immunisation for T-cell measurements (see below). For the 
IgG analysis, the blood samples were allowed to clot, and serum collected and stored 
at -20 0C until they were tested for the T cell analysis, blood was collected 
aseptically into heparin tubes.  All experimental protocols were authorised under the 
UK Animals (Scientific Procedures) Act, 1986. 
 
2.2.4 Phenotypic Data  
2.2.4.1 Whole blood T-cell Proliferation assay  
The T-cell proliferation assay was carried out essentially as described by Glass et al 
1990 [120] with the exception that whole blood was used. Whole blood (150µl) was 
diluted with 750µl RPMI 1640 supplemented with 25mM HEPES, 2mM glutamine, 
10% foetal calf serum, 5 x 10-5 M 2-mercaptoethanol either alone as the negative 
control, 10µg/ml concanavalin A (ConA) (Sigma, UK) as a positive control or 
2.0µg/ml FMDV15 peptide (all final concentrations). 
Quadruplicate cultures were incubated at 37oC with 5% CO2 for 6 days.  For the last 
6 hours the cells were labelled with 0.037MBq 3H-Thymidine per well (GE 
Healthcare, UK) and uptake assessed by liquid scintillation counting using a 1450 
Microbeta (Wallac, now PerkinElmer). The results were expressed as counts per 
minute of 3H-Thymidine incorporation (mean of quadruplicates). 
 
2.2.4.2 ELISA for detection of FMDV15-specific IgG1and IgG2  
FMDV15 peptide specific ELISAs were performed to measure IgG1 and IgG2 
isotypes as detailed in Baxter et al 2009 [119]. ELISA tests were conducted on the 
samples from all three cohorts, over a short period following the final sampling, to 
minimise technical variation.  Briefly, Immunolon 2HB plates (Dynex Technologies) 
were coated with 100l of 1g/ml FMDV15 peptide in carbonate/bicarbonate buffer 
(Sigma), and serum samples were added at predetermined optimal concentrations. 
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100l HPR-conjugated sheep anti bovine IgG1 (Cat. No. A10-116P, pre-optimised at 
1/20,000 dilution) or IgG2 (Cat. No.A10-116P, pre-optimised at 1/25,000 dilution) 
(Bethyl Montgomery, Texas, USA) were added as the secondary antibodies and 
colour developed with Sure Blue Reserve tetramethylbenzidine (TMB) microwell 
peroxidase substrate 1 component (KPL). Optical density was measured at 450nm on 
a Victor2 1420 Multilabel counter (Wallac). Seven serial dilutions of bovine 
reference serum (Bethyl), containing known concentrations of IgG1 and IgG2 in 
carbonate/bicarbonate buffer were included on each plate which enabled the IgG1 
and IgG2 concentrations to be calculated from simple linear regression (Genstat 
[121]).   
2.2.5 Statistical Analysis  
Stimulation Indexes (SI) were calculated for the T-cell proliferation to the FMDV15 
peptide and ConA: 
 
 SI (for the FMDV peptide)= AY / Bx  
 
 SI (for the Con A mitogen)= Az / Bx 
 
Where AY, is the T-cell response to the FMDV peptide, AZ is the T-cell response to 
Con A and Bx is the negative control. 
 
The IgG1 and IgG2 concentrations and the T cell SI for ConA and FMDV15 were 
normalised to obtain a normal distribution and constant variance (log10). Area under 
the curve (AUC) for each of these four traits was also calculated to provide a single 
trait that reflected the overall response of the normalised data. For this the 




Where b1 and b2 are the levels of response and h represents the time elapsed 
between each measurement:  




REML (REsidual Maximum Likelihood) was used, within Genstat [121], to 
determine which factors were significant within the herd. Sex was omitted from the 
model as all of the phenotyped animals in this study were female. The final model 
included sire and dam as random effects; the other effects within the model were, 
with appropriate degrees of freedom (df), line (F2, CB1, HB1; 2d.f) and cohort (1, 2, 
3; 2d.f). Age (age at vaccination; 1d.f) and calculated weight (weights of animals at 
initial vaccination date calculated from regression of animal weights at other time 
points pre and post vaccination; 1d.f) were both covariates.  
Thus the final REML model was: 
 
Yijk= µ +L+C+β1.m+β2.a+uj+gk+eijk 
 
Where: Yijk is the observed value of the phenotypic trait; µ, population mean; L, the 
fixed effect of line (3 Lines); C, the fixed effect of cohort (3 Cohorts); β1, the linear 
regression on the covariate of age at vaccination m (m = d469-d609); β2, the linear 
regression on the covariate of weight a (a= 361-744kg); uj, the random effect of sire; 
gk, the random effect of dam g; eijk, the residual error e ~ N(0,I
2
p). The residual 
variance from the model was used to calculate correlations. 
 
A chi squared test (with 1 df), using the difference of the deviance (-2* log 
likelihood) of the sire and dam, either in or out of the REML model, was used to 
calculate the significance of the sire and dam. Wald tests were used to determine the 
significance of the other effects. 
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2.2.6 Genetic Markers  
Standard phenol-chloroform methods were used to extract DNA from blood samples 
[123]. A panel of microsatellite markers were genotyped across all individuals in the 
herd, with a total of 165 microsatellite markers distributed across all 29 autosomes 
[104]. All of the genotypes were stored in the database ResSpecies [124] and used to 
build linkage maps with CRIMAP 2.4 [125]. The maps were compared to the latest 
bovine linkage map [126]. Once compared for consistency, the maps constructed 
using CRIMAP, were used to conduct the QTL analysis for the immune-related traits 
(Appendix 2.1).  
 
2.2.7 QTL Analysis  
The 24 traits tested in the QTL analysis were: FMDV15 specific IgG1 and IgG2 
concentrations at weeks 0, 1, 2, 4, 8, 10 and AUC; and T-cell proliferation to ConA 
and the FMDV15 peptide at weeks 0, 4, 8, 10 and AUC.  
 
GridQTL [127], internet based software, was used for the QTL analysis. The F2 and 
backcross module was used which assumes that founder lines are fixed for 
alternative alleles at QTL loci (although they can be segregating at markers) and 
implements a least squares analysis. All effects found significant from the previous 
analysis using REML were included in the model, thus for each time point only 
significant effects were added to the QTL model. Information content (IC) along the 
linkage maps was also calculated by the program. Both single and two QTL models 
with additive and dominance effects were fitted at 1cM intervals along the autosomes 
(N=29), using the sex averaged genetic map.  By setting the 2 founder breeds as: 
breed 1 = Holstein and breed 2 = Charolais, the positive or negative sign of the 
additive effects indicated that the Holstein or Charolais allele, respectively, increased 
the trait values. When the dominance effect had the same sign as the additive effect, 
this indicated dominance of the Holstein allele over the Charolais allele, whereas if 
the signs of the additive and dominance effects were opposite, the Charolais allele 
was dominant. 
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In total QTL were sought for 24 traits using the 165 microsatellite markers spread 
across all 29 autosomes of the bovine genome. Significance thresholds were 
calculated by permutation analysis with 1000 permutations [100]. Four significance 
levels were used: chromosome-wide 5% and 1% and genome-wide 5% and 1%. 
 
2.2.8 Refining QTL  
The QTL detected at the 5% chromosome-wide significance level and above were 
included in the model and the genome rescanned for further QTL. By adding the 
initial QTL as background effects, the variance caused by them is removed, thus 
potentially revealing previously undetected QTL. In cases where more than one QTL 
was found for the same trait on the same chromosome, a 2 QTL model was 
performed by fitting two QTL simultaneously and re-analysing the data. A forward 
and backward selection interval mapping approach was used to check whether QTL 
moved, relative to other QTL of the same trait [128], however none did. These 
refining methods were repeated, until no further QTL were detected. Finally, 
bootstrap analysis was performed, using 1000 repeat samples, for all chromosomes 
where a significant QTL was detected at the 5% chromosome-wide threshold [83] to 
estimate the 95% confidence intervals for location of the QTL, except for the 2 QTL 
models which were not bootstrapped. 
 
2.3 Results  
The 195 female F2, Holstein back-cross and Charolais back-cross animals of the 
“RoBoGen” population were immunised with the FMDV15 peptide and the resulting 
antibody and T cell responses were measured across time. The T cell responses to a 
T cell mitogen, Concanavalin A (ConA) were also measured across time. The whole 
herd (males and females in the F0 to F2 generation, in total 984 animals) was 
genotyped with 165 microsatellite markers.  
 




2.3.1 Kinetics of responses to immunisation  
A humoral and cell-mediated response to the FMDV15 peptide was detected in the 
majority of animals (Figure 2.2). From week 2, responses were significantly different 
from week 0 for anti FMDV15 peptide specific IgG1 and IgG2, and from week 4 for 
the T cell proliferative response to the FMDV15 peptide.  Following a second 
immunisation, most animals exhibited an increase in their response. The mean values 
for the IgG1 responses (Standard Deviation, SD) for weeks 0, 1, 2, 4, 8, 10 and AUC 
(area under the curve, to provide a single trait that reflected the overall response, see 
methods.) were 1.2 (1.4), 1.3 (1.4), 69.7 (66.1), 167 (144.4), 291.7 (269.2), 176.1 
(141.6) and 1658.4 (1381.3) g/ml respectively. The IgG2 responses for weeks 0, 1, 
Figure 2.2: Variation in IgG isotype and Tcell responses 
Box plots depicting IgG and T cell responses. In all diagrams: Median (central horizontal line), 
quartiles (outer horizontal lines) and range (outer vertical lines) shown. All data is log10 
transformed. 
On the left: FMDV15 peptide specific IgG1 (A) and IgG2 (B) levels following immunisation at 
weeks 0 and 6 of 195 female cattle.  
On the right: T cell proliferation (stimulation index) across time following immunisation with 
FMDV peptide. 2ug/ml FMDV15 peptide (C),and 10ug/ml Con A (D).  
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2, 4, 8, 10 and AUC were 0.01 (0.04), 0.01 (0.05), 5.6 (8.8), 13.1 (17.3), 24.3 (64.7), 
23.5 (71.7) and 144.4 (302.3) g/ml respectively. The means for the T cell 
stimulation index of response to the FMDV peptide at weeks 0, 4, 8, 10 and AUC 
were 1.131 (0.58), 1.8 (1.5), 2.6 (3.7), 4.6 (14.6), 21.9 (27.3) SI. 
 
Correlations between the time points and between traits (Table 2.1) revealed that 
there was a high correlation between the antibody levels at week 0 and 1 (r =0.88, 
p<0.01 for IgG1; r =0.61, p<0.01 for IgG2). Most of the significant correlations were 
positive.  The early IgG1 response (week 2) correlated with later responses at week 4 
(r =0.31, p<0.01) and 8 (r =0.26, p<0.01) and the pre-boost response at week 4 
correlated with the post-boost response at week 10 (r =0.69, p<0.01).  In addition 
responses at weeks 8 and 10 were also highly correlated (r =0.38, p<0.01). The IgG2 
response showed similar correlations in so far that earlier responses correlated with 
later responses, with the strongest correlations (r >0.4, p<0.01) seen between weeks 2 
and 4, weeks 4 and 8, and weeks 8 and 10.  Similarly, the pre-boost T cell response 
to the FMDV15 peptide at week 4 correlated with the post-boost response at weeks 8 
and 10 (r =0.224 and r =0.155; p<0.01), with the highest correlation between weeks 8 
and 10 (r =0.57, p<0.01).  The ConA T cell responses correlated moderately across 
all time points with r >0.2 (p<0.01), except between weeks 0 and 4 which had an r 
=0.12, which was not significant (p=0.1). 
 





Furthermore, correlations were found between some of the different trait types 
(Table 2.1).  The IgG1 and IgG2 responses were moderately correlated at the same 
weeks from 2 to 10 (r at least 0.21, all values p<0.01), with the exception of the 
correlation of IgG1 week 4 and IgG2 week 2.  No significant correlations were seen 
between the anti FMDV15 T cell response and IgG1 responses.  However, some 
weakly significant correlations were seen between the T cell response and the IgG2 
Figure 2.3: Box plots depicting the distributions of the fixed effects and covariates  
In all diagrams: Median (central horizontal line), quartiles (outer horizontal lines) and range (outer 
vertical lines) shown. 
The distribution of age (A and B) throughout the cohorts and lines, respectively. 
The distribution of calculated weight (C and D) throughout the different cohorts and lines, 
respectively. 
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response.  In addition the T cell response to the FMDV peptide correlated with the 







2.3.2 Analysis of fixed and random effects  
As reported above considerable variation was observed between animals for all three 
immune parameters, IgG1, IgG2 levels and T cell proliferation (Figure 2.2). The 
greatest variation among animals for both isotypes was seen at week 8 at which time 
the IgG2 response, was significantly greater than that of IgG1 (p<0.001). In addition, 
the proliferative response to ConA varied among animals and across time points 
following immunisation (Figure 2.2). The T cell proliferative response to the 
FMDV15 peptide (Figure 2.2) showed less variation among animals across the time 
points than the T cell proliferation to Con A. The skew (Figure 2.2) in the T cell 
response to the FMDV15 peptide changed over time, from a negative skew to a 
positive skew as more animals made a response in the later time points. 
 
When week was included as an interaction within the REML model, cohort was 
significant for both the T cell response to the FMDV peptide (p<0.001) and the T cell 
response to Con A (p<0.001). Further, weight at vaccination was found to be 
Table 2.1: Correlation matrix of traits  
Residuals for the REML model were used to calculate the correlations between each week and 
trait. r values that are +/- 0.2 are coloured grey and are significant to p<0.05 
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significant for both T cell response to the FMDV peptide (p=0.015) and the T cell 
response to Con A (p=0.019), with immune levels increasing with weight. Age at 
initial vaccination was only significant for the IgG2 responses to the FMDV peptide 
(p=0.005) and IgG2 levels increased with age. 
 
When the traits were analysed week by week (Table 2.2) cohort was significant 
throughout for each trait, with the exception of the IgG2 response to the FMDV15 
peptide. The effects of age and weight also differed: age at vaccination was 
significant at weeks 0 and 1 for IgG1 responses and only at week 1 for IgG2 
responses.  No significant age effect was found for either of the T cell proliferation 
responses. Weight was found to be significant for T cell proliferation to the FMDV 
peptide at week 8 post vaccination (p=0.049). Line (F2, CB1, HB1) was not a 
significant factor for any traits. The distributions of age and weight within the 
cohorts and lines are shown in Figure 2.3. No significant interactions were 
discovered, with the exception of an age difference in cohort 1. This however, was 
only significant at week 0 and week 1 post vaccination for the IgG1 and IgG2 
responses. 
 
Sire and dam effects varied throughout the study (Table 2.2). No significant sire 
effects were seen for IgG1 responses and only some dam effects were detected, 
however most dams only had one calf. The IgG2 response had no significant dam 
effects whereas sire was significant from weeks 2 to 10 inclusive (all p<0.05, with 
weeks 8 and 10 being p<0.005). The T cell proliferation responses showed no 
significant association with sire or dam, with the one exception of a dam effect at 
week 0 for the Con A response (p=0.005). 
 







2.3.3 Overall QTL Results  
A total of 77 QTL were identified for all 4 of the trait types (IgG1 and IgG2 
concentrations; T cell proliferation to Con A and FMDV15 peptide) studied (Table 
2.3). Of these, 11 were above the 1% chromosome significance threshold (but below 
the genome wide 5% significance threshold), 2 were above the genome wide 5% 
significance threshold (but below the genome wide 1% significance threshold) and 1 
was above the 1% genome wide significance threshold. The initial analysis revealed 
54 QTL, and a further 23 were located by fitting each QTL as a background effect. 
The majority of the confidence intervals (CI) (Appendix 2.2) were large with an 
average of 72.8cM., calculated across all QTL above the 5% chromosome wide 
significance level.  The CI reflected the estimated QTL effect size, the number of 
animals used in the study and the density of the markers used. The average 
Table 2.2: Factors used in the REML model and their significance 
Only p-values <0.05 are shown for each week for all four traits. Line was not significant for any 
trait at any time point. 
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phenotypic variance (corrected for fixed effects) accounted for in this study across all 
QTL above the 5% chromosome wide threshold was 5.8%. A total of 46 significant 
additive effects were found (Table 2.3). In 18 of these instances the Charolais allele 
increased the traits’ values, whereas the remaining 28, the Holstein allele increased 
the traits’ values. Dominance effects were significant in 42 QTL.  
 
Each of the four trait types (IgG1 response; IgG 2 response; T cell response to 
FMDV and T cell response to Con A), were clearly under polygenic control (Table 
2.3 and Table 2.4), and no QTL were found that controlled all traits. Of the 77 QTL 
detected, the majority (51) played a role in determining the FMDV15 specific 
antibody responses, whereas fewer (26) controlled the T cell response to FMDV15 
and Con A.  
 
With few exceptions, different QTL were detected at different time points. The 
majority of QTL appeared to be specific for a given trait type or for early or late time 
points, suggesting that T cell and antibody response must be, in the main, under the 
control of different genes (Table 2.4). A few chromosomal regions appeared to 
control more than one type of response in particular QTL on BTA 20 (Figure 2.4 and 
Table 2.3), BTA 23 (Figure 2.4) and BTA 25 (all 3 BTA shown in Table 2.3) 
impacted on the greatest number of traits (9, 9 and 7 respectively). QTL on BTA 4, 
19, 20 and 23 all played a role in both the primary and secondary responses (Table 
2.4), whereas QTL on BTA 20, 23, 24 and 25 all affected the FMDV15 specific IgG1 
and IgG2 at several time points (Table 2.4), although the QTL located on BTA 25 
specifically influenced the primary IgG1 and IgG2 responses and not the secondary 
antibody responses. In contrast the QTL on BTA 24 was detected for the secondary 
responses of both antibody isotypes but not the primary responses. Interestingly, the 
QTL on BTA 23 influenced earlier time points for the IgG1 response, and not the 
IgG2 response (Table 2.4 and Figure 2.5). A QTL with a strong additive effect 
(p<0.01) was identified on BTA 23 associated with the IgG2 response at week 10, 
where the additive effect of the Holstein allele was an increase of 10.5 g/ml. IgG2 
responses in week 8 on BTA 12 and 15, both showed large dominance effects of 17.4 
g/ml and 11.0 g/ml (p<0.01 and p<0.1, respectively). 
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Very little overlap was observed in the chromosomal regions controlling the T cell 
response to the FMDV 15 immunising antigen, and the T cell response to the T cell 
mitogen, ConA, with the exception of QTL on BTA 6 and BTA 29.  In addition, very 
little overlap was seen between QTL controlling the T cell responses and the 
antibody responses, with the exception of the QTL on BTA 20, which appeared to 
play a role at several time points for both antibody isotypes as well as the T cell 
response at the initial immunisation time point.  Indeed the QTL with the highest F 
value (10.07; 1% genome wide significance) in the study was for the AUC 
measurement for the anti-FMDV15 IgG1 response, and was located on BTA 20, 
where the clusters of QTL controlling IgG1 and IgG2 traits are also located.  This 
QTL alone accounted for 9.8% of the variance for the overall IgG1 response.  Other 
highly significant QTL included a QTL on BTA 24 for the IgG1 response at week 8 
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2.3.4 2 QTL Model  
Following the initial analysis, each QTL was added as background effect and 2 QTL 
models were run.  This analysis identified 3 significant 2 QTL models (Table 2.3). 
These included the T cell response to Con A at Week 0 on BTA 5; T cell responses 
to the FMDV15 peptide at Week 8 (Figure 2.6) and AUC, both on BTA 6. Each of 
these pairs of QTL on single chromosomes had at least two markers separating them.  
 
Chromosome 1 Trait 2 cM 3 F 4 a 5 d 5 Var% 6 
2 IgG1_week_10 38cM 5.60 -0.21** 0.26** 5.71 
3 IgG2_week_2 58cM 5.93 0.66** 0.40 6.03 
4 IgG1_week_1 31cM 5.35 -0.63** 0.34 5.46 
4 IgG1_week_8 20cM 5.17 0.12 0.17** 1.18 
4 IgG1_week_10 27cM 4.92 0.23 -0.47* 5.05 
4 IgG1_AUC 28cM 6.37* 0.11 -0.43* 6.64 
4 SI_FMDV_Week_0 67cM 4.79 0.00 -0.14** 4.92 
5 SI_CA_Week_0 68cM 8.10* -0.13* 0.24** 8.05 
5 SI_CA_Week_0 100cM 5.76 0.22** -0.14 6.11 
5 SI_CA_Week_10 76cM 5.26 -0.05 0.23** 5.38 
5 SI_CA_10ug_AUC 69cM 5.89 -0.06 0.17** 6.04 
6 SI_CA_Week_0 30cM 8.69** 0.26*** 0.08 8.59 
6 SI_FMDV_Week_8 59cM 6.49 0.14** -0.08 6.56 
6 SI_FMDV_Week_8 133cM 7.35* 0.04 -0.20*** 7.51 
6 SI_FMDV_Week_10 3cM 6.61 0.12** -0.15* 6.67 
6 SI_FMDV_AUC 2cM 7.91* 0.10*** -0.07 7.96 
6 SI_FMDV_AUC 133cM 6.21 0.03 -0.13** 6.56 
7 IgG2_week_8 0cM 6.24 -0.85*** 0.13 6.58 
7 SI_CA_Week_10 0cM 4.89 0.05 0.28** 5.02 
7 SI_FMDV_Week_4 54cM 5.45 -0.11** -0.09 5.62 
9 IgG1_week_0 40cM 5.29 -0.2948* 0.35 5.41 
9 SI_FMDV_Week_10 63cM 4.92 0.05 -0.23** 5.05 
11 IgG1_week_0 0cM 5.26 0.25 -0.61* 5.38 
12 IgG2_week_8 17cM 5.44 -0.03 1.24*** 5.56 
13 IgG1_week_1 0cM 5.08 0.04 -0.54** 5.20 
14 IgG2_week_0 2cM 4.85 0.12 -0.28** 4.98 
15 IgG2_week_8 13cM 5.16 -0.08 1.03** 5.28 
15 IgG2_AUC 27cM 5.39 -0.08 0.67** 5.51 
16 IgG2_week_2 76cM 6.51 -0.71*** -0.16 6.58 
16 SI_FMDV_AUC 64cM 4.42 -0.06* -0.07* 4.61 
18 SI_CA_Week_10 22cM 7.02* -0.20*** 0.10 7.06 
18 IgG2_week_1 57cM 5.23 -0.10 0.34** 5.40 
19 IgG2_week_2 28cM 4.93 -0.50* -0.62* 5.06 
19 IgG2_week_4 34cM 5.64 -0.73*** -0.32 5.75 
19 IgG2_week_8 50cM 5.28 -0.81** -0.25 5.63 
19 SI_CA_Week_8 32cM 8.57* 0.25*** -0.07 8.48 
19 SI_CA_Week_10 32cM 4.54 0.15* -0.13 4.67 
19 SI_CA_10ug_AUC 28cM 4.42 0.13** -0.01 4.61 
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20 IgG1_week_2 28cM 4.74 -0.03 0.48** 4.87 
20 IgG1_week_4 36cM 7.86* 0.20** 0.35** 7.83 
20 IgG1_week_8 9cM 6.49* 0.19 0.64** 6.56 
20 IgG1_week_10 23cM 5.37 0.09 0.38** 5.48 
20 IgG1_AUC 20cM 
10.07**
* 0.12 0.39*** 9.82 
20 IgG2_week_4 32cM 7.48 0.52** 0.65* 7.48 
20 IgG2_week_8 25cM 8.46 0.76** 0.87* 8.38 
20 IgG2_week_10 31cM 6.23 0.33 0.82** 6.31 
20 IgG2_AUC 31cM 8.5* 0.40** 0.67** 8.41 
20 SI_FMDV_Week_0 61cM 7.95* 0.05 -0.18*** 7.92 
21 IgG1_week_2 69cM 4.96 -0.22* 0.38* 5.09 
21 SI_CA_10ug_AUC 84cM 4.10 -0.14** -0.01 4.28 
23 IgG1_week_0 78cM 5.11 -0.19 -0.54** 5.24 
23 IgG1_week_1 65cM 5.83 -0.13 -0.87*** 5.92 
23 IgG1_week_2 39cM 4.16 0.37 -0.53 4.31 
23 IgG1_week_10 18cM 5.25 0.37** 0.03 5.37 
23 IgG1_AUC 18cM 5.34 0.29** 0.06 5.46 
23 IgG2_week_4 0cM 5.45 0.63** -0.18 5.57 
23 IgG2_week_8 5cM 5.85 0.88*** -0.18 5.94 
23 IgG2_week_10 33cM 4.08 1.02** 0.77 4.23 
23 IgG2_AUC 6cM 6.61* 0.66*** -0.18 6.67 
24 IgG1_week_8 35cM 7.83** 0.58*** 0.32 7.80 
24 IgG1_week_10 33cM 4.18 0.27** 0.06 4.32 
24 IgG1_AUC 33cM 6.23 0.25*** 0.12 6.31 
24 IgG2_week_10 21cM 5.09 0.69** 0.61 5.32 
24 SI_CA_Week_4 34cM 5.46 -0.05 0.28** 5.63 
25 IgG1_week_0 0cM 4.48 0.34* 0.28 4.62 
25 IgG1_week_1 0cM 4.88 0.29* 0.35* 5.01 
25 IgG1_week_2 33cM 4.42 0.05 -0.35** 4.66 
25 IgG2_week_1 15cM 4.48 0.18** -0.11 4.62 
25 IgG2_week_2 34cM 4.65 -0.14 -0.73** 4.78 
25 IgG2_week_4 34cM 4.85 -0.14 -0.70** 4.98 
25 IgG2_AUC 34cM 5.28 -0.04 -0.62** 5.40 
25 SI_CA_Week_10 17cM 5.79 -0.11* 0.19** 5.89 
26 IgG1_week_1 21cM 4.90 -0.30* 0.35 5.25 
27 IgG2_week_4 7cM 4.61 -0.57** -0.33 4.75 
29 SI_CA_Week_0 0cM 5.34 0.15** -0.11 5.69 
29 SI_FMDV_Week_8 7cM 4.90 -0.10* 0.12 5.03 
29 SI_FMDV_Week_10 0cM 4.38 -0.11** 0.08 4.61 
 
Table 2.3: All QTL located in this study  
1. Chromosome: the chromosome number of the QTL. Underlined if 2 QTL model. 
2. Trait: each trait is shown as follows: trait type (IgG1; IgG2; SI_FMDV = T cell proliferation to 
the FMDV peptide; SI_CA = T cell proliferation to Concanavalin A), followed by week post 
immunisation.  
3. cM: the position the QTL is on the chromosome, in centiMorgans. 
4. F: the F-statistic for each QTL. Significance level: all are at least 5% chromosome wide, * 
=p<1% chromosome wide, **=p<5% genome wide and ***=p<1% genome wide. 
5. “a” and “d” are the additive and dominance effect, respectively, of each QTL, * =p<5%, 
**=p<1% and ***=p<0.01%. 
6. Var%: the phenotypic variance explained by the QTL.  
Clusters of related traits have been boxed, 6 in total. 
Chapter Two – QTL associated with FMDV  
 57 
Table 2.4: Chromosomal positions of all QTL 
1. Trait = immune response type to the FMDV15 peptide 
2. Week post immunisation  
3. Bos Taurus Autosome (BTA ) number 
4. Each ‘X’ represents the presence of a QTL, ‘XX’ represents 2 QTL. All are at least 5% 
chromosome wide significant 
(AUC results are omitted as they are representative of the overall response across time.) 
 
2.3.5 Clusters  
Although a few chromosomes (BTA 2, 3, 11, 12, 13, 14, 26 and 27) only appeared to 
have QTL affecting an individual immune-related trait at one time point, several 
chromosomes had QTL affecting a trait across time.  All chromosomes with greater 
than 3 QTL for the same trait across time (e.g. IgG1 weeks: 0, 2 and 4) with 
overlapping CI are shown with outline boxes in Table 2.3, and are referred to as 
“clusters”.  There were 6 such clusters located on BTA 4, 5, 6, 20, 23 and 25 (Figure 
2.4 and Figure 2.5 also Table 2.4). The most significant QTL in the study was 
located within the clusters of QTL for IgG1 and IgG2 responses on BTA 20 (Figure 
2.5).  This region also influenced the T cell response to FMDV15 at the time of 
immunisation.  BTA 23 contained two QTL clusters for IgG1 and IgG2 responses. 
All of the clusters, with the exceptions of the clusters on BTA 4 and BTA 5, had 
additive effects showing Holstein alleles increased the phenotype. 
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2.4 Discussion  
This study has revealed that both the humoral and cell mediated immune response to 
a relatively simple 40-mer peptide are under the control of a considerable number of 
chromosomal loci. This study is also unique in that it was possible to measure both a 
primary and secondary immune response across time and thus detect QTL that 
influenced different phases of the immune response (Table 2.4).  Most other studies 
in livestock mammals which have investigated immune or infectious disease related 
QTL have typically focused on infectious disease related phenotypes and generally 
identified QTL from animals exposed to natural infections and not experimental 
challenge. This is particularly true for cattle where QTL have been reported for 
disease resistance in general [129] or resistance to a pathogen [5, 55, 130-132]. In all 
of these studies the phenotypes relied on veterinary observations.  In contrast, the 
phenotypes described in the present study were all obtained using a standardised 
experimental protocol and a uniform dose of a specific antigen. This may, at least in 
part, explain the large number of QTL detected.  The outcomes of disease resistance 
or vaccine induced protection are likely to depend on a range of immune-related 
mechanisms.  The present study concentrated on some of these underlying traits, 
namely antibody and cell mediated responses. 
 
Unexpectedly, a number of QTL were detected for the 0 time point for both antibody 
and T cell proliferation.  It is difficult to interpret these results as the animals were 
naïve to the FMDV peptide.  In a previous study it was noted that the control values 
for T cell proliferation were under genetic control [133], and thus the QTL for the T 
cell proliferation to the FMDV peptide at time 0, may be related to the inherent 
ability of T cells in culture to proliferate.  Measurements of cellular immunity are 
inherently more difficult to conduct than measurements of humoral immunity, partly 
because cell based assays have to be conducted with fresh cells.  For the work 
reported here a high-throughput system had to be devised to measure the cellular 
immune response to the FMDV peptide in large numbers of animals.  Whole blood 
rather than purified peripheral blood mononuclear cells was used, and T-cell 
proliferation was measured on day six for logistical reasons, which may have 
resulted in greater variation compared to the proliferation response by purified 
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peripheral blood mononuclear cells. A further factor that may explain the high 0 time 
values is that the FMDV peptide contains an “RGD” motif which enables the FMDV 
virus to bind to integrins on the cell surface to facilitate virus entry [134]. 
Fluorescently labelled FMDV peptide has been shown to bind to a wide variety of 
cells (Glass unpub.obs.) potentially through integrin binding.  In addition it is 
possible that there are soluble molecules in serum that bind to the “RGD” motif in 
the peptide coated on the ELISA plate: this may well have caused a “background” 
non-FMDV specific binding.  Thus possibly the QTL might be reflect variants in 
integrin molecules.  The genes for the main integrin receptor by FMDV for entry into 
cells are ITGAV and ITGB6 on BTA 2 (unpub.obs) which does not appear to 
influence the values for the 0 and 1 time points.  Nonetheless, the values seen at time 
0, for both antibody and proliferation, are orders of magnitude lower than the 
adaptive immune responses generated to the peptide, and for the main part the time 0 
values did not correlate with the responses observed at later time points. 
 
Previous research by members of the Glass group and others have implicated the 
MHC locus as an important factor in determining the immune response to peptides 
derived from FMDV as well as protection against viral challenge [117-119]. A 
previous study [119], using the same population of animals indicated that MHC 
DRB3 alleles and polymorphisms in pocket 4 of the peptide binding cleft were 
significantly associated with the variation in response to the peptide. The study 
described here also detected QTL on BTA 23 covering the MHC locus (BoLA) [43] 
which were significantly associated with both the IgG1 and IgG2 responses across 
time, emphasising the importance of this locus in influencing the immune response 
and adding further confidence to the QTL found in the current study.  However the 
current study has shown that even the response to a relatively simple antigen is 
complex and controlled by many loci.   
 
Throughout the study the cohort of the animals was significant (the cohorts 
correspond to the year of birth of the animals). Environmental sources of variation 
were minimised as far as possible, including husbandry, food, food supplements and 
farm.  Cohort was, however, found to be significant in the same herd for response to 
Chapter Two – QTL associated with FMDV  
 60 
a BRSV vaccine [52], a mastitis causing pathogen [133] as well as in meat and milk 
traits [104]. Weight and age at vaccination were also significant throughout the 
study. Linear regression of IgG1 AUC against age showed that the older animals had 
significantly higher immune responses.  This suggests that even in older animals the 
immune system may still be developing, although possibly these changes may be 
hormonally related as all the animals in this study were female and there are clear  
gender and hormone related differences in immunity [135]. The increase in response 
is not a result of exposure to FMDV, unlike the situation for endemic pathogens such 
as BRSV which could conceivably influence the response to BRSV derived 
antibody.  Age was also a significant factor in the IgG1 and IgG2 response to a 
BRSV vaccine in this experimental herd [52]. However, the animals were much 
younger than in the present study.  
 
Significant breed effects have previously been shown for response to a BRSV 
vaccination [52], but not in response to Staph. aureus [133]. The current study also 
did not find any breed effects.  It is possible that the founder breeds, Holstein and 
Charolais, have similar immune responses to the FMDV15 peptide, although this has 
not been formally tested. Villa-Angulo et al [136] have shown that Holstein and 
Charolais cattle breeds have highly correlated haplotype blocks, thus it is feasible 
that the similar immune response seen in this study is due to the two breeds being 
highly related.  However, within the QTL study 6 of the 8 QTL clusters had 
increased phenotypes resulting from Holstein alleles, indicating that there might be 
breed differences in the pathways used to initiate and maintain a response to the 
FMDV15 peptide. Sire effects have previously been demonstrated in this herd, both 
in the immune response to a BRSV vaccine [52] and also to Staph. aureus [133]. In 
the present study sire effects were only significant for the IgG2 response to the 
FMDV15 peptide. Dam was only sporadically significant without any obvious 
patterns to explain the weeks it appeared significant. However, the number of calves 
per dam was small, so it is unlikely that enough statistical power existed to detect 
dam effects. 
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The immune response is a complex trait and across time different factors will play a 
role in affecting the level of a particular response e.g. the initiation of an immune 
response involves components of innate immunity such as macrophages and 
dendritic cells which signal alarm to the adaptive immune system which takes longer 
to respond to immunisation and invasion by pathogens.  In addition, the primary 
response is under the influence of different factors from the secondary response, 
which is generally of greater magnitude and longer duration.  Nonetheless, several 
QTL which influenced the same traits were detected across time, suggesting that 
there may be gene(s) that impact on both the primary and secondary responses. Thus 
genetic factors may underlie some of the significant correlations across time and 
within traits (Table 2.4). The data presented here also suggests that there are several 
loci which have more specific effects either at single time points or on specific 
immune traits, which may reflect the different cell types and factors operating at 
different phases of the immune response. 
 
Inter-trait correlations were observed between the IgG1 and IgG2 responses (Table 
2.3), although for the most part the QTL controlling these traits did not coincide on 
the same chromosomes, with the notable exceptions of the QTL on BTA 23, 95% 
confidence interval of which harboured the BoLA locus, and BTA 20.  Both of these 
chromosomes may have genes that control both types of antibody response across 
time.  All animals had considerably higher IgG1 than IgG2 responses, with a 
proportion having no detectable IgG2 response at any time point [119]. The QTL 
with the greatest influence on the overall IgG1 responses were BTA 4, 20, 23 and 24 
which together accounted for over 25% of the variance.  Apart from BTA 20 and 23, 
two different regions on BTA 15 and 25 were also linked to the overall IgG2 
response, and these 4 regions also accounted for over 25% of the variance for overall 
IgG2 response.  In cattle it appears that IgG1 is associated with type 2 T cell 
responses and IgG2 with type 1 [137].  Thus regions controlling the differing 
responses may harbour genes that influence the balance between Th1 and Th2 
responses; plausible candidate genes under QTL include IL18 on BTA 15 and IL4R 
on BTA 25. 
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The T cell responses to the ConA mitogen and the FMDV15 peptide were also 
correlated, in particular the responses at the same time points. This was unexpected 
as immunisation with the FMDV15 peptide should not influence the responses to 
ConA, as the latter is a T cell mitogen.  One possible explanation may be that the T 
cells stimulated by the FMDV peptide become more responsive to T cell mitogens; 
indeed proliferation was observed in the presence of medium alone and increased 
across time, suggesting that immunisation may have activated the overall T cell 
population.  However, with the exception of BTA 6, 7 and 29, no co-incident QTL 
for T cell response to ConA and FMDV15 were observed.  
 
Interestingly, every QTL cluster, with the exception of the cluster on BTA 25, 
contained at least one QTL above the 1% chromosome-wide significance level. Thus 
the clusters appear to highlight regions of the bovine genome that are highly 
associated with the immune response to the FMDV15 peptide. The two clusters 
containing the QTL associated with the greatest number of traits were located on 
BTA 20 (Table 2.3; Figure 2.4) and 23 (Table 2.3; Figure 2.5; both included in Table 
2.4). The cluster located on the telomeric region of chromosome 20 has highly 
significant dominant effects, suggesting that over-dominance may have a role to play 
in these QTL. Further, this region has also been associated with a number of 
diseases, including resistance to Mycobacterium avium ssp Paratuberculosis the 
causative bacterium of Johne’s disease [130], bovine keratoconjunctivitis (pinkeye) 
[55]and respiratory disease and pododermatitis (footrot) [4]. Taken together with the 
data presented here this suggests that gene(s) located in this region may control the 
response to several bacterial and viral pathogens, possibly by influencing antibody 
production. The current data suggest that the gene(s) underlying this QTL impact on 
the antibody responses across time. Further research to identify the gene(s) 
underlying these associations is warranted as they may represent genes for 
“generalised immune competence” or resistance to a broad range of pathogens. 
 
The QTL cluster located on BTA 23 includes the bovine MHC (BoLA) region [43]. 
However, few markers were spaced across BTA 23, and the QTL CIs covered the 
whole of BTA 23. Baxter et al  [119] recently reported that the highly polymorphic 
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BoLA DRB3 gene is significantly associated with the response to FMDV15 in this 
herd and earlier studies have indicated that DRB3 polymorphisms are also linked to 
protection against viral challenge following immunisation with FMDV15 and similar 
peptides [118]. It is therefore likely that the causal genes underlying the part of the 
BTA 23 QTL effect may be coded for within the BoLA region.  However, there are 
at least 154 predicted genes in this region [68], which may make it difficult to 
identify the causative mutations.  
 
The QTL cluster on BTA 6 overlaps with a QTL that is associated with a mastitis 
related trait [132].  Recently Jann et al [138] have identified the toll like receptor 
(TLR) cluster of TLR1, 6 and 10 genes as the most likely candidate genes within this 
region on BTA 6. TLRs play an important role in both innate and adaptive immunity 
[139]. Villa-Angulo et al  [136] demonstrated that BTA 6 has haplotype blocks that 
are similar (r = 0.61) between the breeds used in the current study, thus the genes in 
both breeds are likely to be in the same regions and orders in the cluster of TLR 1, 6 




QTL have been associated with a variety of traits in diseased and infected animals 
[129]. This study focused specifically on immune responses across time following a 
specific immunisation procedure to identify QTL controlling defined immune 
responses. The density of markers and numbers of animals used is not sufficient to 
fine map the QTL regions identified, however, further work is warranted especially 
to refine the QTL clusters, which appear to be the most promising regions.  With the 
availability of the bovine genome sequence [68], the bovine HapMap [140] and 
dense bovine SNP arrays [141] unprecedented opportunities are now available to 
identify genes and pathways underlying immune-related traits.













Chapter 3  
 
____________________________________________________________________ 
Quantitative trait loci associated 
with the immune response to a 
Bovine Respiratory Syncytial 
Virus vaccine  
____________________________________________________________________ 
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3.1 Background  
In this chapter the same theory, methodology and animals were used as with chapter 
2, except that a different immunogen, Bovine Respiratory Syncytial Disease Virus 
(BRSV) vaccine was used to elicit an immune response over time. A linkage analysis 
was completed using the antibody response to the BRSV vaccine as the phenotype.  
Finally, the immune responses to the two immunogens were analysed for possible 
correlations, and overlapping QTL. 
 
BRSV is a pneumovirus. Like many viruses BRSV is constantly evolving, with 12 
strains currently reported (www.ncbi.nlm.nih.gov/Taxonomy). The virus consists of 
11 proteins with two accounting for much of its variability. The first being the most 
variable protein within the virus, the G (Glycoprotein) protein, which varies in size 
depending on which isolate is being studied, but contains a conserved region in all 
strains [142-143]. The G protein is also found in two forms: a membrane bound form 
and a secreted form, which inhibit the activation of an  immune response [143]. The 
second protein is the F (Fusion) protein, which is also a surface protein on BRSV. 
The F protein is the mediator protein which aids BRSV binding to host cells [143]. 
 
The virus not only infects cattle, different strains affect sheep, goats and humans 
(HRSV) [144]. It is endemic in the Western world and a major cause of respiratory 
infections in livestock worldwide. It also causes high morbidity and thus has a high 
economic cost. In cattle the outcome of a BRSV infection is widely variable 
depending on a number of factors including age and sex [145]. In general, natural 
infection induces poor immunity and re-infection is common. Such is the variation 
within the immune response that naïve cattle can be severely affected, or, display 
little or no clinical signs, when infected [146]. In young cattle the virus is particularly 
difficult to immunise against, partially due to maternally derived antibody interfering 
with vaccination [144, 147-148]. O’Neill et al have shown a heritable component to 
BRSV is present, potentially allowing for breeding for increased IgG levels post 
BRSV vaccination. 
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Vaccination is a popular method of control for BRSV with both inactivated and live 
strain vaccines available. Administration is often via the mucosal route as this is the 
natural route of infection [142-143, 148]. However, there is still no consensus over 
which form of vaccine is best, especially in relation to vaccinating young calves, as 
infection is possible before the vaccination course is complete [142, 148]. Immunity 
to BRSV is generally considered to require neutralising antibody, but cellular 
immunity also plays an important role. However, cellular immunity may also induce 
pathology [149]. The balance between Th1 versus Th2 responses may be critical in 
determining the outcome of BRSV vaccination and infection, in addition, an 
optimum level and timing of each type of response may be required to ensure that 
vaccines are protective and do not predispose to disease. The Th1 cytokine, 
interferon-γ (IFNγ) has been associated with protection against BRSV pathology 
[150-152] as has the corresponding Th1 antibody isotype ,IgG2 [150]. However the 
Th2 associated antibody isotype, IgG1, may be required for viral clearance and 
protection [153]. It therefore seems likely that a balance between both Th1 and Th2 
responses are required for optimal protection and reduced pathogenesis. In addition, 
little is known about the reservoir sites the virus uses, or how cattle eventually shed 
the virus [144]. 
 
Genetic loci have been shown to play a role in human susceptibility to the related 
pathogen, Human Respiratory Syncytial Virus (HRSV) [154], and as the 
epidemiology and pathology of HRSV and BRSV are similar [143],  it is possible 
that at least a proportion of the variation in BRSV outcome, may be related to the 
genetically controlled response to HRSV infection. However, to date, no study of the 
genetic loci controlling the response to a BRSV infection has been conducted in 
cattle. 
 
A previous study investigating the BRSV vaccine using the RoBoGen herd [52] 
showed that the vaccine induced a good immune response within the RoBoGen 
population, yet individual animals had highly variable levels of antibody response. 
O’Neill et al [52] went on to show that this variation was indeed influenced by 
genetic factors, such as sire, sex and pre-existing antibody. I have followed up the 
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work of O’Neill et al [52], and conducted a quantitative trait loci (QTL) study, to 
investigate the contribution of different regions of the genome to the genetic 
variation described in the O’Neill et al study. In chapter 2 and this chapter the 
immune responses to the BRSV vaccine and the FMDV peptide were measured 
using the same animals, across time. Thus I was also able discover some correlation 
between the traits from chapter 2 (FMDV) and this chapter (BRSV). In addition I 
was able to detect specific regions of the genome that appeared to control the 
response to BRSV vaccination as well as to the FMDV peptide.
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3.2 Materials and methods 
3.2.1 Acknowledgements 
All statistical analysis, within this chapter, was conducted by Richard Leach. All the 
laboratory based assays, in this chapter, were completed by Ronan O’Neill. 
Immunisations were done by the Roslin Institute farm staff. John Williams’ group 
completed the genotyping of the RoBoGen herd with the microsatellite markers. 
 
3.2.2 Animals  
The second generation of the RoBoGen herd was vaccinated with the BRSV vaccine. 
All male calves had unrestricted suckling with their dams, at grass, until 
approximately 4 months old. All female calves were weaned by 36h, segregated from 
the rest of the herd and raised indoors, initially on milk-replacer then weaned early 
onto a propriety compound diet. Any differences in the results observed between 
sexes were therefore compounded by differences in management. 
 
3.2.3 Phenotypic Data 
3.2.3.1 Vaccination with Rispoval and sampling 
Immune response measurements were collected on 468 second generation crossbred 
calves (294 F2, 90 HB1 and 81 CB1). The age at first immunisation with the BRSV 
vaccine (Rispoval ©, Pfizer Animal Health, Surrey, UK) ranged from 88-195 days. 
All animals were vaccinated and IgG levels measured as described by O’Neill et al 
[52]. Each animal received 2ml of the attenuated live vaccine, intramuscularly, 
according to the manufacturer's recommendations. All calves were re-immunized 
with 2ml of the vaccine intramuscularly, 3 weeks following the initial vaccination. 
Blood samples were collected by jugular venipuncture: 4 and 2 weeks pre-
vaccination; at week 0 (the day of first vaccination) and at 2, 5 and 7 weeks post-
vaccination, providing six samples per calf. Serum was collected within 2h of 
sampling and stored at −20 C until testing. 
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3.2.3.2 ELISA for detection of BRSV-specific total IgG, IgG1 and IgG2 
This assay was carried out as described in O’Neill et al, 2006 [52]. Briefly, sera were 
tested quantitatively by solid-phase antibody capture ELISA specific for total BRSV-
IgG according to the manufacturer’s guidelines (Svanovir BRSV-Ab, Svanova 
Biotech, Uppsala, Sweden). Samples were tested in duplicate, at a dilution of 1/25 
and optical densities (OD) read at 450nm. The corrected optical density value for 
each sample and the control sera was calculated by subtraction of the OD value of 
each control antigen-coated well from that of the corresponding viral antigen-coated 
well and the relative optical density (ROD) value for each sample was calculated as a 
proportion of a positive control serum on a per-plate basis. 
 
BRSV-IgG2 levels were tested using a modified form of the above assay. All 
dilutions were as described above but 100l of 1/10,000 horse-radish peroxidase-
conjugated anti-bovine IgG2 (Acris Antibodies GmBH, Hiddenhausen, Germany) 
was used as the secondary antibody. The corresponding ROD values were also 
calculated as above. To obtain the IgG1 levels, IgG2 was subtracted from the total 
IgG. 
 
Area under the curve (AUC) for each trait was also calculated (using the trapezoidal 
rule [35]) to provide a single trait that reflected the overall response of each animal 
(explained further in section 2.2.5). 
 
3.2.3.3 Immunisation with the FMDV15 peptide  
Please see section 2.2.3 
 
3.2.4 Statistical Analysis  
The IgG concentrations were log10 transformed to obtain a normal distribution and 
constant variance, allowing for REML analysis.  
  
Significant factors, such as sire, within this study have been previously calculated by 
O’Neill et al [52] . For the QTL calculation, the final model included sire and dam as 
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random effects; the fixed effects within the model, with appropriate degrees of 
freedom (df), were line (F2, CB1, HB1; 2d.f), age (age at vaccination), cohort (1, 2, 
3; 2d.f) and calculated weight (weight of the animal at first vaccination date 
calculated from regression of animal weight at other time points pre and post 
vaccination).  
 
Thus the model was: 
Yijk= µ +L+C+S+β1.m+β2.a+uj+gk+eijk 
 
Where: Yijk is the observed value of the phenotypic trait; µ, population mean; L, the 
fixed effect of line (3 Lines); C, the fixed effect of cohort (3 Cohorts); S, the fixed 
effect of sex (male or female); β1, the linear regression on the covariate of age at 
vaccination m (m = d469-d609); β2, the linear regression on the covariate of weight a 
(a= 361-744kg); uj, the random effect of sire; gk, the random effect of dam g; eijk, the 




The residuals, for each time point, from the REML models were saved and used to 
calculate all the correlations between the immune responses at differing time points 
throughout the study. With the exception of sex, the same REML models were as 
used in the previous FMDV study [155]. 
 
A direct comparison of the IgG levels in response to the FMDV15 peptide could not 
be made with the IgG levels in response to the BRSV vaccine, as they were 
measured in differing units. Thus a Spearman’s rank correlation, using the residuals 
of the REML models, was used to calculate the correlations between the responses to 
the FMDV15 peptide and to the BRSV vaccine for animals that were tested for both 
traits (i.e. the 195 second generation females immunised with the FMDV peptide and 
vaccinated with BRSV vaccine). 
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3.2.6 Genetic Markers 
Please see section 2.2.6 
3.2.7 QTL Analysis 
Please see 2.2.7 
3.2.8 Refining QTL  
Please see 2.2.8 
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3.3 Results  
A total of 468 second generation (245 male and 223 female) animals of the 
RoBoGen Charolais X Holstein herd were phenotyped for total IgG, IgG1 and IgG2 
responses to a BRSV vaccine across time. The whole herd (984 animals) was 
genotyped with 165 microsatellite markers. The female heifers were both vaccinated 
with the BRSV vaccine and immunised with the FMDV peptide and the data from 
both studies were compared.  
 
3.3.1 Kinetics of vaccination  
Essentially all of the parameters of all the traits in this study have been previously 
described (for BRSV [52] and for FMDV [155]). A summary table of the means, 
ranges and standard deviations of the traits are presented here for clarity (Appendix 
3.1). Considerable variation between animals was apparent, although all animals 
made a significant response to both immunogens. In both studies, the IgG2 response 
was lower than the IgG1 response. 
 
All traits were analysed for possible correlations with each other and many 
significant correlations within specific traits were found across time (Appendix 3.2). 
The FMDV traits have been described previously [155] and similar results were 
found for the BRSV traits, in that the IgG1 and IgG2 responses to BRSV vaccination 
at earlier time points correlated with their next corresponding time points. Thus the 
IgG1 level at week 2 correlated with the IgG1 level at week 5 (r=0.26, p<0.01) and 
the IgG1 level at week 5 correlated with the IgG1 level at week 7 (r=0.69, p<0.01). 
Similar correlations were found for the IgG2 levels. Furthermore, each time point 
correlated with the AUC for each respective isotype level, with the highest 
correlation found between the IgG2 week 5 post vaccination and the IgG2 AUC 
measurement (r=0.79, p<0.01). The two BRSV specific IgG isotype levels were also 
significantly positively correlated with each other (Appendix 3.2). The highest 
correlation was between IgG1 and IgG2 at week 7 (r=0.47, p<0.01). As expected, 
there were also negative correlations between the levels of antibody at week 0 and 
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levels post-vaccination as the animals had pre-existing levels of IgG derived from 
colostrum, which inhibited the vaccine response [156-157].  
 
Correlations between the responses to BRSV vaccination and the FMDV15 peptide 
immunisations were analysed using Spearman’s rank correlations. It should be noted 
that the two immunisation schedules were carried out at completely different times, 
when animals were of different ages and thus they were unlikely to interact with each 
other. Few significant correlations were found between the responses to FMDV and 
BRSV, and these were generally low (Appendix 3.2). There was some evidence that 
the IgG2 isotype responses to both immunogens may have a relationship in that the 
FMDV specific IgG2 response at week 8 was correlated with the BRSV specific 
IgG2 response at week 5 (r=0.2 , p<0.01) and the FMDV IgG2 and the BRSV IgG2 
AUC measurements also correlated, with an r=0.15 (p<0.05).  
 
3.3.2 QTL Results 
A total of 27 QTL for BRSV response were discovered across 13 autosomes, with 9 
QTL found on the initial genome scan and 4 QTL discovered when background 
effects were taken it account (Table 3.1). Seven QTL were above the 1% 
chromosome level, and of these, one QTL on BTA 17 was at the 5% genome wide 
significance level, explaining 3.47% of the phenotypic variance (p) (Figure 3.1). 
The remaining 16 QTL were all above the 5% chromosome wide significance level.  
 
Of the 27 QTL detected, 16 were associated with the IgG2 response, whilst 7 QTL 
were associated with the total IgG response and only 4 with the IgG1 response. Thus 
loci accounting for a greater proportion of genetic effects controlling the phenotypic 
variance of the IgG2 antibody levels were identified in comparison to the total IgG 
and IgG1 antibody levels. However the traits are linked (as IgG1 and IgG2 are 
components of total IgG), and one QTL that spans time maybe counted multiple 
times, thus if multiple QTL have the same flanking markers upon a chromosome it is 
possible that they are the same QTL. If the 27 QTL are again summed taking this 
into account then there appears to be 17 individual QTL that exist independently of 
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time and trait (1 on BTA2; 2 on BTA3; 2 on BTA7; 1 on BTA8, BTA9, BTA10, 
BTA14 and BTA15; 2 on BTA17 and BTA18; 1 on BTA23, BTA24 and BTA28).    
 
 
Nearly all of the QTL (23) identified showed significant additive effects (p<0.05), 
whereas only 7 showed significant dominant effects (p<0.05). Both Holstein and 
Charolais derived alleles were shown to have additive and/or dominance effects on 
Table 3.1: All QTL located in this study 
1. Chromosome: the chromosome each QTL is located on.  
2. Trait: each trait is shown as follows: total IgG or IgG isotype response, followed by the 
week relative to vaccination.  
3. cM: the QTL position on the chromosome (centiMorgans). 
4. F: the F-statistic of each QTL, all are at least 5% chromosome wide, * 1% Chromosome 
wide and ** 5% Genome wide. 
5. “a” and “d” are the additive and dominance effects of each QTL, *=p<5%, 
 **= p<1% and *** = p<0.01%. 
6. Var%: the additive phenotypic variance explained by the QTL. 
Chromosome1 Trait2 cM3 F4 a5 d5 Var%6
2 Total_IgG_week_0 18cM 5.47 -3.67** 6.22** 2.11
2 IgG2_minus_week_2 19cM 6.25 -4.22* 9.07** 2.67
3 IgG2_minus_week_2 37cM 5.19 1.89 6.77** 2.24
3 IgG2_week_2 98cM 4.88 1.03** 0.35 2.12
7 IgG2_week_0 69cM 5.21 0.74** -0.1083 2.26
7 Total_IgG_week_2 22cM 4.92 3.97* -4.8454 2.14
8 IgG1_AUC 38cM 5.9 26.36*** -3.34 2.52
8 IgG1_week_7 44cM 5.63 4.77*** 0.32 2.42
8 Total_IgG_AUC 43cM 4.98 25.80** -3.62 2.12
8 Total_IgG_week_7 47cM 5.53 5.63*** 0.7997 2.40
9 IgG2_week_2 45cM 5.47 -0.87* 0.87 2.37
10 IgG2_week_0 53cM 7.01* -0.07 -1.03*** 3.01
14 IgG2_AUC 15cM 6.82* 13.67*** 5.77 2.92
14 IgG2_week_2 23cM 5.79 0.99** 1.19* 2.51
14 IgG2_week_7 16cM 5.82 4.14*** -0.13 2.51
15 Total_IgG_week_0 60cM 4.85 3.64** -2.73 2.10
17 IgG2_minus_week_2 15cM 4.88 -6.13 6.83 2.09
17 IgG2_minus_week_2 57cM 4.92 -6.44** 3.51 2.10
17 IgG1_week_2 76cM 8.17** -4.30*** 1.99 3.47
17 Total_IgG_week_2 76cM 6.67* -4.20*** 1.51 2.87
18 IgG2_week_2 19cM 7.29* -3.58*** -2.20* 3.15
18 IgG2_week_2 38cM 5.81* -0.96** -0.90 2.52
18 Total_IgG_week_7 18cM 5.27 -4.67** -1.83 2.28
23 IgG2_AUC 27cM 4.97 17.17** 1.71 2.15
23 IgG2_week_2 31cM 6.82* 2.03*** 0.36 2.86
24 IgG2_week_2 11cM 4.15 0.16 1.48** 1.81
28 IgG1_week_7 0cM 4.37 3.41* 0.64 1.89
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QTL. Fourteen of the 27 QTL with significant additive effects had the Holstein 
derived alleles increasing the trait value (4 total IgG QTL, 2 IgG1 QTL and 8 IgG2 
QTL); the other 9 had Charolais derived alleles increasing the trait value (3 total IgG 
QTL, 1 IgG1 QTL and 6 IgG2 QTL) as shown in Table 3.1. Seven QTL had 
significant dominance effects, and of these 3 QTL had dominance effects with 
increases of the trait attributed to the Holstein alleles (all IgG2 QTL), whilst 2 QTL 
were traceable to Charolais alleles increasing the trait (Total IgG QTL and one IgG2 
QTL). Overall, there did not appear to be a breed bias towards additive or dominance 
effects. However, the alleles derived from the Holstein breed appeared to increase 
the immune traits more frequently than the Charolais alleles in this study. 
 
The QTL associated with total IgG levels tended to overlap (+/- 7cM of the peaks) 
with either IgG1 or IgG2 QTL. Five of the seven total IgG QTL overlapped (BTA2, 
two on BTA8, BTA17 and BTA18; Table 3.1), reflecting the fact that the total IgG 
phenotype was made up from the components of the IgG1 and IgG2 phenotypes. 
These overlapping QTL also included an overlap between QTL associated with total 
IgG AUC and the IgG1 AUC on BTA 8 (Figure 3.2).  
 
A total of 8 QTL were associated with the IgG levels prior to vaccination, whereas 
the majority of QTL were associated with the response post vaccination and were 
mostly on different chromosomes from those associated with the pre-vaccination 
levels (Table 3.1). The trait with the greatest number of different QTL associated 
with it was the IgG2 response 2 weeks post vaccination, with a total of 7 QTL, in 
contrast to the single QTL associated with the IgG1 response at the same time point. 
Fewer QTL were associated with the antibody response following the vaccine boost, 
with only one associated with the IgG2 response at week 7, but two for the IgG1 
response at this time point. 
 
The most significant QTL were mainly associated with the IgG2 responses, with 5 of 
the 7 QTL above the 1% chromosome significance level (including the QTL also at 
the 5% genome wide significance level). These QTL also had other QTL within the 
confidence intervals for differing traits and time points (with the exception of the 
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QTL located on BTA 10, Table 3.1). For example: BTA 14 contains a QTL 
associated with the IgG2 AUC measurement at the 1% chromosome wide 
significance level (Figure 3.3) and within 8cM of the peak of this QTL are QTL for 
IgG2 week 2 and IgG2 week 7 post vaccination. In addition, another 2 QTL 
associated with the immune response post vaccination (IgG2 week 2, 1% 
chromosome wide and the IgG2 AUC measurement, 5% chromosome wide) were 
discovered on BTA 23, with their peaks separated by 5cM (Figure 3.4). 
 
Fourteen of the QTL identified in this study were within the confidence intervals of 
QTL detected in the FMDV study [155]. Further, the peaks of four of these QTL 
were within 10cM of QTL peaks associated with the response to the FMDV peptide 
and included BTA 9 at 45cM, BTA23 at 27cM and 31cM and BTA24 at11cM. Of 
the overlapping QTL, the QTL on BTA 23 were the most striking, as two QTL from 
both studies overlapped across the same regions of BTA23 (Figure 3.4) which 
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3.4 Discussion 
In this study I have discovered a number of distinct QTL which control the immune 
response to BRSV vaccination as well as clearance of maternal antibody in cattle. 
Although there was evidence for QTL within the MHC region on BTA23, the 
majority of the QTL described in this paper do not lie within this region. The results 
suggest that some chromosomal regions may control both the IgG1 and IgG2 
responses, however, most of the QTL detected appear to play a role in the IgG2 
response. This study is a follow on from a previous study of the same crossbred herd 
which found strong heritability (h2 =0.52 with respect to total IgG levels over time 
(day0-day35)) and significant sire effects in the IgG response post vaccination [52]. 
In the present study 27 significant QTL were associated with BRSV specific IgG1, 
IgG2 and total IgG levels, pre- and post-vaccination, which were located on 13 
bovine autosomes. The multigenic nature of the response must at least in part, reflect 
the complexity of host immunity. 
 
In the previous study the Holstein backcross calves were shown to exhibit 
significantly higher antibody levels than the Charolais backcross calves pre-
vaccination but not post-vaccination [52]. The QTL found in the current study did 
not reflect this, as both breeds had similar QTL additive effects, although the 
Holstein backcrosses generally had higher antibody levels pre-vaccination. This is in 
contrast to a study which investigated bovine keratoconjunctivitis [4], where the 
additive effects of QTL originated from a breed with known low prevalence of the 
disease [158]. This suggests that further QTL are yet to be discovered, which may 
explain the higher antibody levels in the Holstein backcross cattle pre-vaccination. 
Furthermore, most of the significant dominance effects of QTL associated with pre-
vaccination levels, were derived from the Charolais breed, suggesting a complex 
mode of inheritance may be responsible for the observed phenotypes, such as parent-
of-origin effects [159] or over-dominance [160]. Further studies would be warranted 
to investigate these dominance effects as breeding programs only utilise additive 
effects and not dominance effects [161]. 
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Although a considerable number of QTL were discovered in this study, there were 
fewer QTL than reported for the response to an FMDV peptide in the same 
RoBoGen herd [25] (Chapter 2). One reason for this may have been that in the 
current study the antibody levels were measured by a commercial kit intended for 
epidemiological surveys of prevalence and the sera were used at a fixed dilution 
(1/25). Whereas sera used in the FMDV ELISAs were titrated to identify the 
optimum dilution [25]. Thus it is possible that variation in IgG level in high titre 
samples, that were above the maximum O.D for the assay for anti BRSV antibody, 
would not have been detected. 
 
The persistence of circulating maternal antibodies has been shown to have an effect 
on the efficacy of vaccination against several important infectious diseases [162]. It 
is considered preferable to vaccinate calves against BRSV at an early age, because it 
is endemic, even though maternal antibodies affect BRSV vaccine efficacy [163]. In 
the present study the levels of anti-BRSV IgG were declining prior to vaccination, 
which is most likely due to the reduction in the levels of circulating maternal 
antibody [52, 157]. Thus the detection of QTL for antibody response post-
vaccination may have also been affected by the unknown effect of maternal antibody 
on the efficiency of immunisation.  
 
Eight QTL were detected associated with the BRSV-specific antibody levels pre-
vaccination. Two QTL on BTA 10 and 15, were not associated with the response 
post-vaccination, while the others were on chromosomes with post-vaccination QTL, 
but with apparently different peaks. These QTL may therefore reflect 
genes/pathways which are responsible for regulating the levels of maternal antibody. 
The transfer of IgG from dam to calf via colostrum has high heritability [164] and 
results presented here suggest that IgG transfer may be partly controlled by the 
genetics of the calf. Furthermore, the neonatal Fc receptor, a heterodimer consisting 
of a MHC class I -chain homolog located on BTA18 [165] and beta-2-
microglobulin (b2m), located on chromosome 10 [166], may play a significant role 
in regulating the level of maternal antibody [165]. Polymorphisms in the MHC -
chain homolog on BTA 18 have been associated with the levels of IgG in newborn 
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calves [165]. However the QTL detected on BTA18 were associated with the post-
vaccination response and not pre-vaccination levels. Furthermore, the gene for the 
MHC -chain homolog is located outside of the final marker on that chromosome, 
and thus outside the confidence intervals for these QTL; further genotyping in this 
region may be able to provide better resolution. In addition, the gene encoding b2m, 
which has been associated with the failure of transfer of maternal IgG to calves [167] 
is positioned just outside of the confidence interval of the pre-vaccination QTL 
located on BTA10 which was the only QTL detected in the current study on this 
chromosome. Addition of markers to the analysis of BTA 10 may better define the 
QTL position and determine whether b2m is a putative candidate gene controlling 
pre-immune IgG.  Identifying the genes underlying the QTL associated with 
variation in levels of maternal antibody could potentially aid the design of vaccines 
which reduce or avoid the effects of maternal antibodies.  
 
A single QTL was identified, located on BTA 14, which influenced the response at 
different time points, which appears to influence the IgG2 response at 2 and 7 weeks 
as well as the overall (AUC) IgG2 response post vaccination. This is in marked 
contrast to the 8 clusters of QTL that were associated with the response to the FMDV 
peptide across time [155]. However more time points were measured in the FMDV 
study which may have increased the chances of detecting QTL across time. Also the 
FMDV antibody levels were measured with greater accuracy and were not influenced 
by maternal antibody, both of which may have reduced the ability to detect BRSV 
related QTL in the current study. Nonetheless the data indicate that distinct genes 
operate early in the BRSV vaccine response compared to those that underlie 
variation following the boost. The QTL associated with the IgG2 response at week 2 
following the first immunisation also accounted for the most phenotypic variance. In 
addition, the IgG2 response at week 2 had the most QTL associated to it within this 
study, which altogether explained over 17% of the IgG2 response at this time point. 
As the responses at later time points also correlate with the week 2 response, this 
suggests that these QTL may be particularly important in determining the overall 
IgG2 response. In contrast, no QTL were identified which were associated with 
either IgG isotype, 5 weeks post vaccination. Previously, it has been shown that the 
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variation in IgG1 and IgG2 at this time point is small among the different second 
generation classes (F2 CB1 and HB1) [157]. Understanding the genetic control of the 
variation  in  the IgG2 response (associated with Th1 responses) at early time points, 
may suggest new ways to modulate the Th1 and Th2 balance induced by vaccination, 
which may be relevant for improved protection and avoidance of adverse pathology 
following vaccination  [168]. Furthermore markers associated with these genes 
would be valuable for breeding for enhanced disease resistance.  
 
In contrast to the response to the FMDV peptide [155] (shown in Chapter 2), the anti 
BRSV IgG1 and IgG2 levels were highly correlated, both pre and post vaccination,, 
however, no QTL for IgG1 levels were identified that overlapped with QTL for IgG2 
levels, which is in contrast to the QTL for FMDV peptide response where three 
chromosomal regions on BTA 20, 23 and 25 had QTL peaks for both antiFMDV 
peptide IgG1 and IgG2 responses [155] (Chapter 2). These findings imply strong 
correlation seen at the phenotypic level does not necessarily indicate that the 
phenotypes share genetic control. Thus although the levels of both antibody isotypes 
for BRSV increased at similar rates post-vaccination, different genes may be 
involved in controlling the response of IgG1 and IgG2. If so, these genes may 
explain, at least in part, how a balance between Th1 and Th2 is maintained [153], by 
animals which show little pathology post infection, potentially enabling the markers 
discovered here to be included in marker assisted selection for reduced pathology of 
BRSV. 
 
Almost half of the 27 QTL significantly associated with IgG levels pre and post 
BRSV vaccination, lie within the 90% confidence intervals of the QTL associated 
with antibody responses to the FMDV peptide [155] (Chapter 2). Indeed, 10 of these 
QTL are associated with the same IgG isotype, suggesting that the same genes 
influence IgG levels post immunisation with different immunogens. Furthermore, 
QTL identified in the current study also fall within the confidence intervals of QTL 
associated with other immune traits, including: the change of somatic cell score in 
response to Mastitis [169] on BTA15; antibody response to Mycobacterium avium 
ssp. paratuberculosis [170] on BTA 8 and 9; and bovine spongiform encephalopathy 
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infection [171] on BTA 17. This raises the possibility that the immune responses to 
different stimuli may be controlled, to some degree, by similar pathways, even if the 
initial detection of the infection occurs through distinct mechanisms, downstream 
signalling may converge on similar pathways. If the genes underlying these QTL are 
involved in pathways that control responses to a wide range of pathogens they may 
be suitable for selective breeding for disease resistance in general. In addition, 
understanding of the underlying genes and pathways could point to new targets for 
future adjuvants.  
 
The MHC locus is expected to be a significant component underlying variation in 
immune response [6], as it contains many polymorphic and immune-related loci [43, 
68]. Indeed in both the current study and the FMDV peptide study [155] (Chapter 2) 
QTL were discovered that span the MHC locus. Indeed, earlier studies have shown 
that polymorphisms at the DRB3 locus are associated with response to BRSV [118, 
172] as well as protection against viral challenge following immunisation with the 
FMDV peptide and similar peptides [119]. However, the two QTL that span the 
MHC loci that were identified in the present study only account for 3% of the 
phenotypic variation, which together with previous data from the FMDV study [155] 
(Chapter 2), indicates that many other regions of the genome are involved in 
controlling variation in immune responses. 
  
The human strain of respiratory syncytial virus (HRSV), which is closely related to 
BRSV, is a major cause of respiratory disease in young children, where the 
epidemiology and pathogenesis of infection is similar to that of BRSV [173]. The 
severity of disease in young children caused by HRSV is significantly associated 
with genes expressed during both innate and acquired immune responses [174]. Eight 
of the twenty one genes implicated in the human response to HRSV [174], have 
orthologs within the QTL in the current study, on BTA 2, 3, 15, 17 and 23. These are 
STAT1 (BTA 2), TNF (BTA 23), VCAM1 (BTA 3) and IL15 (BTA17) which play 
roles in innate immunity and CD28 (BTA 2), STAT1, IL17 (BTA23) which play 
roles in adaptive immunity [175]. The QTL with the highest significance in the 
current study (on BTA 17) encompassed IL17 within its 95% confidence intervals. 
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Two further genes, from the Janssen et al study [174], within these QTL confidence 
intervals (MS4A2; FCER1A, both located on BTA 15) are associated with asthma 
allergies as well as severe RSV disease. It has also been suggested that a Th2 biased 
response in cattle, associated with induction of IgE, is correlated with pathology 
[176], and thus polymorphisms in these genes may also influence the pathology 
observed in young cattle infected with BRSV. It is interesting to note that some of 
the SNPs within IL15, STAT1, VCAM1 and TNF associated with HRSV in the 
human study [174] are also polymorphic in the bovine genome, making them very 
good candidates for further study.
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3.5 Conclusion 
This is the first time that the natural variation in the clearance of maternal antibody 
and the immune response to a BRSV vaccine has been successfully exploited to 
locate significant QTL in distinct regions of the bovine genome. A greater number of 
QTL were found associated with IgG2 response, and these explained a larger part of 
the genetic variation, than were found for IgG1 response. Some of the QTL identified 
overlap with QTL associated with the response to a FMDV peptide (Chapter 2). 
Research is ongoing to further reduce the QTL confidence intervals, with the aim of 
identifying the underlying gene variants. This information may be used to breed for 
disease resistance and the production of more efficacious vaccines through the 
discovery of pivotal genes and gene pathways. 













Chapter 4  
 
____________________________________________________________________ 
Fine mapping genome regions 
significantly associated with the 
immune response following 
immunisation 
____________________________________________________________________ 
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4.1 Introduction  
 
Chapter 4 uses the same phenotypes defined in chapter 2 (FMDV peptide responses) 
and chapter 3 (BRSV vaccine responses). In addition an extra phenotype is used, the 
interferon gamma (IFN ) levels following immunisation with the FMDV peptide at 
weeks 0, 4 and 10. The AS methodology used in this chapter makes use of 
population-wide LD, rather than familial LD that LM uses, to detect SNP that are 
significantly associated with a trait, thus making fine mapping QTL within the 
RoBoGen herd possible. 
 
The results from chapters two and three in this thesis have shown that multiple 
regions of the bovine genome play a role in the antibody response to a peptide 
derived from a Foot-and-Mouth Disease Virus (FMDV) [155], as well as the 
antibody response to a vaccine against Bovine Respiratory Syncytial Virus (BRSV) 
[177]. In addition, a number of coincident QTL occurred in both chapters, suggesting 
that there may be underlying genes that control the immune response to multiple 
pathogens. However, the quantitative trait loci (QTL) spanned relatively large 
regions, making it impossible to highlight any candidate genes or causal 
polymorphisms with any certainty.  
 
Difficulties in identifying causal polymorphisms are partly because complex traits, 
such as the immune response, reflect the outcome of many processes. In livestock 
species, two main approaches to identifying gene variants controlling complex traits 
have been employed: candidate gene studies and whole genome scans.  The former 
are dependent on prior knowledge of the main pathways involved in the trait whereas 
a whole genome scan makes no prior assumptions. Both approaches have limitations 
as generally there are many candidate genes, and the availability of markers and 
genetic architecture of the population being surveyed restricts the precision with 
which the causal polymorphisms can be identified. Within this chapter, a limited 
number of SNP were genotyped in the RoBoGen herd using two different methods 
which used the principles of both candidate gene studies and whole genome studies 
to attempt to refine QTL from chapters 2 and 3 and detect novel significant SNP 
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associations. The first method selected SNP that were in candidate genes such as the 
Toll-like receptors (TLRs) and their down stream signalling partners. Whereas the 
second method selected SNP, with equal distances between them, that were located 
within the QTL confidence intervals of chapters 2 and 3. These methods aimed to 
select markers which were most likely to present significant results. 
 
The first method selected SNP in TLRs as they are strong candidates for disease 
resistance traits as well as targets for vaccine adjuvants [178]. The host employs 
Pathogen Recognition Receptors (PRRs), such as TLRs, to detect the initial invasion 
of pathogens and signal alarm. The Glass laboratory have previously identified a 
number of non-synonymous and positively selected SNP in bovine TLRs which may 
have functional consequences [179]. In addition, QTL associated with the immune 
response to the FMDV peptide were located on BTA6, which contains the TLR1, 6 
and 10 cluster. Furthermore, many TLRs and their down-stream signalling partners 
have been identified as strong candidates within QTL associated with disease 
resistance traits across multiple species [138], strongly suggesting that TLRs indeed 
play a pivotal role during an immune response.  
 
In the second approach SNP were selected which fell within the confidence intervals 
of the QTL discovered in chapters 2 and 3. The phenotypes measured in response to 
the FMDV peptide and BRSV vaccine would likely use the B or T cell pathways. If 
genes within these pathways were within the confidence intervals of previously 
detected QTL, then SNP would also be selected and genotyped in these genes. This 
approach aimed to capitalise on regions of the genome which had already been 
significantly associated with the immune responses in previous chapters. As a result, 
the SNP found to be significant in these regions would refine previous QTL and 
possibly highlight genes in which SNP were in LD with causal polymorphisms. 
 
An Association Study was conducted using phenotypes that were considered relevant 
to protection against FMD and BRSV. A panel composed of 183 SNP markers 
located within some of the identified QTL regions [138, 155, 177], as well as within 
the ten TLRs and their down-stream signalling partners [138, 180] aimed to increase 
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the power with which QTL could be detected. The results of this chapter show that 
significant SNP were located in genes with known biological relevance to an 
immune response, including TLR4 and TLR8 as well as in novel genes not 
previously associated with variation in immune responsiveness. This study may lead 
to the identification of selectable markers for increased disease resistance, and also 
may suggest new targets for the design of vaccines that enhance the host immune 
response to pathogens in all individuals regardless of genotype.
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4.2 Materials and Methods 
4.2.1 Acknowledgements  
Richard Leach completed all statistical work in this chapter, with the exception of the 
PAML section (4.2.9), which was conducted by Oliver Jann. In addition, Oliver Jann 
also compiled a table of SNP located in TLR genes. 
4.2.2 Animals  
Please see sections 2.2.2 and 3.2.2 for details about the FMDV and BRSV animals, 
respectively  
 
138 RoBoGen animals had IFN levels measured (98 from the F2, 25 from the HB1 
and 15 from the CB1).  
 
4.2.3 Immunisation and sampling 
4.2.3.1 FMDV15 peptide  
Please see section 2.2.3 
 
For the T cell and IFN- analysis blood was collected aseptically into heparin tubes.  
 
4.2.3.2 BRSV vaccine 
Please see section 3.2.3.1 
 
4.2.4 Phenotype measurement 
4.2.4.1 Whole blood T-cell Proliferation assay for the FMDV peptide 
Please see section 2.2.4.1 
4.2.4.2 ELISA for detection of FMDV15-specific IgG1and IgG2 
Please see section 2.2.4.2 
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4.2.4.3 IFN-  Assay 
 A Biosource Bovine IFN-γ Enzyme Amplified Sensitivity Immuno Assay (EASIA) 
kit (Catalogue number KAC123, Biosource International, now Invitrogen) was used 
to detect the IFN- levels essentially according to the manufacturer’s guidelines, 
except that FMDV peptide and ConA were used as the test antigens, and ovine 
recombinant IFN- (a kind gift from Professor Gary Entrican, Moredun Research 
Institute, UK) was used to determine IFN- concentrations. Duplicate whole blood 
samples were incubated as described above for the T cell assay, except that the final 
concentrations were: 2.5g Con A/ml and 1ug FMDV peptide/ml and the samples 
were centrifuged after 24 hours, at 2000rpm for 10 minutes and supernatants 
collected and stored at -20 0C until they were tested. Initially, 100l of the samples 
and IFN- standards (4000, 3000, 2000, 1000, 500, 100pg/ml diluted as described 
above for the samples), were incubated with 50l of “Incubation Buffer” (Biosource 
kit) in 96-well strips coated with a capture monoclonal antibody to bovine IFN- 
(which cross-reacts with ovine IFN- ) at room temperature (RT) for 60 minutes on a 
shaker, before being washed 3 times with 400l of “Working Washing Solution” 
(Biosource kit). 100l of an anti-bovine IFN- horse radish peroxidise (HRP) 
conjugate was added to each well, and again incubated at RT for 60 minutes, on a 
shaker. The plates were washed again and then 100l of TMB was added to each 
well and all samples were incubated at RT for 15 minutes on a shaker. Finally 200l 
of stop solution was added and the optical density of each well was read at 450nm on 
a Victor2 1420 Multilabel counter (Wallac, now PerkinElmer). Optical density (OD) 
values were converted into concentrations using a standard curve derived from 
dilutions of ovine IFN- using a simple linear regression (Genstat) and the results 
were expressed in pg/ml. The intra- and inter-plate replicates were high with r2 values 
of at least 0.80.  The negative control values for the IFN- levels were then 
subtracted from the results obtained for FMDV15 and ConA and these values were 
used to convert the IFN- levels to a binomial trait (see statistical tests below).   
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4.2.4.4 ELISA for detection of BRSV-specific total IgG and IgG2 
Please see section 3.2.3.2 
 
4.2.5 Genetic Markers for the Genotyping Panel 
All SNP markers  for the genotyping panel were sourced from Ensembl [181]. 
Markers were placed in three ways (Appendix 4.1). Firstly, a program script (Perl 
[182]) was written to select bovine SNPs for genotyping using a Perl-Ensembl 
Application Programming Interface (API) 
(http://www.ensembl.org/info/docs/api/index.html).  SNP were selected if they fell 
within the 95% confidence intervals of QTL from our previous studies [155, 177] 
(Appendix 4.4 and route 1 Appendix 4.1). Antibody levels and T cell proliferation 
were measured as phenotypes, thus a list of genes from the B-cell and T-cell 
pathways were downloaded from the KEGG database (http://www.genome.jp/kegg/).  
If these genes were located within the 95% confidence intervals of the QTL, then 
SNPs within the exons of these genes were preferentially chosen for the genotyping 
panel. In addition, a set of 31 SNPs on BTA 6 derived from a previous study 
investigating meat quality (Gutierrez-Gil et al, manuscript in prep), were also 
included (Appendix 4.3, SNP without “rs” numbers) as they fell between the 
confidence intervals of QTL in the FMDV study [155]. 
 
The other two methods of selected non-synonymous SNPs within the TLR genes 
(TLR1 – TLR10) (route 2 in Appendix 4.1), and their down-stream signalling 
partners and in other genes identified as within the syntenic blocks identifying cross-
species QTL for disease resistance [138, 179-180] (route 3 in Appendix 4.1), in a 
candidate gene approach (Appendix 4.5).  
 
A total of 425 selected SNPs were genotyped using an Illumina BeadArray platform 
(http://www.illumina.com/technology/goldengate_genotyping_assay.ilmn, Appendix 
4.3). Genotyping was performed by ARK genomics (http://www.ark-genomics.org) 
with at least 5l of DNA (50ng/l) per sample from each phenotyped animal.  
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Each marker was tested for quality to ensure reliable results. To pass quality control 
each SNP had to have: a minor allele frequency above 5%, a call rate of above 95% 
and be within Hardy-Weinberg equilibrium (FDR<0.2). The SNP alleles were then 
recoded as 0, 1, 2 with 0 =AA, 1=AB and 2=BB, to aid statistical analysis. 
 
Appendix 4.6 provides a list of SNP markers, together with their success rate, and 
method for selection. 
 
4.2.6 Statistic analysis 
4.2.6.1 Differences in response over time 
Stundent’s T-tests have already been calculated to test for significant differences in 
the responses at  each time point throughout the FMDV peptide responses (IgG1, 
IgG2 and T-cell levels (section 2.3.1)) and the responses measured before and after 
vaccination with the BRSV vaccine (IgG1, IgG2, total IgG (section 3.3.1)). In this 
chapter, T-tests were also conducted to test for significance differences between each 
week of the IFN- response to the FMDV peptide (INF- and the T cell positive 
control) responses at week 0, 4 and 10. 
 
4.2.6.2 Association Study  
To conduct the Association Study (AS), all the data was normalised to give a normal 
distribution and constant variance, however each data set was normalised using a 
different method: 
 
• The T cell response to the FMDV peptide was converted into a stimulation 
index, to account for the negative control. Following this, both the 
stimulation index of the T cell response and the antibody responses were 
normalised using a log10 transformation (section 2.2.5).  
 
• The BRSV IgG responses were normalised using the logit function (section 
3.2.4). 
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• The IFN- data was converted into a binary trait, with responders = 1 and 
non-responders =0. 
 
For both the FMDV and the BRSV data an Area Under the Curve (AUC) 
measurement was taken (using the trapezoidal rule [122]) to provide a single trait 
that reflected the overall response of each animal. 
 
As AS methodology does not account for relationship structure, a genetic Identity By 
State (IBS) matrix was constructed using all the SNP genotyped in the RoBoGen 
herd. The statistical analysis program, R (http://www.r-project.org/), was used to 
construct the IBS matrix using the GenABEL package 
(http://127.0.0.1:25804/library/GenABEL/html/GenABEL-package.html). To 
calculate the principal components the command princomp 
(http://127.0.0.1:25804/library/stats/html/princomp.html) was used. The principal 
components were all tested at each time point for significance (REML models were 
used). If they reached a p-value of 0.05, or they improved the Akaike's Information 
Criterion (AIC) [183] and were significant to a p-value of 0.1, they were retained in 
the REML model for that week. As a result, different combinations of the first 10 
principal components were used at various time points. 
 
The REML models used at each time point were based on the models used for 
chapter 2 for the FMDV peptide responses and chapter 3 for the BRSV vaccine 
responses. However, each model had the addition of SNP as a fixed effect and a 
selection of principal components 1 to 10 (to account for relationship structure of the 
second generation) animals. In brief the new model was:  
 
Yijk= µ +L+C+S+T+β1.m+β2.a+β2.p +uj+gk+eijk 
 
Where: Yijk is the observed value of the phenotypic trait; µ, population mean; L, the 
fixed effect of line (3 Lines); C, the fixed effect of cohort (3 Cohorts); S, the fixed 
effect of sex (male or female);T, the fixed effect of the SNP (AA, AB or BB); β1, the 
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linear regression on the covariate of age at vaccination m (m = d469-d609); β2, the 
linear regression on the covariate of weight a (a= 361-744kg); β2, the linear 
regression on the covariate of a principal component p (p= -0.9-1.3); uj, the random 




The false discovery rate of the SNPs was determined using the Bonferroni correction  
[99] (section 1.3.3.1). For the calculation of the genome wide 5% and 1% the total 
number of SNP used was ‘n’, the number of tests (section 1.3.3.1). To calculate the 
chromosome wide 5% and 1% levels, only the number of SNP of each chromosome 
was used as ‘n’, thus each chromosome had a different significance threshold.  
 
4.2.7 SNP effects and Variances 
The trait values were used to estimate additive and dominance effects for each SNP. 
The equations used were:  
 
Additive effect: 
a = (AA − BB)/2 
(However, if no BB alleles were available a=AA and dominance was not calculated) 
 
Dominance effect: 
d = AB − [(AA + BB)/2] 
In both instances AA, AB and BB were the predicted trait values for each genotype 
class. 
 
The additive genetic variance (VSNP) for each SNP was calculated by the following 
equation: 
VSNP = 2pq[a + d(q - p)]
2 
Where, p and q, were the allelic frequencies at the SNP locus. 
 
The phenotypic variance (Vp) was obtained from: 
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VP = VE + VS + VSNP 
Where, VE is the residual variance and VS is the sire variance. The proportion of 
phenotypic variance accounted for by each SNP (%VSNP), was calculated by the 
following equation: 
 
%VSNP  = VSNP/VP 
 
4.2.8 Functional Roles of SNP  
Ensembl was used to place SNPs and discover their status (synonymous/non-
synonymous) and the locations of the SNP relative to gene exons. Ensembl was also 
used to detect homology of bovine genes with unassigned functions and to conduct 
BLAST searches (http://www.ensembl.org/Multi/blastview).  
 
Significant SNPs located within TLR genes were analysed further for potential 
functional consequences using LRRfinder [184] and SMART [185] to locate their 
positions within the protein domains encoded by the TLR genes. SMART was used 
to predict the TIR domain of the TLR.  However  as this programme has been shown 
to miss many Leucine Rich Repeats (LRRs) within TLRs [186], LRRfinder [184] 
was used to predict the ectodomain structure.  
 
4.2.9 Phylogenetic Analysis using Maximum Likelihood 
An analysis of functional constraint and molecular evolution of the TLR genes was 
conducted using PAML [187]. 
 
The methods used for the calculations of the dn/ds (non synonymous / synonymous) 
and the classification of the type of selection (purifying, neutral or positive) were 
based on a paper by Jann et al.[179]. 
 
The SNP information on each animal was loaded into PAML and compared to the 
consensus sequence (Btau 4.0) to detect nsSNP. Ratios between synonymous and 
non-synonymous substitutions () at Amino Acid (AA) sites were estimated. Using 
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maximum likelihood, the probability of each AA in a protein being one of the three 
possible classes (low  (purifying selection), intermediate  (neutral) or high  
(positively selected)) was calculated. The class with highest probability is assigned to 
that amino acid.
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4.3 Results 
4.3.1 The Traits 
195 female F2, Holstein back-cross and Charolais back-cross animals were 
immunised with the FMDV15 peptide and 468 animals were vaccinated with the 
BRSV vaccine. The responses measured, across time, post immunisation to the 
FMDV15 peptide were: IgG1 antibody, IgG2 antibody, IFN and T cell responses. 
The T cell and IFN- responses to a T cell mitogen, Concanavalin A (ConA) were 
also measured at each time point as a positive control. The BRSV vaccinated animals 
also had IgG1 antibody and IgG2 antibody levels measured post immunisation across 
time.  Thus there were a total of 8 distinct traits investigated. 
 
The means, ranges and standard deviations of all the traits in this study can be seen in 
Table 4.1. Analysis of the FMDV (IgG and T cell responses) [155] and BRSV (IgG 
responses) datasets have already been conducted [177]. In summary, the FMDV 
peptide elicited both humoral and cellular immunity in all animals, although 
considerable variation between animals was observed.  Similarly the BRSV vaccine 
induced variable antibody responses.  Following both immunisations the IgG2 
response tended to be lower than the IgG1 response 
 
However the IFN- results have not been reported previously. Unlike the antibody  
and T cell responses [119, 155], many animals were non-responders (with IFN-) to 
the FMDV peptide at one or more time points.  At weeks 4 and 10, the average 
response to the FMDV peptide was 388 pg/ml (standard deviation (SD) 504) and 402 
pg/ml (SD 813), to Con A at the same weeks it was 418pg/ml (SD 484) and 
315ng/ml (SD 323), respectively.  The IFN responses to the positive proliferation 
control, Con A, were not significantly different from each other at any week, 
including week 0 versus week 10, as expected. However, the IFN response to the 
FMDV15 peptide was significantly different between week 0 and week 4 (p<0.001), 
week 4 and week 10 (p < 0.05) and also between week 0 and week 10 (p<0.001). 










IgG1_week_0 1.22 0.00 - 9.31 1.36
IgG1_week_1 1.33 0.00 - 8.86 1.402
IgG1_week_2 69.74 0.00 - 322.86 66.16
IgG1_week_4 166.95 0.00 - 672.03 144.39
IgG1_week_8 291.65 0.00 - 1254.56 269.20
IgG1_week_10 176.12 0.00 - 670.78 141.63
IgG1_AUC 1658.47 0.08 - 6421.13 1381.31
IgG2_week_0 0.01 0.00 - 0.35 0.05
IgG2_week_1 0.01 0.00 - 0.49 0.0505
IgG2_week_2 5.64 0.00 - 51.07 8.80
IgG2_week_4 13.09 0.00 - 87.85 17.32
IgG2_week_8 24.35 0.00 - 810.60 64.70
IgG2_week_10 23.50 0.00 - 968.30 71.77
IgG2_AUC 144.41 0.01 - 3622.06 302.30
SI_CA_10ug_0 13.85 0.04 - 177.04 23.37
SI_CA_10ug_4 17.67 0.00 - 197.68 29.15
SI_CA_10ug_8 13.35 0.02 - 95.01 16.79
SI_CA_10ug_10 18.76 0.12 - 145.38 25.57
SI_CA_10ug_AUC 157.43 0.00 - 1214.95 187.51
SI_FMDV_2ug_0 1.13 0.01 - 5.32 0.58
SI_FMDV_2ug_4 1.80 0.00 - 10.12 1.50
SI_FMDV_2ug_8 2.57 0.37 - 28.29 3.64
SI_FMDV_2ug_10 4.58 0.30 - 173.76 14.56
SI_FMDV_2ug_AUC 21.83 0.00 - 289.59 27.19
SI_CA_IFN_Week_0 0.41 0.00 - 1.00 0.49
SI_CA_IFN_Week_4 0.66 0.00 - 1.00 0.47
SI_CA_IFN_Week_10 0.59 0.00 - 1.00 0.49
SI_FMDV_IFN_Week_0 0.39 0.00 - 1.00 0.46
SI_FMDV_IFN_Week_4 0.63 0.00 - 1.00 0.49
SI_FMDV_IFN_Week_10 0.53 0.00 - 1.00 0.50
IgG1_week_0. 13.82 0.03 - 94.03 20.40
IgG1_week_2. 20.03 1.24 - 93.03 15.44
IgG1_week_5. 38.96 4.03 - 110.95 19.13
IgG1_week_7. 31.20 1.32 - 98.77 20.31
IgG1_AUC 191.13 10.37 - 592.77 89.66
IgG2_week_0. 2.16 0.02 - 20.14 2.57
IgG2_week_2. 4.54 0.05 - 30.44 4.09
IgG2_week_5. 12.55 0.15 - 86.09 10.75
IgG2_week_7. 13.07 0.06 - 81.03 13.23
IgG2_AUC 57.36 0.50 - 327.39 43.15
FMDV peptide - IFNg 
Responses
BRSV Vaccine - IgG 
Responses 
Range4
FMDV peptide - IgG 
Responses
FMDV peptide - Tcell 
Responses
 
Table 4.1: Trait means, ranges and standard deviations.  
1. Immunisation type and response measurement recorded. 
2. Trait: each trait is shown as follows: trait type (IgG1; IgG2; SI_FMDV = T cell 
proliferation to the FMDV peptide; SI_CA = T cell proliferation to Concanavalin A), 
followed by week post immunisation. 
3. Arithmetic mean of each trait. FMDV: IgG1 and IgG2 = ng/ml, T cell = Stimulation index 
and IFN = binary trait (response detected 1, no response detected 0). BRSV IgG1 and IgG2 
= %relative Optical Density (OD). 
4. The minimum and maximum value of each trait. 
5. The Standard Deviation of the raw data. 
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4.3.2 SNP Selection 
A total of 425 SNP satisfied our selection criteria from the two methods of selection 
(a candidate gene approach and a QTL refinement approach of previously detected 
QTL [155, 177], see Materials and Methods) and were used for genotyping the 
RoBoGen herd (Appendix 4.3). The selected SNP were genotyped onto every 
chromosome with the exceptions of chromosomes 1, 10, 28, which had none (Table 
4.2). From the 425 SNPs, 187 satisfied all quality checks (see Materials and 
Methods) across the second generation (Appendix 4.3). The FMDV dataset however, 
consisted of only female heifers, and only 158 SNP were eligible for use, whereas 
175 were eligible for use for the BRSV dataset analysis. 32 animals were removed 
from the FMDV dataset as having a low call rate, thus 150 animals remained for the 
AS analysis. Of the 468 animals in the BRSV dataset 56 animals were removed from 
further analysis, leaving 412 animals for the AS. 
 
Many (238) of the selected SNP failed and particularly those across the MHC region 
on BTA23 where 64 SNPs out of total of 88 SNPs (73%) failed (Table 4.2).  In 
contrast, those on BTA6 were more successful with 50 SNPs out of 87 SNPs (57%) 
passing quality control (Table 4.2). In general SNP failed because they were not 
polymorphic in the test population.   










4.3.3 Overall AS results 
The REML models had already been optimised in previous publications [155, 177] 
and so each SNP was added, one by one, as a fixed effect at each time point 
throughout the FMDV and the BRSV datasets. This resulted in a total of 35 SNP 
Table 4.2: SNP placement. 
1) Chromosomal location of SNP 
2) Region size of chromosome (bp) the SNP covered (placing them under QTL from chapters two and 
three). Number in parenthesis highlights the number of SNP used, if SNP were placed using both 
methods (refining QTL and candidate gene study) 
3) Region size of chromosome (bp) the SNP covered when placed within candidate genes. Number in 
parenthesis highlights the number of SNP used, if SNP were placed using both methods (refining 
QTL and candidate gene study). 
4) Total number selected on the chromosome 
5) Number of informative SNP genotyped on to chromosome. The parenthesis highlight the split 
between informative SNP selected under QTL (left) and within candidate genes (right).  
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associations across the time courses to the immune responses of the BRSV vaccine 
(19 associations from 14 SNPs) and the FMDV15 peptide (16 associations from 10 
SNPs) that were above the 5% chromosome wide significance level (Table 4.3). 
Very few SNPs were significantly associated with both FMDV and BRSV traits 
during the time course (Table 4.3). Only the T cell proliferation to the FMDV15 
peptide and the IgG2 response to the BRSV vaccine had at least one significant SNP 
association at each time point throughout the study. In addition, only the early to mid 
(weeks 2 to week 4) IgG responses to the FMDV15 peptide had significant 
associations, and from all of the IFN measurements only two time points had 
significant SNP associations (Con A response at week 4 and FMDV15 response at 
week 10 post immunisation), Table 4.3.  
 
The most significant SNP (rs43702384) (F statistic of 11.6; above the 1% genome 
wide significance level) was located on BTA6, placed in the predicted gene, 
glucosidase beta acid 3 (GBA3) [188]. The SNP was located in the first exon and 
was non-synonymous, substituting a Methionine for a Threonine (Table 4.4). It was 
associated with the IgG2 response to the BRSV vaccine at week 2 following 
vaccination and accounted for over 11% of the genetic variance. However it was not 
associated with any other trait. The second most significant SNP (rs42765470) (F-
statistic of 9.8; above the 5% genome wide significance level) was also located on 
BTA6 although in a different region.  It was associated with the overall T cell 
response (AUC measurement) to the FMDV peptide, and additionally was 
significantly associated with related traits for the T cell response following the boost 
at weeks 8 and 10.  A further 2 SNPs were above the 1% chromosome wide 
significance level and were associated with the response to the BRSV vaccine. In 
addition significant SNP on this chromosome were also located under the peaks of 
previously detected QTL (Figure 4.1). Another SNP that was significant and place 
beneath a QTL was on BTA7   
 
A SNP on BTA8 (rs8193069) was significantly associated with both the BRSV 
specific IgG1 (for week 5) and the IgG2 (overall) response to the vaccine.  This SNP 
again explained a relatively large proportion of the variance, over 9% for both traits.  
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Additionally, a SNP on BTA 25 (rs42060100) was significantly (above 1% 
chromosome level) associated with the BRSV specific IgG2 response at week 5 and 






Figure 4.1: Significant regions on BTA6. 
Comparison of QTL regions previously described (Chapters 2 and 3) for responses to FMDV and BRSV with 
significant SNP positions in this study, located on BTA6. 
The previously discovered significant regions are shown using linkage mapping profiles (Chapter 2) in light 
blue, red and yellow. SNPs are shown as purple and dark blue points. The only significant SNP shown was 
associated with the BRSV IgG2 response at week 2, rs43702384, which reached an F-statistic of 11.6. 
Figure 4.2: Significant regions on BTA7. 
Comparison of QTL regions previously described (Chapter 3) for responses to the BRSV vaccine 
are compared with significant SNP positions discovered in this study, located on BTA7. The 
previously discovered significant regions are shown using linkage mapping profiles (Chapter 3). 
SNPs are shown as purple (IgG2 week 2) and dark blue points (IgG 1 week 5). Only one 
significant SNP was located on this chromosome, rs42371911, which was associated with the 
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The additive variance accounted for by each SNP varied greatly in this study (Table 
4.3), with the highest being 12.31% (IgG2 response to the FMDV15 peptide at week 
4) and was the only SNP to be significantly associated with the IgG2 response to the 
FMDV15 peptide at any time point..  
 
4.3.4 Further Analysis of Significant SNPs  
All SNPs that were above the 5% chromosome wide significance level were analysed 
further for their relative location to genes and to discover if they were non-
synonymous (Table 4.4). The majority of significant SNPs were located within gene 
exons and were also non-synonymous (ns) (Table 4.4). In addition, SNP were 
selected (by the Perl script), in genes with unknown function, to be genotyped. Of 
these, some were shown to have significant associations with the immune responses 
measured (Table 4.4). 
 
Two genes, with known function, which contained significant SNP within this 
chapter are TLR4 and TLR8 (SNP within TLR8 are shown in Figure 4.3). TLRs are 
one of the first defences against pathogens. Due to their direct link in eliciting an 
immune response, further analysis was conducted upon the SNP located within the 
TLR genes. 
Figure 4.3 Manhattan plot of Chromosome X:  
SNP on chromosome X with their F-statistic highlighting the significance to the IgG1 response to the 
FMDV peptide across time, pink squares (AUC). The SNP associated with the responses to the BRSV 
vaccine for IgG1 (yellow triangles) and IgG2 (blue diamonds) is also shown at week 2 and 5, 
respectively. The significant SNP are labelled and located with TLR8. 
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In order to explore whether the 3 nsSNPs, within TLR4 and TLR8, were likely to 
have functional consequences two programs were used. The precise positions of the 
associated nsSNP were determined using SMART [185] for the TIR domain 
structural analysis. LRR finder [189] was used to identify the Leucine Rich Repeats 
(LRRs) within their (putative) ligand binding domains. In addition, since positively 
selected SNPs are more likely to have functional effects [179], the selective pressure 
on these SNPs was also estimated.  
 
The significant SNP, rs8193069, coded for a Threonine to Isoleucine substitution and 
was located at the start of the TIR domain in the bovine protein sequence of TLR4 
(NP_776623) (Figure 4.4). PAML analysis determined that the SNP is likely to be 
under positive selection with a  of 1.62 (p = 0.05). LRRfinder identified 23 LRR 
matches from the protein sequence of bovine TLR8 (NP_001029109). In addition, 
LRRfinder indicated that the two significant SNP located in TLR8 (rs55617145 and 
rs55617390) coded for amino acid exchanges within the 12th and C-terminal LRRs 
respectively (Figure 4.5). The former SNP (rs55617145) coded for a Histidine to 
Glutamine substitution which was under significant purifying selection (= 0.03, 
p=0.02) whilst the other amino acid change (Phenylalanine to Leucine substitution) 
coded for by SNP, rs55617390, was not under significant selection with a  of 0.286 
(p=0.15). However, a change in amino acid may change the structure, altering the 
TLRs affinity to bind pathogen.  
 
  
 Figure 4.4: Significant SNP within the TIR domain of TLR4 
Visualisation of the secondary structure of TLR4. The diagram was generated by SMART. The 
green rectangles are Leucine Rich Repeats. The C-Terminal Leucine Rich Repeat is depicted by 
a blue circle. The blue rectangle is the transmembrane region of the TLR4. The TIR domain is 
shown as a green diamond. 
 








Figure 4.5: 2D Diagram of the significant SNP within the Leucine Rich Repeats of TLR8. 
The visualisation of TLR8, highlighting the Leucine Rich Repeats (blue) that contain a non-









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this study we have built on our earlier results which identified QTL regions, via 
LM mapping, that were associated with immune related traits [155, 177]. Using a 
fine mapping approach with a selected SNP panel, 21 SNPs were significantly 
associated with the response to a 40-mer FMDV peptide [112] and a commercially 
available BRSV vaccine. Of the SNPs in the panel which were within the confidence 
intervals of the QTL discovered in the previous studies [155, 177], 18 (162 were 
successfully genotyped) were significant, whilst of the SNP placed in a candidate 
gene approach 3 (25 were successfully genotyped) were significant.  Interestingly, 
one of the three syntenic blocks associated with cross-species QTL for disease 
resistance [138], was found to harbour a significant SNP (rs43702384) in the current 
study on BTA6, although it was not within the TLR1, 6, 10 cluster.  
 
Previous chapters in this thesis (chapters 2 and 3) have used within-family LD to 
detect QTL for the immune traits used in this chapter. However, the aim of fine 
mapping the QTL of chapters 2 and 3 was conducted using AS methodology, which 
detects QTL in association with the immune traits using population wide LD. The 
idea of using linkage and then association methodology to fine map has been used 
before (see section 1.3.2.2), indeed methodology has been developed which increases 
the power of such a study by using linkage data to weight association p-values [190]. 
However, the methodology was developed for use where 100k or more markers are 
used, and would have very little effect on the current results, which had 183 
informative SNP. AS methodology is unlikely to find a causative polymorphism (a 
high proportion of purported causal polymorphisms are eventually shown as false, 
for example: [191]) and is more likely to highlight a marker in LD with a causal 
polymorphism. This is reflected within the results of this chapter, although some of 
the SNP are indeed intriguing candidates, they are most likely in LD with a causal 
polymorphism, and not the causal polymorphism. In addition, the results of this 
chapter cannot be tested to investigate if the significant SNP are true associations. 
Chapter Four – Fine Mapping  
 112 
Only through further validation within other populations (see section 5.3) will show 
if the significant SNP are in LD with a causal variants. 
 
Perl is a programming language developed for fields such as biology as scripts can 
be written to solve highly computational and complex problems [192]. The script 
developed in the current study selected up-to-date SNPs in a species specific manner, 
via a connection to the Ensembl API. Since we did not have prior information about 
the allele frequency of the selected SNPs in the test population, SNPs were 
deliberately chosen in clusters with the aim that at least one SNP per cluster would 
be polymorphic.  Thus the Perl script has the potential to select SNPs within QTL for 
other fine mapping projects. A limited number of SNP could be selected in the 
current study. Thus, the coverage of the genome was limited, compared to the 
coverage of the 50K SNP chip, which has a SNP placed every 50 kb (on average) 
(http://www.illumina.com/Documents/products/datasheets/datasheet_bovine_snp5O.
pdf). The coverage of the regions of interest varied greatly in the current chapter, 
with some chromosomes not having any SNP placed on them, whilst some candidate 
genes had a SNP genotyped every ~250 bases. Further, only one SNP was selected in 
the current chapter that exists on the Illumina SNP chip (rs29017177); however this 
SNP was not successfully genotyped in the RoBoGen herd. With over 1,970,267 
short variants (SNPs, indels, somatic mutations) 
(http://www.ensembl.org/Bos_taurus/Info/StatsTable?db=core) in the bovine 
genome, the probability of many SNP being in both this study and the 50K SNP chip 
were low. 
 
One region expected to be significantly associated with the immune response in this 
study was the MHC region as previous chapters (chapters 2 and 3) and other studies 
had shown that QTL spanning the MHC region and polymorphisms within the BoLA 
DRB3 gene accounted for some of the variation in the immune response to the 
FMDV peptide and BRSV vaccine [118-119, 193-194].  However no significant 
SNPs were discovered on chromosome 23 which may be due to the failure of most 
(64 out of 88 SNP on BTA23) of the SNPs across this region. The low rate of 
successful genotyping was caused by many of the SNP being uninformative. 
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Sequencing the second generation of the RoBoGen herd across the MHC region may 
enable the discovery of SNP, within the herd, that are polymorphic and significantly 
associated with the immune traits discussed in this paper.  
 
In chapter 1 three QTL on BTA6 were associated with the T cell responses to the 
FMDV peptide [155].  BTA6 harbours the TLR1, 6, 10 cluster [180], however, the 
SNPs placed using the candidate gene methodology within this region were not 
significant. The Perl script selected SNP in an attempt to fine map the previously 
detected QTL [155, 177]. Some of the selected SNP were within genes that have no 
known effect on the immune response. From these SNP, two were discovered to be 
above the 5% genome wide significance level, both of which were located on BTA6. 
Both SNPs were within gene exons and were predicted to change the encoded amino 
acids, suggesting that they may have functional consequences. SNP rs43702384, 
which was above the 1% genome wide significance level, was placed in the predicted 
gene, glucosidase beta acid 3 (GBA3), and SNP rs42765470 was placed in a “known 
coding gene” that is similar to Armadillo repeat containing 1 (ARMC1), neither of 
which have been reported to have a link to immunity. The human homolog of GBA3, 
is suggestively involved in a nonlysosomal catabolic pathway of glycosylceramide 
metabolism [188] and ARMC1 is a nuclear-encoded mitochondrial protein, with only 
one study in the literature testing its function, finding it not significantly associated 
with Acquired Immune Deficiency Syndrome [195]. 
 
The Perl script also selected a SNP (rs42205048, associated with the IgG1 response 4 
weeks post immunisation to the FMDV15 peptide) within the gene, B-cell-specific 
co-activator (OBF-1). Although the script did not select this SNP in the gene due to 
its ‘immune relevance’ (it was not within the pathways specified, see Materials and 
Methods) it has been shown in humans to be essential for the response of B-cells to 
antigens and is required for the formation of germinal centres [196]. Furthermore this 
transcriptional co-activator has been shown to regulate the balance between Th1 and 
Th2 immunity [197]. Considering the human gene shares 92% homology with the 
bovine gene, it is probable that bovine OBF-1 will function in a highly similar way to 
the human OBF-1. The SNP in this study only accounted for 0.77% of the 
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phenotypic variance, nonetheless its significance may point to a novel pathway that 
regulates immune responses and may have relevance for vaccine design.  
Furthermore, detailed analysis of the gene and region may reveal further SNPs which 
maybe closer to or in high LD with a causal polymorphism.  
 
As well as fine mapping previously detected QTL, a candidate gene approach was 
used, which selected SNP within the TLR genes and their down-stream signalling 
partners [138, 179-180]. TLRs are strong candidates for disease resistance traits as 
well as targets for vaccine adjuvants [178], as they are a form of pattern recognition 
receptor (PRR). PRRs are essential components of the innate immune system which 
also help to establish an adaptive immune response [30, 139]. Many of the TLRs 
induce intracellular signalling to activate a type I interferon response and thus 
combat viral pathogens [198]. To detect pathogens, TLRs are both on the cell surface 
and localised within the cell.  
 
TLR4 is an example of a cell surface TLR, that responds to gram-negative bacteria 
[199]. SNP within TLR4 have been associated with Moraxella bovis, the gram-
negative bacteria which can cause infectious bovine keratoconjunctivitis [200]. 
Significant SNP within TLR 4 have also been associated with mastitis [201-202].  
Within this study, however, we have detected that an nsSNP (rs8193069, Table 4.3) 
in TLR4 was significantly associated with both the IgG1 and IgG2 responses to the 
BRSV vaccine. Others have previously shown that TLR4 knockout mice have a 
decreased ability to clear RSV infections [203] and suggested that BRSV activates 
TLR4 [204]. Furthermore, the same nsSNP (rs8193069), has also been associated an 
increase in percentage of protein and fat in milk [205], and with decreased somatic 
cell score [206], suggesting that this SNP, could be used in dairy breeding programs 
for both general disease resistance and increase performance. The amino acid change 
caused by the SNP substitution occurs in the TIR domain of TLR4 (Figure 4.4). The 
TIR domain is responsible for initiating an intracellular signalling cascade to elicit an 
immune response [199]. The base change substitutes a Threonine, an amino acid that 
has a polar side chain, with an Isoleucine, which is non-polar, highly hydrophobic 
and larger. Further analysis revealed that this site is also under significant positive 
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selection, suggesting that the base change may be increasing in frequency, thus the 
SNP maybe very close to a causal polymorphism which affects the immune 
responses.   
 
Further significant associations were also discovered in TLR8, which is an 
intracellular TLR that detects ssRNA [199]. TLR8 is located in a cluster on 
chromosome X, along with TLR7 [180], and is expressed in  immune related cells 
such as macrophages and dendritic cells where it interacts with ssRNA to initiate an 
anti-viral immune response [178].  In humans however, TLR8 has been associated 
with susceptibility to the bacterium, Mycobacterium tuberculosis [207], suggesting it 
may play a role in defence against a wider range of pathogens. Bovine TLR8 can be 
activated by some TLR7 ligands and other differences in ligand interactions suggest 
that BoTLR8 may have subtle differences in function compared to other species 
[208].  Two nsSNPs (rs55617145 and rs55617390) significantly associated with the 
immune response in the current study are located within the TLR8 gene. Both SNPs 
were located within LRRs in the TLR ectodomain, a region of TLR 8 which is 
responsible for ligand binding [209], although the SNPs are not in LRRs previously 
associated with ligand binding [208]. In addition, one SNP rs55617390, was found to 
be significant in both the responses to the FMDV peptide and the BRSV vaccine, 
suggesting that this SNP association may be used by breeders to select for higher 
antibody levels following immunisation. Furthermore, the amino acid change caused 
by rs55617145 is in a site under purifying selection (p=0.02). The wild type allele 
(Histidine, coded by the A allele of the SNP) was associated with significantly higher 
IgG1 antibody levels than the ‘C’ allele of the SNP that codes for Glutamine.  IgG1 
may be particularly important for BRSV clearance and protection [153], and a 
Histidine in this position, may therefore enhance the properties of TLR8 to bind 
certain viral pathogens, leading to a greater adaptive response. This suggests that the 
‘C’ allele is being reduced in frequency, which is consistent with the hypothesis that 
purifying selection preserves the function of most protein-coding genes [210-211]. 
Regions under purifying selection have also been documented in other TLRs, for 
example in TLR2 and TLR10 [179, 212]. 
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4.5 Conclusion  
This study has analysed the immune responses following immunisation to a 
FMDV15 peptide and a BRSV vaccine. Significant SNP were successfully chosen 
using three methodologies. Although we do not know that the significant SNP 
discovered in this study would influence protection, they may be functionally 
relevant. From the results, three significant SNPs affected the immune response to 
both the FMDV15 peptide and the BRSV vaccine, located within TLR4, TLR 8 and 
upstream from olfactomedin 4. In addition, SNP within TLR4 have also been 
significantly associated with different immune related traits in other herds [204, 206], 
suggesting this SNP as a candidate for breeding for general disease resistance. The 
significant SNPs discovered in this study may aid the selection of disease resistant 
livestock as well as suggesting new pathways that may regulate immune responses 
and therefore be of value for improving the efficacy of current vaccines.
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5.1 General discussion  
Infectious disease of livestock continues to be a cause of substantial economic loss 
and has adverse welfare consequences, even in well managed agricultural systems 
[1]. The results and methodologies used in this thesis may provide a greater 
understanding of the underlying genetics of immunity which may ultimately be 
valuable for developing future strategies that result in breeding more disease resistant 
cattle and developing more efficacious vaccines. 
 
Traditionally, breeders have selected cattle using only phenotypic merit, to produce 
the next generation. Modern techniques now use DNA markers, that are linked to a 
favourable phenotype, to aid selection [161]. The phenotypes selected for, however, 
such as weight gain, milk yield, growth rate, etc do not account for health traits. 
Thus, as these production phenotypes have been improved, immunity has not been 
addressed. In addition, infectious disease has continued to cause a significant loss to 
the cattle industry [213], in part exacerbated by modern farming methods such as 
feed lot herds in the United States, where many animals live in constant close 
proximity to each other, allowing pathogens to rapidly infect large numbers of 
animals. In addition, globalisation of trade is resulting in increased spread of disease, 
as infected cattle are transported across country borders. The discovery of genetic 
loci that play a role during an immune response has the potential to be exploited in 
the design of vaccines that enhance the host immune response to pathogens in all 
individuals regardless of genotype. Thus understanding the genetic controls 
underpinning variation in immunity is now of paramount importance. 
 
This thesis has focused on the identification of non-MHC regions in the bovine 
genome determining variation in immune response and has exploited a cattle-cross 
resource population set up at the Roslin Institute, which was genotyped with 
microsatellite markers, and was extensively phenotyped for many traits.  Originally 
the population which is a cross between a dairy breed, Holstein, and a beef breed, 
Charolais, was established to detect QTL for milk and meat related production traits.  
This approach was very successful and several QTL papers have resulted on 
production traits [104, 214-216], as well as coat colour [105] and temperament [106]. 
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Further, a number of immune traits were also measured using this resource herd, 
including: IgG1 and IgG2 responses before and after BRSV vaccination; peripheral 
blood mononuclear cell proliferation in response to a mastitis causing pathogen, 
Staphylococcus aureus; IgG1, IgG2, T cell and IFN γ responses following 
immunisation with a FMDV peptide. Prior to this thesis, a genetic component was 
established for the immune response following vaccination with the BRSV vaccine 
[52], as well as to Staph. aureus [133], with both traits showing significant sire and 
breed effects. In addition to the microsatellite markers, the second generation cattle 
cross were also genotyped for the second exon of the bovine MHC (BoLA) DRB3 
gene which  was associated with the immune related traits measured following 
immunisation with the FMDV peptide [119]. Although the FMDV traits had been 
measured prior to this thesis no statistical analysis of this data had been undertaken. 
In addition, the kinetics of the FMDV immune responses was also analysed.  This 
PhD built on some of these earlier studies, and utilised the microsatellite markers 
previously genotyped as well as genotyping extra SNP to identify regions of the 
genome which are significantly associated with the immune responses to the FMDV 
peptide and the BRSV vaccine.  
 
The RoBoGen herd was primarily established to investigate production phenotypes. 
Thus using the herd to study immune responses had to be considered carefully to 
avoid influencing the production trait measurements. In addition no resources for 
challenge experiments were available which further restricted the types of 
immunogen which could be used. Thus a commercial BRSV vaccine was used that 
did not need any form of extra licensing and previous experiments had established 
that the FMDV peptide did not cause any adverse effects [6]. In addition, both cell 
mediated and humoral responses were measured from blood to minimise disruption 
to both the collection of production phenotypes and the herd. T cell levels were 
measured as a correlate of the cell mediated immune response, whilst IgG1 and IgG2 
levels were measured as a correlate of the humoral immune response. Although it is 
clear that cell mediated immunity is important in BRSV infections [149], preliminary 
experiments did not detect any T cell responses to the BRSV vaccine and indeed 
other workers have also found that considerable immunostimulation is required to 
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detect cell mediated responses to BRSV in blood (Glass, personal communication). 
Thus IgG1, which may be required for viral clearance of and protection of BRSV 
[153] and IgG2 which has also been correlated with protection [150], were the only 
phenotypes available in response to the BRSV vaccine. In contrast, the T cell 
response, which has been shown to play a role in protection against FMDV [115-
116], was measured following FMDV immunisation along with the IgG1 and IgG2 
levels which are thought to correlate with protection [113-114]. Conducting a 
challenge study would further the potential to discover regions of the genome which 
play a role in the immune response. The challenge study would select animals by 
their genotypes, to be predicted high and low responders to the original phenotypes 
measured. Following challenge with FMDV and BRSV, extra phenotypes could also 
be utilised to measure morbidity, such as fever, rapid breathing and appetite 
depression for BRSV [143], and the detection of lesions on the tongue and foot, 
laboured breathing and viral shedding for FMDV [2]. In addition to adding to the 
information available to validate and detect significant QTL/SNP, measuring extra 
phenotypes as well as the original phenotypes, would enable further conclusions to 
be drawn, for example, if the original phenotypes correlate with resistance.  
 
In contrast to the MHC region which has been associated with many immune traits, 
for example: in humans [217-219], mice [220-221] and livestock [6, 43, 118] 
(chapter 2), the role of non-MHC regions of livestock genomes in relation to immune 
responsiveness and disease resistance have received less attention. However, some 
non-MHC regions have been associated with infectious diseases, for example: 
infectious bovine keratoconjunctivitis (IBK) [4, 200], mastitis [169, 205-206, 222] 
and Mycobacterium avium subspecies paratuberculosis [223], in addition to the 
regions discovered in this thesis, which were associated to FMDV peptide [155] 
(chapter2) and the BRSV vaccine [177] (chapter 3). One of the first non-MHC genes 
to be successfully associated with an immune response, in cattle, was bovine 
leukocyte adhesion deficiency [224]. Mutations in this gene resulted in multiple 
defects in leukocyte function [225]. More recently, a gene associated with the 
response to multiple antigen types has been TLR4. TLRs are pattern recognition 
receptors which detect the initial invasion of pathogens and signal alarm. The same 
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SNP, within TLR 4, that was significantly associated to the FMDV peptide and the 
BRSV vaccine [226], has also been significantly associated with mastitis [206], 
implying this SNP may be used to breed cattle for general disease resistance.  
 
Investigating significant polymorphisms which affect the immune response before 
and after vaccination will ultimately lead to a better understanding of disease 
processes and the mechanisms through which pathogens evade host immunity [227]. 
MHC regions have been shown to significantly affect the immune response, in cattle, 
following vaccination [57], however, the results in this thesis, and others have shown 
that non MHC genes also have a significant effect on the immune response before 
and after vaccination [6, 8-9]. By targeting the genes causing the high/low response 
during vaccination, it may be possible to improve vaccine components to increase 
overall vaccine efficacy, regardless of an animal’s genotype. For example, two SNPs, 
rs55617390 and rs55617145, were significantly associated with BRSV vaccination 
and were located within separate Leucine Rich Repeats (LRRs) of TLR8. LRRs are 
responsible for ligand binding [209]. As the SNPs were non-synonymous, the 
structure of the LRRs , at least at these sites, would likely change with the amino 
acid substitutions, perhaps allowing animals with the substitutions in TLR8 to bind 
ligands with higher affinity. Thus developing an adjuvant that will trigger TLR8 in 
low responding animals may improve the efficacy of the BRSV and other viral 
vaccines. 
 
The published studies of non-immune traits within the RoBoGen herd, used linkage 
analysis (LM) methodology to detect QTL, as the herd was produced as a typical F2 
and backcross design, and genotyped with microsatellite markers.  These studies 
were based on the assumption that genes underpinning dairy and beef traits would be 
fixed in the two founding breeds (Holstein and Charolais respectively) and indeed 
significant QTL relating these traits were discovered. However, nothing was known 
about the differences in the immune traits in the founder breeds. It is unlikely that the 
genes controlling the immune traits were fixed in the founder breeds thus making it 
more difficult to detect QTL in the RoBoGen herd. Nonetheless, significant QTL 
were detected as described in this thesis. Furthermore, no single breed was 
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responsible for a significant majority of QTL detected. Implying there is little 
difference between the immune systems of the Holstein and Charolais breeds.   
  
The publications using the RoBoGen herd show the versatility it possesed, as studies 
investigated multiple production traits [104-106, 228] and immune related traits [52, 
118-119, 133, 155, 177, 226, 229], with a focus on both quantitative genetics, QTL 
discovery and the discovery of significant effects during vaccination and infection. 
However, the herd was established over 10 years ago and methodology and marker 
technology has progressed along way since (see chapter 1). Modern resource herds 
tend to be much larger and have many more markers genotyped across their 
genomes, greatly increasing the power to detect QTL. In addition, money can be 
saved, using modern herds, by genotyping across one generation as AS approaches 
do not need detailed pedigreed information across generations. 
 
This thesis has concentrated on analysing the genetic effects of two sets of immune-
related data. At the start of the AS study, the data analyses took a relatively long time 
to complete. However as I developed my scripts, the time taken to complete 
computations was drastically reduced. With around 500 animals, several time points, 
and two immunogens, the trait data sets would take around 2 hours to calculate the 
significance of all the SNPs using the AS methodology discussed in chapter 4. In 
addition, empirically calculating significance thresholds for SNP [100], took around 
12 hours per immunogen. However as I developed my scripts to use vectors for 
repetitive calculations rather than loop structures [192, 230-231], and use parallel 
computing [232], at the Roslin site, the computational time was reduced to around a 
quarter of the original time. A further issue was computational capacity which 
became a limiting factor in terms of how much data could be generated. For 
example, empirically calculating significant thresholds of SNP via permutation of the 
phenotypes and genotypes would create up to 2 GB of data per time point, per trait. 
Adjusting my scripted programs to run more efficiently, reduced the amount data that 
was stored, thus, if a result was stored, yet only used once at the beginning of a 
calculation, deleting it after it was used saved space. 
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5.2 Future perspectives  
There are many ways to continue exploiting the genomic data of the RoBoGen herd 
to further detect loci/markers that are associated with the immune response following 
immunisation. Discussed below are a few possibilities in which the RoBoGen herd 
could continue to be investigated. In addition, there are a few ideas which would 
require further resources, but are still within the remit of the thesis hypothesis. 
 
As the RoBoGen herd no longer exists, collecting further phenotypes is not possible.   
However, as many phenotypes were measured including performance traits such as 
carcass weights and growth rates, it would be possible to address the controversy 
surrounding the relationship between production traits and immune related traits 
[233]. In addition, with the genomic data already collected from the RoBoGen herd, 
investigating the association of markers with both production and immune related 
phenotypes may highlight the potential of breeding for both immunity and 
production. Results from chapter 4 have shown that a marker in TLR4 (rs8193069), 
is associated with both the FMDV peptide and the BRSV vaccine. The same marker 
has also been associated reduced with somatic cell score [206] and increased 
percentage of protein and fat in milk [205]. This suggests that for the SNP, within 
TLR4 at least, it would be possible to breed cattle for both production and health 
traits. 
 
Although no further phenotyping is possible, extensive DNA banks are still available 
for further analysis. Thus further genotyping of the RoBoGen herd to discover novel 
SNP associations with the immune-related phenotypes would be possible. However, 
the herd had few founders and its size is relatively small, compared to modern herds. 
Thus, extensive genotyping would likely lead to highlighting haplotype blocks, and 
not novel SNP associations. This would likely occur if the herd was genotyped with a 
50,000 SNP chip (personal communication, Dr. De Koning). However, as only a 
small amount of the phenotypic variation has been accounted for within chapter 4, 
relative to the peak heritability’s (BRSV, 0.36 [52], and FMDV, 0.44), further 
genotyping the RoBoGen herd should be successful. Extra SNPs would be best 
placed within regions of the genome which have already been associated with an 
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immune response in other herds or species, as shown by Jann et al [138]. In addition, 
also placing SNP into candidate genes which are involved in mediating immune 
responses elicited by FMDV and BRSV infections, such as Interferon  [234], 
double stranded RNA-dependent protein kinase (PKR) [235] and v	6 integrin 
receptor [134] will also increase the potential of discovering novel SNP associations. 
 
Further genotyping would increase the power of future genetic studies, increasing the 
probability of detecting significant SNP associations, and possibly enabling further 
forms of genetic analysis, for example, with extra SNPs, epistatic effects (section 
5.2.1.1) may be detectable within the herd. 
 
5.2.1 A wider search 
 
Using immune-related phenotypes already collected from the RoBoGen herd to 
detect different forms of gene-environment interaction may highlight novel gene 
interactions during an immune response following vaccination. Below, different 
approaches that could be used on the RoBoGen resource are outlined. In addition, 
further genotyping would benefit the following techniques.  
 
5.2.1.1 Epistasis 
Epistasis is the interaction of two genes. It refers to the changes in phenotypic effects 
of one gene caused by that of another gene [69]. As the immune response is highly 
complex, interactions between regions of the genome involved in eliciting an 
immune response is highly likely, with the MHC region in cattle being a good 
candidate, as epistatic effects have been discovered in the human MHC [236]. 
Investigating interactions between SNP could implicate SNP that individually are not 
significant, yet when combined together explain a disproportionately large amount of 
the phenotypic variance. However, as many calculations are made to test for an 
interaction between every loci, detecting epistasis can be extremely computationally 
exhaustive, especially a on genome wide scale [237]. However, with the current level 
on markers genotyped in the RoBoGen herd, computation should not be an issue. 
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Discovering significant interactions may highlight novel pathways and genes 
involved in the immune response following immunisation.  
 
Time was the limiting factor which meant that epistasis was not investigated during 
this thesis. To begin analysis no extra data would be required. Detecting epistasis 
using the RoBoGen herd, which is a relatively small herd, with few founders would 
be improbable due to the lack of markers and the expected existence of large 
haplotype blocks (as previously mentioned). However, detecting epistasis in highly 
polymorphic regions such as the MHC region may be possible.  
 
5.2.1.2 Time modelling  
As the immune phenotypes in this study were measured across time, further 
modelling is possible which may generate new phenotypes for more precise QTL 
detection. Throughout chapters 2 to 4, some time modelling, was completed, such as 
the “Area under the Curve” calculations [122]. These gave one concise measurement 
for each animal which summarised that animals’ response across time. This was 
successful and did discover QTL (see chapters 2-4) that could be valuable to animal 
breeders and vaccinologists as the underlying regions of these QTL have a sustained 
effect throughout an immune response. However the AUC method is relatively crude 
and does not indicate any fluctuations in response an animal may have had. A 
different method of modelling time, which tabulated each week, was employed in 
Chapter 2. This enabled a comparison between traits in terms of their responses 
across time. Thus by including week into the REML model it was possible to test if, 
for example, breed had an effect on the IgG1 levels significantly increasing or 
decreasing at specific weeks. However few significant results were obtained and 
these additional steps were only implemented in Chapter 2. 
 
The two forms of time modelling mentioned above were successful to varying 
degrees, suggesting more precise forms of time modelling may discover further 
significant and novel QTL/SNP associated with the immune response. Methods such 
as random regression and Gompertz curve regression may be applicable to this 
dataset. These forms of regression have been used to map many time dependant traits 
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in livestock (for example, [238-240]), and the same form of sigmoid curve is seen in 
the immune response following immunisation. As a result a sigmoid curve would 
probably ‘fit’ the data well. Thus if the curve was mathematically integrated to 
obtain the area beneath the curve, a better representation of the immune response 
over time would be available. Also both suggested curves would allow extra 
phenotypes to be calculated, such as time of initial immune response, time at the 
maximum immune response and the point at which the immune response is being 
elicited at its fastest rate. Thus SNP associated with the maximum rate of responses, 
for example, may enable breeders to select for faster reacting immune responses. In 
addition, extra phenotypes would have the advantage of further explaining the 
variance in terms of QTL. 
 
5.2.2 Additional Phenotypes  
As previously described in Chapter 1, many phenotypes were measured in the 
RoBoGen herd, including further immune related phenotypes (antibody responses to 
a Bovine parainfluenza-3 virus and bovine herpes virus-1 vaccine and peripheral blood 
mononuclear cell proliferation to Staphylococcus aureus). As scripts have now been 
written, to obtain, analyse and ensure the quality and significance of QTL and SNP, 
from the RoBoGen source (outlined in Chapter 4), the amount of time spent 
analysing the extra phenotypes would be minimal. From this analysis further 
SNP/QTL may be discovered that are significantly associated with a number of 
immune responses, further highlighting regions for breeding and vaccine 
development. 
 
5.2.3 Molecular studies  
The statistics obtained during this thesis show that SNP and QTL are significantly 
associated to the immune responses elicited to a FMDV15 peptide and a BRSV 
vaccine. Breeders may be able to use these SNP, post validation (see validation 
section 5.3). This study does not, however, show how the interactions between genes 
and thus translated proteins change the phenotype to be more desirable to breeders. 
From an academic and industry standpoint, further study of the QTL and significant 
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SNP in this thesis should be continued to discover, unequivocally, what occurs 
during immunisation. Once key pathways and genes are highlighted, they can be 
targeted to develop more efficacious vaccines and adjuvants. 
 
There are many different forms of molecular study that could be used to provide 
biological context to the discoveries within this thesis. Outlined below are a few 
methods that could be used to further investigate the major findings of this Ph.D.  
 
• Transfecting the significant SNP variants of bovine TLR4 and TLR8 and 
comparing the variants’ ability to bind pathogen (using a ligand binding 
assay and reporter assay) against that of the wild type would show if any 
functional change had occurred. This experiment would show that the 
TLR SNP variant has the potential to cause a change in how an immune 
response is elicited. 
 
• If a significant change in the ability to bind is detected, it would be 
important to test whether the variants had effects in the target species.  
Thus APCs (such as dendritic cells and macrophages) from animals 
which possess the SNP variants could be incubated with appropriate 
ligands and functional readouts performed. For example a microarray 
containing the downstream genes of the TLR pathway would be able to 
detect if levels of gene expression were higher or lower, when binding to 
different pathogens, in the APCs containing the SNP variants. This 
experiment would determine whether the SNPs in TLRs are likely to 
influence relevant immune outcomes in the target species. 
 
5.3 Validation and Commercial Applications 
Cattle breeders use genomic data in two main ways. The first, involves discovering a 
marker in LD with a causal polymorphism. Exploitation of such markers is termed 
Marker Assisted Selection (MAS) and is used to breed animals for the best possible 
phenotypes [101] (further detail in section 1.3.4).  
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Before a novel SNP association or QTL can be used in a commercial capacity its 
association must be validated, to confirm the SNP exists in other populations. Thus 
once a SNP/QTL of significance is associated with a beneficial trait in a single 
population, the next step is to validate that SNP by checking that it has the same 
effect within another population, using the same phenotypes.  If such SNPs are 
significantly associated with the desired phenotype in other herds then they could be 
utilised by breeders. However, before the SNP will be used on a commercial basis 
(for example, in a SNP chip) it must also be checked against other selection criteria. 
If for example, the SNP has a positive effect on antibody levels following 
vaccination, but it also has a detrimental effect on the growth rate of the animal, then 
the economic needs of cattle breeders will be taken into consideration [101].  
 
The second form of selection is termed Genomic Selection as it uses all the markers 
available. GS uses markers (usually SNP) to calculate genomic breeding values 
(GEBV) [161], which are the sum of all the SNP effects obtained regressing the 
phenotype of interest on all SNPs, simultaneously [241]. Usually either Bayesian or 
genomic BLUP techniques are required to achieve this, as generally many more 
SNPs are fitted than there are animals. Once GEBVs have been calculated, only 
marker information is need for the next generation, thus cattle can be selected before 
they are sexually mature [161]. This can greatly speed up the selection and 
production of cattle.  
 
The markers which have been significantly associated with immune traits in this 
thesis are ideal candidates to be included in a SNP panel for MAS. Although both 
MAS and GS are currently used in livestock to breed for growth rate, milk yield, 
meat quality and other economically important traits, neither have been developed 
commercially to improve immune related traits. As immune related traits are now 
becoming more important to farms and governments, these forms of selection may be 
an ideal way to increase disease tolerance and resistance.
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5.4 Conclusion  
This investigation has discovered regions of the bovine genome that are significantly 
associated with the immune response before and after immunisation. Initially, broad 
regions of the bovine genome were discovered, which were associated with immune 
responses following immunisation with a FMDV15 peptide (Chapter 2) and a BRSV 
vaccine (Chapter 3). The knowledge gained from these chapters was used to refine 
the QTL by genotyping SNPs within the QTL confidence intervals and by 
genotyping SNPs within candidate genes. This led to significant SNP associations 
with the immune responses elicited to either the BRSV vaccine or the FMDV15 
peptide. In addition, SNP were also discovered to be significantly associated to both 
immunogens, possibly highlighting common genes/pathways used in the defence of 
multiple pathogens. 
 
Although this thesis has discovered multiple SNP/QTL associated to the immune 
response before and after vaccination with the BRSV vaccine and following 
immunisation with the FMDV peptide, further work is warranted to fully understand 
the DNA variants which cause the animal to animal variance detected in an immune 
response. However, the results presented in this thesis have the potential to 
contribute, at least in part, to the design of more efficacious vaccines and towards the 
SNP panels that animal breeders may use to select animals with higher immune 
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Marker distances (cM Kosambi) are shown for the sex-average maps built for the Charolais × 






Supplementary table showing extra detail of each QTL: 
1. Chromosome: the chromosome number of the QTL. Underlined if 2 QTL model. 
2. Trait: each trait is shown as follows: trait type (IgG1; IgG2; SI_FMDV = T cell proliferation to the 
FMDV peptide; SI_CA = T cell proliferation to Concanavalin A), followed by week post 
immunisation.  
3. cM: the position the QTL is on the chromosome, in centiMorgans. 
4. F: the F-statistic for each QTL. Significance level: all are at least 5% chromosome wide, * =p<1% 
chromosome wide, **=p<5% genome wide and ***=p<1% genome wide. 
5. Flanking markers of each QTL peak. 
6. The 95% confidence intervals of each QTL. 
7. “a” and “d” are the additive and dominance effect, respectively, of each QTL, * =p<5%, **=p<1% 
and ***=p<0.01%. 








1. Immunisation with FMDV peptide (Chapter 1); BRSV vaccine  
2. Trait: each trait is shown as follows: total IgG or IgG isotype response, followed by the week 
relative to vaccination.  
3. Mean: mean average of each time point. BRSV measured in Optical Density whilst FMDV is 
measured in l/ml. 
4. Range: Minimum and maximum response for each time point (units as 3.). 













IgG1_week_0 1.22 0.00 - 9.31 1.36
IgG1_week_1 1.33 0.00 - 8.86 1.402
IgG1_week_2 69.74 0.00 - 322.86 66.16
IgG1_week_4 166.95 0.00 - 672.03 144.39
IgG1_week_8 291.65 0.00 - 1254.56 269.20
IgG1_week_10 176.12 0.00 - 670.78 141.63
IgG1_AUC 1658.47 0.08 - 6421.13 1381.31
IgG2_week_0 0.01 0.00 - 0.35 0.05
IgG2_week_1 0.01 0.00 - 0.49 0.0505
IgG2_week_2 5.64 0.00 - 51.07 8.80
IgG2_week_4 13.09 0.00 - 87.85 17.32
IgG2_week_8 24.35 0.00 - 810.60 64.70
IgG2_week_10 23.50 0.00 - 968.30 71.77
IgG2_AUC 144.41 0.01 - 3622.06 302.30
IgG1_week_0. 13.82 0.03 - 94.03 20.40
IgG1_week_2. 20.03 1.24 - 93.03 15.44
IgG1_week_5. 38.96 4.03 - 110.95 19.13
IgG1_week_7. 31.20 1.32 - 98.77 20.31
IgG1_AUC 191.13 10.37 - 592.77 89.66
IgG2_week_0. 2.16 0.02 - 20.14 2.57
IgG2_week_2. 4.54 0.05 - 30.44 4.09
IgG2_week_5. 12.55 0.15 - 86.09 10.75
IgG2_week_7. 13.07 0.06 - 81.03 13.23
IgG2_AUC 57.36 0.50 - 327.39 43.15

























































































































































































































































































































































































































































































































































Flow chart explaining the SNP selection criteria 
The process begins in the centre of the diagram, at the Ensembl SNP data base. From the centre, 3 
searches occur (blue circles). From the search results further refining of potential SNPs occurs in the 
orange diamonds. Thus, SNP are accepted into the SNP panel (green rectangles), rejected (red oval) or 
have to be further refined (yellow squares) before being accepted into the SNP panel.  
Is the SNP within a 
gene of the B Cell or 
T Cell pathway? 
Include SNP in 
SNP panel 

























Find SNP within 
the FMDV and 
BRSV QTL CI 
Find SNP 
located in  
TLRs 




























2 rs43282727 1,145,842 Success 
2 rs42368097 3,372,686 Fail 
2 rs43099540 4,145,241 Fail 
2 rs43288056 4,526,658 Success 
2 rs43287110 5,009,410 Fail 
2 rs43284763 5,385,388 Fail 
2 rs43287124 6,173,061 Fail 
2 rs43283828 7,758,030 Fail 
2 rs42271298 8,547,313 Success 
2 rs43289279 9,577,829 Success 
2 rs43287355 10,408,218 Fail 
2 rs42534616 14,113,356 Fail 
2 rs42300304 14,868,782 Success 
2 rs42239339 15,119,485 Fail 
2 rs42239334 15,132,187 Fail 
2 rs43291704 18,283,013 Success 
2 rs43293712 21,407,841 Fail 
2 rs43297955 34,981,686 Success 
2 rs42710296 37,975,105 Fail 
2 rs43306573 43,161,115 Fail 
2 rs42557939 44,190,522 Fail 
2 rs43325273 125,502,733 Fail 
3 rs42447625 64,189,555 Fail 
3 rs43346321 65,229,353 Success 
3 rs42820431 82,342,593 Success 
3 rs42223380 82,660,195 Success 
4 rs42661063 4,872,040 Fail 
4 rs41811275 7,533,744 Success 
4 rs41848377 9,040,359 Success 
4 rs43372164 10,064,006 Success 
4 rs42555252 11,583,413 Success 
4 rs43158855 12,698,631 Fail 
4 rs43376075 15,979,413 Fail 
4 rs43380234 19,482,457 Success 
4 rs43372439 21,486,169 Success 
4 rs43379261 26,101,583 Fail 
4 rs42628233 27,701,164 Success 
4 rs43062765 31,522,127 Success 
4 rs42601449 31,855,593 Fail 
4 rs43380660 32,752,933 Success 
4 rs43706506 32,760,739 Fail 
4 rs43396806 45,828,047 Success 
4 rs43397964 45,839,476 Success 
4 rs43410172 77,534,161 Success 
4 rs17870216 78,900,409 Fail 
5 rs29023087 64,857,106 Fail 
5 rs43434899 67,635,108 Fail 
6 rs42688655 230,007 Success 
6 rs42578633 531,485 Success 
6 rs29022925 2,212,858 Success 
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6 rs42579196 2,255,433 Success 
6 rs42765470 10,812,211 Success 
6 rs42976134 12,632,047 Success 
6 rs43450138 13,225,484 Success 
6 rs43451327 13,429,185 Fail 
6 rs43455095 23,422,841 Success 
6 rs43457496 23,575,406 Fail 
6 rs43457274 26,738,103 Fail 
6 SNP20_ADH7_b1_224C_T_GQ 27,088,618 Success 
6 rs42573616 28,467,373 Fail 
6 rs29026551 36,787,039 Success 
6 SNP36_BTA-75976 36,848,688 Success 
6 SNP37_BTA-75814 37,231,101 Fail 
6 SNP01_ABCG2_int_29444 37,384,988 Fail 
6 SNP57_ABCG2_256_Olsen2007 37,418,728 Fail 
6 SNP06_OPN_11740_AC_Sch 37,512,064 Fail 
6 SNP07_OPN_ex7_156531_CohZ 37,512,073 Success 
6 SNP05_OPN_10043_TC_Sch 37,513,761 Success 
6 SNP04_OPN_5896_GA_Sch 37,517,911 Fail 
6 SNP03_OPN_5075_CT_Sch 37,518,733 Fail 
6 SNP02_OPN_3492_AG_Schn 37,520,315 Fail 
6 SNP26_OPN_1406_TC_Schn 37,522,401 Success 
6 SNP33_IBSP_exon7_802post 37,681,944 Success 
6 SNP38_BTA-75780 37,689,720 Fail 
6 rs43455199 37,703,987 Fail 
6 SNP08_MEPE_int2_151126166 37,704,773 Fail 
6 SNP62_NCAPG_exon9Ile442Met 38,164,403 Fail 
6 SNP42_BTA-23366 38,876,957 Fail 
6 SNP43_BTA-23368 39,030,695 Success 
6 SNP44_BTA-75882 39,748,005 Success 
6 SNP45_BTA-114459 40,049,321 Success 
6 SNP39_BTA-75889 41,077,118 Success 
6 rs42852239 41,352,734 Fail 
6 SNP61_KCNIP4_SNP09_exon3 41,431,834 Success 
6 SNP60_KCNIP4_SNP08_exon3 41,431,873 Success 
6 SNP59_KCNIP4_SNP02_intron1 41,439,745 Success 
6 SNP58_KCNIP4_SNP01_exon1 41,522,884 Success 
6 SNP40_BTA-75916 41,674,742 Success 
6 SNP41_BTA-75900 41,867,013 Success 
6 SNP46_BTA-75936 42,512,116 Success 
6 SNP47_BTA-08168 43,365,830 Fail 
6 rs43702384 43,533,567 Success 
6 SNP48_BTA-97410 44,180,262 Success 
6 SNP49_BTA-76032 44,670,127 Success 
6 SNP16_PPARGC1A_3UTR_5314 44,733,159 Success 
6 SNP14_PPARGC1A_3UTR_3359 44,735,115 Success 
6 SNP13_PPARGC1A_in9_1892_19 44,753,377 Success 
6 SNP12_PPARGC1A_ex9_1847 44,753,441 Success 
6 SNP11_PPARGC1A_ex8_1209 44,754,643 Success 
6 SNP17_PPARGC1A_BTA76037 44,768,150 Success 
6 SNP18_PPARGC1A_BTA_76036 44,768,513 Success 
6 SNP10_PPARGC1A_intI_49-9 44,833,216 Success 
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6 SNP09_PPARGC1A_prom_-920 44,839,533 Success 
6 rs43457945 44,843,375 Success 
6 SNP50_BTA-76040 44,853,423 Fail 
6 SNP51_BTA-119876 45,758,667 Fail 
6 SNP52_BTA-76106 45,960,114 Success 
6 SNP53_BTA-76112 46,812,852 Fail 
6 SNP55_BTA-76147 48,249,827 Success 
6 SNP56_BTA-02857 48,676,372 Success 
6 rs55617297 60,339,445 Fail 
6 rs55617311 60,340,667 Fail 
6 rs55617324 60,340,745 Success 
6 rs55617197 60,340,811 Fail 
6 rs55617325 60,340,994 Fail 
6 rs55617137 60,341,354 Fail 
6 rs55617437 60,341,651 Fail 
6 rs55617267 60,356,135 Success 
6 rs55617317 60,356,375 Fail 
6 rs55617385 60,357,533 Fail 
6 rs55617254 60,357,900 Fail 
6 ss104796354 60,373,429 Success 
6 ss104796353 60,373,564 Fail 
6 ss104796352 60,373,576 Fail 
6 ss104796350 60,373,615 Success 
6 ss104796347 60,373,714 Fail 
6 ss104796344 60,374,010 Success 
6 ss104796341 60,374,554 Fail 
6 rs43702941 60,374,554 Fail 
6 ss104796340 60,374,934 Fail 
6 ss104796339 60,375,010 Success 
6 ss104796338 60,375,065 Success 
6 rs43465290 63,382,448 Success 
6 rs43144881 63,856,283 Fail 
7 rs42371911 372,053 Success 
7 rs43494261 817,185 Success 
7 rs43502716 17,900,867 Success 
7 rs43502714 17,900,946 Success 
7 rs43502712 17,901,772 Success 
7 rs43502711 17,901,960 Success 
7 rs42468294 42,159,162 Fail 
7 rs42754503 42,406,483 Success 
7 rs29024743 81,122,729 Success 
7 rs42123134 82,574,137 Fail 
8 rs43551637 40,328,094 Fail 
8 rs43551679 42,212,253 Fail 
8 rs43556471 62,463,474 Fail 
8 rs42254196 67,719,297 Fail 
8 rs43289334 89,845,143 Fail 
8 rs43572154 90,426,160 Success 
8 rs8193041 112,427,272 Fail 
8 rs8193048 112,431,958 Fail 
8 rs8193049 112,435,012 Success 
8 rs8193050 112,435,274 Fail 
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8 rs8193053 112,435,599 Fail 
8 rs8193055 112,435,702 Fail 
8 rs8193066 112,436,507 Fail 
8 rs8193069 112,436,580 Success 
9 rs43596425 35,663,409 Success 
9 rs42932713 36,045,372 Success 
9 rs42472240 63,602,153 Fail 
9 rs43608009 66,562,158 Fail 
11 rs42312327 5,732,048 Success 
11 rs43549594 6,120,325 Success 
11 rs29011157 15,996,717 Success 
11 rs43671260 16,899,234 Fail 
12 rs43689833 3,685,550 Fail 
12 rs43038502 9,310,538 Success 
12 rs42420659 13,010,703 Fail 
13 rs42633118 32,620,521 Success 
13 rs41688025 38,310,581 Success 
14 rs41716631 571,324 Fail 
14 rs41716552 1,124,497 Fail 
14 rs41718866 10,064,223 Success 
14 rs41726305 19,210,519 Success 
14 rs41722114 23,535,844 Success 
15 rs41746924 14,222,942 Fail 
15 rs42205048 19,855,733 Success 
15 rs42309927 65,451,191 Success 
16 rs55617166 23,622,625 Fail 
16 rs55617270 23,623,111 Fail 
16 rs55617251 23,623,174 Fail 
16 rs55617330 23,623,824 Fail 
16 rs55617329 23,624,016 Fail 
16 rs55617168 23,624,607 Fail 
16 rs43715512 46,625,896 Fail 
16 rs43156472 53,793,735 Fail 
16 rs41823113 64,715,652 Fail 
16 rs41817317 67,077,026 Success 
17 ss95214878 4,282,692 Fail 
17 ss95214875 4,282,845 Success 
17 ss95214874 4,282,879 Fail 
17 ss95214873 4,283,027 Fail 
17 ss95214869 4,283,153 Fail 
17 ss95214868 4,283,336 Success 
17 ss95214867 4,283,384 Fail 
17 ss95214865 4,283,590 Success 
17 ss95214864 4,283,627 Fail 
17 ss95214863 4,283,831 Success 
17 ss95214862 4,283,852 Fail 
17 ss95214861 4,283,863 Fail 
17 ss95214860 4,283,916 Fail 
17 ss95214859 4,283,926 Fail 
17 ss104796314 4,283,970 Fail 
17 ss95214858 4,284,160 Fail 
17 ss95214857 4,284,209 Success 
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17 ss95214856 4,284,373 Fail 
17 ss95214855 4,284,386 Success 
17 ss95214854 4,284,639 Success 
17 ss104796308 4,284,651 Fail 
17 ss95214853 4,284,652 Fail 
17 rs41840540 18,434,183 Fail 
17 rs41846165 53,639,297 Fail 
17 rs41843359 59,991,168 Success 
18 rs43073975 7,627,591 Fail 
18 rs41861310 9,450,758 Fail 
18 rs41861475 12,608,656 Fail 
18 rs41871255 17,513,388 Success 
18 rs41882274 42,990,977 Fail 
18 rs41881585 43,008,150 Success 
18 rs41883772 45,466,996 Success 
18 rs41889047 45,985,711 Fail 
18 rs41889048 45,992,932 Fail 
18 rs17871896 55,089,314 Success 
18 rs41897525 55,089,413 Success 
18 rs41893756 55,201,773 Success 
18 rs41893757 55,201,874 Success 
18 rs41890230 55,297,550 Fail 
18 rs41890229 55,299,321 Fail 
18 rs41893490 55,856,642 Success 
18 rs41894171 55,872,024 Success 
18 rs41894194 55,914,102 Fail 
18 rs41893053 56,536,828 Fail 
18 rs41895599 56,762,980 Success 
18 rs41895600 56,763,022 Success 
18 rs41895602 56,763,691 Fail 
18 rs41895604 56,763,769 Fail 
18 rs41890820 57,351,399 Success 
19 rs42399876 8,909,768 Fail 
19 rs41903052 10,047,803 Fail 
19 rs41255557 10,047,900 Success 
19 rs41899079 14,643,966 Fail 
19 rs41909225 17,477,209 Fail 
19 rs41903246 22,710,810 Success 
19 rs41909114 25,258,154 Success 
19 rs41910166 28,079,648 Success 
19 rs43329536 28,376,932 Success 
19 rs42467700 32,953,578 Fail 
19 rs41915330 36,738,471 Success 
19 rs41914650 38,967,695 Success 
20 rs42288095 1,670,625 Fail 
20 rs43349824 4,719,720 Fail 
20 rs42661323 5,043,835 Fail 
20 rs42263233 5,749,563 Fail 
20 rs42638947 6,387,054 Success 
20 rs41977113 6,901,362 Success 
20 rs42755290 7,976,253 Success 
20 rs41935052 8,415,423 Success 
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20 rs41933917 8,434,911 Fail 
20 rs41932920 8,463,797 Success 
20 rs41931981 9,874,394 Fail 
20 rs41931155 9,973,787 Fail 
20 rs17871699 10,128,876 Success 
20 rs42931384 12,933,656 Success 
20 rs42819473 13,172,735 Fail 
20 rs42241895 13,401,254 Success 
20 rs41939013 14,562,036 Success 
20 rs41939858 14,765,661 Fail 
20 rs41940658 14,931,073 Success 
20 rs41257426 15,536,536 Fail 
20 rs41935901 19,180,080 Fail 
20 rs41938903 21,702,493 Fail 
20 rs42745029 21,946,837 Fail 
20 rs41939754 24,584,116 Fail 
20 rs41255556 25,605,974 Success 
21 rs41971213 20,838,959 Fail 
21 rs42164128 20,858,512 Success 
21 rs41976145 34,904,887 Fail 
21 rs29016829 35,150,184 Success 
21 rs42502308 41,267,701 Success 
22 rs41994846 6,078,800 Fail 
22 rs41997469 8,095,553 Fail 
22 rs41997472 8,116,283 Fail 
22 rs17871073 11,569,447 Fail 
22 rs41998546 11,627,557 Success 
22 rs41995921 11,690,241 Success 
22 rs41995914 11,696,113 Success 
22 rs42000457 15,043,101 Fail 
22 rs42655015 16,029,150 Success 
22 rs55617136 49,673,859 Fail 
22 rs55617258 49,674,747 Success 
23 rs42022743 344,771 Fail 
23 rs42022227 1,497,055 Fail 
23 rs42021087 1,939,695 Fail 
23 rs43707857 2,797,676 Success 
23 rs42021749 3,422,699 Fail 
23 rs42021755 3,550,188 Fail 
23 rs42021824 3,735,697 Fail 
23 rs42023442 7,255,826 Fail 
23 rs43008782 7,342,237 Fail 
23 rs42023448 7,368,999 Fail 
23 rs43049152 8,758,710 Fail 
23 rs42020089 9,344,087 Fail 
23 rs42612806 9,703,201 Fail 
23 rs42612805 9,710,886 Fail 
23 rs42025129 10,147,019 Fail 
23 rs43706486 10,330,943 Success 
23 rs42022558 12,548,875 Fail 
23 rs41255662 12,989,057 Fail 
23 rs42451594 13,659,714 Fail 
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23 rs42451592 13,675,312 Fail 
23 rs41257079 15,615,455 Fail 
23 rs42021406 15,702,335 Fail 
23 rs42021387 16,002,474 Fail 
23 rs42027576 17,166,685 Fail 
23 rs42027575 17,172,021 Fail 
23 rs42026557 18,385,689 Fail 
23 rs42025725 18,396,766 Fail 
23 rs43054367 19,024,064 Fail 
23 rs41255407 19,886,383 Fail 
23 rs42026571 20,104,460 Fail 
23 rs42027749 20,521,898 Fail 
23 rs42541025 21,192,214 Fail 
23 rs43703954 22,575,043 Success 
23 rs42028278 23,813,406 Fail 
23 rs42028267 23,880,248 Success 
23 rs42027020 25,004,112 Fail 
23 rs42028329 25,399,173 Fail 
23 rs29015593 25,583,126 Success 
23 rs42311145 26,280,492 Fail 
23 rs42311136 26,280,557 Fail 
23 rs42023981 27,021,896 Fail 
23 rs42023980 27,124,500 Fail 
23 rs42032378 27,434,885 Fail 
23 rs42032371 27,444,055 Fail 
23 rs17870353 27,444,757 Fail 
23 rs42032370 27,451,908 Fail 
23 rs41642092 27,541,569 Fail 
23 rs41587590 27,731,019 Success 
23 rs17871955 28,074,549 Fail 
23 rs42579977 28,684,909 Fail 
23 rs42580008 28,687,100 Fail 
23 rs42024011 28,895,621 Fail 
23 rs41257015 28,965,211 Success 
23 rs42029155 29,328,304 Fail 
23 rs42030040 29,763,471 Fail 
23 rs43030763 29,940,497 Success 
23 rs29017177 30,273,732 Success 
23 rs29015191 30,502,689 Success 
23 rs43350855 30,853,358 Fail 
23 rs43708439 31,601,937 Success 
23 rs42030070 32,010,522 Fail 
23 rs42851411 32,187,753 Fail 
23 rs41257282 33,221,160 Success 
23 rs41699902 33,833,542 Fail 
23 rs41666288 34,809,053 Fail 
23 rs41666290 34,949,047 Fail 
23 rs43160956 35,060,107 Fail 
23 rs42027035 35,951,533 Fail 
23 rs42372315 37,855,828 Fail 
23 rs43705168 38,240,446 Success 
23 rs43281402 39,589,320 Fail 
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23 rs42109669 39,771,140 Fail 
23 rs42027059 39,879,827 Fail 
23 rs29021595 40,284,987 Success 
23 rs42027176 40,604,396 Fail 
23 rs42027632 41,547,061 Fail 
23 rs42027230 41,567,237 Fail 
23 rs41257112 42,049,908 Success 
23 rs42032036 43,227,492 Success 
23 rs41743748 43,368,217 Success 
23 rs41256961 43,476,116 Success 
23 rs42029541 44,923,043 Success 
23 rs42029586 44,959,165 Success 
23 rs42028513 45,489,977 Success 
23 rs42034874 45,779,639 Fail 
23 rs42342086 46,094,090 Success 
23 rs42342962 46,182,144 Success 
23 rs42345438 46,401,034 Success 
24 rs41805428 20,552,592 Fail 
24 rs42041883 24,415,723 Fail 
24 rs42819260 26,689,961 Fail 
24 rs42048416 27,077,243 Fail 
24 rs41257081 27,130,822 Success 
24 rs42049356 29,741,673 Success 
24 rs42045874 30,519,872 Fail 
24 rs42042620 30,796,671 Success 
24 rs42441026 31,550,540 Fail 
24 rs42053876 38,815,332 Success 
24 rs42054102 43,464,945 Fail 
25 rs42057017 20,719,152 Fail 
25 rs42057705 22,152,954 Fail 
25 rs43695847 22,178,379 Fail 
25 rs42060100 23,945,464 Success 
25 rs42058469 24,157,508 Fail 
25 rs42061802 26,534,002 Fail 
25 rs42074207 27,954,457 Fail 
25 rs42068459 28,404,390 Fail 
25 rs42690103 30,915,753 Success 
25 rs42068744 34,696,283 Success 
25 rs42068083 34,703,184 Fail 
25 rs42070647 34,829,906 Success 
26 rs42102914 36,858,669 Success 
26 rs42631147 38,247,006 Fail 
27 rs42544474 348,147 Success 
27 rs42851916 17,492,663 Fail 
27 rs55617204 17,497,632 Success 
27 rs55617272 17,497,892 Fail 
27 rs42852439 17,498,607 Success 
27 rs42118884 21,956,554 Fail 
27 rs43708798 23,118,868 Success 
27 rs43731750 35,329,115 Fail 
27 rs43729240 36,428,655 Fail 
29 rs42978304 288,597 Fail 
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29 rs42155456 574,482 Success 
29 rs42189764 43,688,138 Fail 
X rs55617390 82,015,995 Success 
X rs55617351 82,016,881 Success 
X rs55617145 82,017,087 Success 
X rs55617174 82,017,180 Success 
X rs55617354 82,017,265 Success 
X rs55617433 82,120,395 Fail 
X rs55617309 82,121,227 Fail 
X rs55617183 82,122,372 Success 
X rs55617320 82,122,592 Fail 
 
All SNPs selected for genotyping. 
1. Chromosome the SNP is located on. 
2. The common name of the SNP. 
3. The position (Base Pairs) of the SNP along its chromosome. 
4. Status of the SNP: Success = genotyped successfully on the F2 and backcross of the 

















2 rs43282727 1,145,842 1 1 
2 rs43288056 4,526,658 1 1 
2 rs42271298 8,547,313 1 1 
2 rs43289279 9,577,829 1 1 
2 rs42300304 14,868,782 1 1 
2 rs43291704 18,283,013 1 1 
2 rs43297955 34,981,686 1 2 
3 rs43346321 65,229,353 1 3 
3 rs42820431 82,342,593 1 1 
3 rs42223380 82,660,195 1 1 
4 rs41811275 7,533,744 1 1 
4 rs41848377 9,040,359 1 1 
4 rs43372164 10,064,006 1 1 
4 rs42555252 11,583,413 1 1 
4 rs43380234 19,482,457 1 1 
4 rs43372439 21,486,169 1 1 
4 rs42628233 27,701,164 1 1 
4 rs43062765 31,522,127 1 1 
4 rs43380660 32,752,933 1 1 
4 rs43396806 45,828,047 1 1 
4 rs43397964 45,839,476 1 1 
4 rs43410172 77,534,161 1 1 
6 rs42688655 230,007 1 1 
6 rs42578633 531,485 1 2 
6 rs29022925 2,212,858 1 1 
6 rs42579196 2,255,433 1 1 
6 rs42765470 10,812,211 1 1 
6 rs42976134 12,632,047 1 1 
6 rs43450138 13,225,484 1 2 
6 rs43455095 23,422,841 1 1 
6 SNP20_ADH7_b1_224C_T_GQ 27,088,618 1 1 
6 rs29026551 36,787,039 1 1 
6 SNP36_BTA-75976 36,848,688 1 1 
6 SNP07_OPN_ex7_156531_CohZ 37,512,073 1 1 
6 SNP05_OPN_10043_TC_Sch 37,513,761 1 1 
6 SNP26_OPN_1406_TC_Schn 37,522,401 1 1 
6 SNP33_IBSP_exon7_802post 37,681,944 1 2 
6 SNP43_BTA-23368 39,030,695 1 1 
6 SNP44_BTA-75882 39,748,005 1 1 
6 SNP45_BTA-114459 40,049,321 1 3 
6 SNP39_BTA-75889 41,077,118 1 1 
6 SNP61_KCNIP4_SNP09_exon3 41,431,834 1 1 
6 SNP60_KCNIP4_SNP08_exon3 41,431,873 1 1 
6 SNP59_KCNIP4_SNP02_intron1 41,439,745 1 1 
6 SNP58_KCNIP4_SNP01_exon1 41,522,884 1 1 
6 SNP40_BTA-75916 41,674,742 1 1 
6 SNP41_BTA-75900 41,867,013 1 1 
6 SNP46_BTA-75936 42,512,116 1 2 
6 rs43702384 43,533,567 1 1 
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6 SNP48_BTA-97410 44,180,262 1 2 
6 SNP49_BTA-76032 44,670,127 1 1 
6 SNP16_PPARGC1A_3UTR_5314 44,733,159 1 1 
6 SNP14_PPARGC1A_3UTR_3359 44,735,115 1 3 
6 SNP13_PPARGC1A_in9_1892_19 44,753,377 1 2 
6 SNP12_PPARGC1A_ex9_1847 44,753,441 1 1 
6 SNP11_PPARGC1A_ex8_1209 44,754,643 1 1 
6 SNP17_PPARGC1A_BTA76037 44,768,150 1 1 
6 SNP18_PPARGC1A_BTA_76036 44,768,513 1 2 
6 SNP10_PPARGC1A_intI_49-9 44,833,216 1 1 
6 SNP09_PPARGC1A_prom_-920 44,839,533 1 1 
6 rs43457945 44,843,375 1 1 
6 SNP52_BTA-76106 45,960,114 1 1 
6 SNP55_BTA-76147 48,249,827 1 2 
6 SNP56_BTA-02857 48,676,372 1 2 
6 rs55617324 60,340,745 2 2 
6 rs55617267 60,356,135 2 2 
6 ss104796354 60,373,429 2 2 
6 ss104796350 60,373,615 2 1 
6 ss104796344 60,374,010 2 1 
6 ss104796339 60,375,010 2 1 
6 ss104796338 60,375,065 2 1 
6 rs43465290 63,382,448 1 1 
7 rs42371911 372,053 1 1 
7 rs43494261 817,185 1 1 
7 rs43502716 17,900,867 1 3 
7 rs43502714 17,900,946 1 2 
7 rs43502712 17,901,772 1 1 
7 rs43502711 17,901,960 1 1 
7 rs42754503 42,406,483 1 1 
7 rs29024743 81,122,729 1 2 
8 rs43572154 90,426,160 1 2 
8 rs8193049 112,435,012 2 1 
8 rs8193069 112,436,580 2 1 
9 rs43596425 35,663,409 1 1 
9 rs42932713 36,045,372 1 1 
11 rs42312327 5,732,048 1 1 
11 rs43549594 6,120,325 1 1 
11 rs29011157 15,996,717 1 1 
12 rs43038502 9,310,538 1 1 
13 rs42633118 32,620,521 1 2 
13 rs41688025 38,310,581 1 1 
14 rs41718866 10,064,223 1 1 
14 rs41726305 19,210,519 1 3 
14 rs41722114 23,535,844 1 1 
15 rs42205048 19,855,733 1 1 
15 rs42309927 65,451,191 1 1 
16 rs41817317 67,077,026 1 2 
17 ss95214875 4,282,845 2 1 
17 ss95214868 4,283,336 2 1 
17 ss95214865 4,283,590 2 1 
17 ss95214863 4,283,831 2 2 
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17 ss95214857 4,284,209 2 3 
17 ss95214855 4,284,386 2 1 
17 ss95214854 4,284,639 2 1 
17 rs41843359 59,991,168 1 3 
18 rs41871255 17,513,388 1 2 
18 rs41881585 43,008,150 1 1 
18 rs41883772 45,466,996 1 3 
18 rs17871896 55,089,314 1 1 
18 rs41897525 55,089,413 1 1 
18 rs41893756 55,201,773 1 1 
18 rs41893757 55,201,874 1 2 
18 rs41893490 55,856,642 1 1 
18 rs41894171 55,872,024 1 2 
18 rs41895599 56,762,980 1 1 
18 rs41895600 56,763,022 1 1 
18 rs41890820 57,351,399 1 2 
19 rs41255557 10,047,900 1 1 
19 rs41903246 22,710,810 1 1 
19 rs41909114 25,258,154 1 1 
19 rs41910166 28,079,648 1 1 
19 rs43329536 28,376,932 1 1 
19 rs41915330 36,738,471 1 2 
19 rs41914650 38,967,695 1 1 
20 rs42638947 6,387,054 1 1 
20 rs41977113 6,901,362 1 1 
20 rs42755290 7,976,253 1 1 
20 rs41935052 8,415,423 1 1 
20 rs41932920 8,463,797 1 1 
20 rs17871699 10,128,876 1 1 
20 rs42931384 12,933,656 1 1 
20 rs42241895 13,401,254 1 1 
20 rs41939013 14,562,036 1 1 
20 rs41940658 14,931,073 1 1 
20 rs41255556 25,605,974 1 1 
21 rs42164128 20,858,512 1 1 
21 rs29016829 35,150,184 1 1 
21 rs42502308 41,267,701 1 1 
22 rs41998546 11,627,557 1 1 
22 rs41995921 11,690,241 1 1 
22 rs41995914 11,696,113 1 1 
22 rs42655015 16,029,150 1 1 
22 rs55617258 49,674,747 2 1 
23 rs43707857 2,797,676 1 2 
23 rs43706486 10,330,943 1 1 
23 rs43703954 22,575,043 1 3 
23 rs42028267 23,880,248 1 3 
23 rs29015593 25,583,126 1 3 
23 rs41587590 27,731,019 1 3 
23 rs41257015 28,965,211 1 1 
23 rs43030763 29,940,497 1 1 
23 rs29017177 30,273,732 1 1 
23 rs29015191 30,502,689 1 1 
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23 rs43708439 31,601,937 1 1 
23 rs41257282 33,221,160 1 1 
23 rs43705168 38,240,446 1 1 
23 rs29021595 40,284,987 1 1 
23 rs41257112 42,049,908 1 1 
23 rs42032036 43,227,492 1 1 
23 rs41743748 43,368,217 1 1 
23 rs41256961 43,476,116 1 1 
23 rs42029541 44,923,043 1 1 
23 rs42029586 44,959,165 1 1 
23 rs42028513 45,489,977 1 1 
23 rs42342086 46,094,090 1 2 
23 rs42342962 46,182,144 1 1 
23 rs42345438 46,401,034 1 1 
24 rs41257081 27,130,822 1 1 
24 rs42049356 29,741,673 1 1 
24 rs42042620 30,796,671 1 1 
24 rs42053876 38,815,332 1 1 
25 rs42060100 23,945,464 1 1 
25 rs42690103 30,915,753 1 2 
25 rs42068744 34,696,283 1 1 
25 rs42070647 34,829,906 1 1 
26 rs42102914 36,858,669 1 1 
27 rs42544474 348,147 1 2 
27 rs55617204 17,497,632 2 1 
27 rs42852439 17,498,607 2 1 
27 rs43708798 23,118,868 1 1 
29 rs42155456 574,482 1 1 
X rs55617390 82,015,995 2 1 
X rs55617351 82,016,881 2 1 
X rs55617145 82,017,087 2 1 
X rs55617174 82,017,180 2 2 
X rs55617354 82,017,265 2 1 
X rs55617183 82,122,372 2 1 
SNP analysed in chapter 4 
Listed are all the SNP that passed all quality control measures (see Materials and Methods). The 
highlighted SNPs were found significant in the current study. 
1. Chromosome: The chromosome the SNP is located on. 
2. SNP name: The name of each SNP. Those without the standard ‘RS’ or ‘SS’numbers have 
been used from Gutierrez-Gil et al [228]. 
3. Position: The position of SNPs. Measured in Base Pairs (bp). 
4. Placement Type: Methodology of placing the SNP:  
(1) SNP positioned within the confidence intervals of the previous Leach et al. studies [155, 
177], (Chapters 2 and 3). 
(2) SNP located in either TLR genes or SNP positioned in the RoBoGen herd by Gutierrez-
Gil et al [228]. 
5. Status: Which phenotypes the SNPs were significantly associated with:  
(1) Both FMDV and BRSV phenotypes. 
(2) BRSV phenotypes only. 







 Reference ID2 Allele
3
 Gene_ID4 
6 rs43144881 T/A ATP8A1 
6 ss73689504 A/G TLR1 
6 ss73689408 A/G TLR1 
6 ss73689412 A/G TLR1 
6 ss73689415 A/G TLR1 
6 ss73689416 A/G TLR1 
6 ss73689466 T/C TLR10 
6 ss73689467 G/A TLR10 
6 ss73689468 C/A TLR10 
6 ss73689469 C/A TLR10 
6 ss73689470 C/G TLR10 
6 ss73689474 T/C TLR10 
6 ss73689475 A/T TLR10 
6 ss73689477 A/T TLR10 
6 ss73689478 A/G TLR10 
6 ss73689479 A/G TLR10 
6 ss73689485 A/C TLR10 
6 ss73689486 G/A TLR10 
6 ss104796338 T/G TLR6 
6 ss104796339 A/G TLR6 
6 ss104796340 A/G TLR6 
6 ss104796344 A/G TLR6 
6 ss104796347 T/A TLR6 
6 ss104796350 C/T TLR6 
6 ss104796352 C/G TLR6 
6 ss104796353 G/A TLR6 
6 ss104796354 G/A TLR6 
6 ss104796356 A/G TLR6 
6 rs43702941 G/A TLR6 
7 rs43502709 T/G TICAM1 
7 rs43502716 G/A TICAM1 
7 rs43502712 G/T TICAM1 
7 rs43502707 G/A TICAM1 
7 rs43502717 G/C TICAM1 
7 rs43502711 A/G TICAM1 
7 rs43502718 C/T TICAM1 
7 rs43502714 T/C TICAM1 
8 rs8193041 (C/T) TLR4 
8 rs8193048 (G/A) TLR4 
8 rs8193049 (A/C) TLR4 
8 rs8193050 (C/G) TLR4 
8 rs8193053 (C/A) TLR4 
8 rs8193055 A/G) TLR4 
8 rs8193066 (G/A) TLR4 
8 rs8193069 (C/T) TLR4 
16 ss73689445 A/G TLR5 
16 ss73689447 A/G TLR5 
16 ss73689448 T/C TLR5 
16 ss73689451 G/A TLR5 
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16 ss73689452 C/G TLR5 
16 ss73689455 G/A TLR5 
17 ss104796308 T/C TLR2 
17 ss95214853 G/T TLR2 
17 ss95214854 G/A TLR2 
17 ss95214855 G/A TLR2 
17 ss95214856 T/G TLR2 
17 ss95214857 G/A TLR2 
17 ss95214858 A/T TLR2 
17 ss104796314 T/G TLR2 
17 ss95214859 A/C TLR2 
17 ss95214860 G/A TLR2 
17 ss95214861 T/A TLR2 
17 ss95214862 G/A TLR2 
17 ss95214863 A/G TLR2 
17 ss95214864 C/T TLR2 
17 ss95214865 A/G TLR2 
17 ss95214867 G/A TLR2 
17 ss95214868 T/G TLR2 
17 ss95214869 G/A TLR2 
17 ss95214873 C/T TLR2 
17 ss95214874 G/T TLR2 
17 ss95214875 C/G TLR2 
17 ss95214878 C/A TLR2 
17 ss104796336 G/A TLR2 
18 rs41895599 C/T AC010325.7-202 
18 rs41895600 G/A AC010325.7-202 
18 rs41895602 C/G AC010325.7-202 
18 rs41895604 G/A AC010325.7-202 
18 rs41894171 C/T ALDH16A1 
18 rs41889048 C/T APLP1 
18 rs41889051 T/C APLP1 
18 rs41883772 T/C CD22 
18 rs41894194 C/G FCGRT 
18 rs41893755 G/A FUT1 
18 rs41893756 A/G FUT1 
18 rs41893757 C/T FUT1 
18 rs41882274 C/G GPATCH1 
18 rs41881585 T/C GPATCH1 
18 rs41889047 G/T KIRREL2 
18 rs41893053 T/A MYBPC2 
18 rs41890820 C/T NKG7 
18 rs41891067 T/C NUCB1 
18 rs41891068 G/T NUCB1 
18 rs41893490 T/G PIH1D1 
18 rs41890230 T/G PPP1R15A 
18 rs41890229 T/A PPP1R15A 
18 rs17871896 C/T SPHK2 
18 rs41897525 G/T SPHK2 
22 rs42655015 G/A ABHD5 
22 rs41998546 G/A DLEC1 
22 rs41995921 C/T DLEC1 
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22 rs41995914 C/G DLEC1 
22 rs41995915 G/A DLEC1 
22 rs41997469 T/A PDCD6IP 
22 rs41997472 G/T PDCD6IP 
22 rs41994846 C/G STT3B 
22 ss69357334 C/T TLR9 
22 ss69357336 G/A TLR9 
22 rs17871073 C/T VILL 
22 rs42000457 C/A VIPR1 
27 rs42851916 T/A TLR3 
27 rs55617204 A/G TLR3 
27 rs55617272 G/A TLR3 
27 rs42852439 G/T TLR3 
X ss69357304 C/T TLR7 
X ss69357305 G/A TLR7 
X ss69357306 A/C TLR7 
X ss69357307 G/A TLR7 
X ss69357308 G/A TLR7 
X ss69357309 G/A TLR7 
X ss69357318 T/C TLR8 
X ss69357319 A/T TLR8 
X ss69357320 A/C TLR8 
X ss69357321 C/A TLR8 
X ss69357322 G/A TLR8 
X ss69357323 G/A TLR8 
X ss69357324 C/A TLR8 
    
SNPs used in TLRs and signalling pathways 
1. Chromosome name: Chromosome the SNP marker is positioned on. 
2. Reference ID: The common name for the SNP 
3. Allele: The DNA base substitution cased by the SNP 





Locus Name Comment 
ARK_rs41933917 SNP Failed 
ARK_rs42026571 SNP Failed 
ARK_rs42027576 SNP Failed 
ARK_rs42223380 SNP Failed 
ARK_rs42311145 SNP Failed 
ARK_rs42580008 SNP Failed 
ARK_rs43156472 SNP Failed 
ARK_ss64726273_rs42819473 SNP Failed 
ARK_ss95214853 SNP Failed 
ARK_ss95214854 SNP Failed 
ARK_ss95214856 SNP Failed 
ARK_ss95214859 SNP Failed 
ARK_ss95214861 SNP Failed 
ARK_ss95214862 SNP Failed 
ARK_rs29017177 SNP Uninformative 
ARK_rs29024743 SNP Uninformative 
ARK_rs41257079 SNP Uninformative 
ARK_rs41666288 SNP Uninformative 
ARK_rs41666290 SNP Uninformative 
ARK_rs41699902 SNP Uninformative 
ARK_rs41716552 SNP Uninformative 
ARK_rs41716631 SNP Uninformative 
ARK_rs41722114 SNP Uninformative 
ARK_rs41746924 SNP Uninformative 
ARK_rs41823113 SNP Uninformative 
ARK_rs41840540 SNP Uninformative 
ARK_rs41846165 SNP Uninformative 
ARK_rs41861310 SNP Uninformative 
ARK_rs41903246 SNP Uninformative 
ARK_rs41909225 SNP Uninformative 
ARK_rs41939754 SNP Uninformative 
ARK_rs41976145 SNP Uninformative 
ARK_rs42020089 SNP Uninformative 
ARK_rs42021087 SNP Uninformative 
ARK_rs42021387 SNP Uninformative 
ARK_rs42021749 SNP Uninformative 
ARK_rs42021755 SNP Uninformative 
ARK_rs42022227 SNP Uninformative 
ARK_rs42022743 SNP Uninformative 
ARK_rs42023442 SNP Uninformative 
ARK_rs42023448 SNP Uninformative 
ARK_rs42023981 SNP Uninformative 
ARK_rs42025129 SNP Uninformative 
ARK_rs42025725 SNP Uninformative 
ARK_rs42026557 SNP Uninformative 
ARK_rs42027035 SNP Uninformative 
ARK_rs42027059 SNP Uninformative 
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ARK_rs42027176 SNP Uninformative 
ARK_rs42027230 SNP Uninformative 
ARK_rs42027575 SNP Uninformative 
ARK_rs42027632 SNP Uninformative 
ARK_rs42027749 SNP Uninformative 
ARK_rs42028278 SNP Uninformative 
ARK_rs42028329 SNP Uninformative 
ARK_rs42029155 SNP Uninformative 
ARK_rs42030040 SNP Uninformative 
ARK_rs42030070 SNP Uninformative 
ARK_rs42032036 SNP Uninformative 
ARK_rs42032370 SNP Uninformative 
ARK_rs42032371 SNP Uninformative 
ARK_rs42032378 SNP Uninformative 
ARK_rs42034874 SNP Uninformative 
ARK_rs42054102 SNP Uninformative 
ARK_rs42109669 SNP Uninformative 
ARK_rs42123134 SNP Uninformative 
ARK_rs42189764 SNP Uninformative 
ARK_rs42205048 SNP Uninformative 
ARK_rs42239334 SNP Uninformative 
ARK_rs42239339 SNP Uninformative 
ARK_rs42254196 SNP Uninformative 
ARK_rs42311136 SNP Uninformative 
ARK_rs42312323 SNP Uninformative 
ARK_rs42342086 SNP Uninformative 
ARK_rs42345438 SNP Uninformative 
ARK_rs42372315 SNP Uninformative 
ARK_rs42447625 SNP Uninformative 
ARK_rs42451592 SNP Uninformative 
ARK_rs42451594 SNP Uninformative 
ARK_rs42467700 SNP Uninformative 
ARK_rs42468294 SNP Uninformative 
ARK_rs42541025 SNP Uninformative 
ARK_rs42557939 SNP Uninformative 
ARK_rs42612805 SNP Uninformative 
ARK_rs42612806 SNP Uninformative 
ARK_rs42631147 SNP Uninformative 
ARK_rs42745029 SNP Uninformative 
ARK_rs42851411 SNP Uninformative 
ARK_rs42851916 SNP Uninformative 
ARK_rs43008782 SNP Uninformative 
ARK_rs43054367 SNP Uninformative 
ARK_rs43160956 SNP Uninformative 
ARK_rs43281402 SNP Uninformative 
ARK_rs43325273 SNP Uninformative 
ARK_rs43346321 SNP Uninformative 
ARK_rs43350855 SNP Uninformative 
ARK_rs43434899 SNP Uninformative 
ARK_rs43551637 SNP Uninformative 
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ARK_rs43556471 SNP Uninformative 
ARK_rs43671260 SNP Uninformative 
ARK_rs43689833 SNP Uninformative 
ARK_rs43706486 SNP Uninformative 
ARK_rs43706506 SNP Uninformative 
ARK_rs43708798 SNP Uninformative 
ARK_rs43715512 SNP Uninformative 
ARK_rs43731750 SNP Uninformative 
ARK_rs8193041 SNP Uninformative 
ARK_rs8193050 SNP Uninformative 
ARK_rs8193066 SNP Uninformative 
ARK_rs8193069 SNP Uninformative 
ARK_ss104796314 SNP Uninformative 
ARK_ss104796336 SNP Uninformative 
ARK_ss104796347 SNP Uninformative 
ARK_ss28452040_rs17871699 SNP Uninformative 
ARK_ss28452237_rs17871896 SNP Uninformative 
ARK_ss38336212_rs29022925 SNP Uninformative 
ARK_ss38336374_rs29023087 SNP Uninformative 
ARK_ss46526981_rs41257426 SNP Uninformative 
ARK_ss46527012_rs41255557 SNP Uninformative 
ARK_ss62257493_rs41805428 SNP Uninformative 
ARK_ss62359007_rs41848377 SNP Uninformative 
ARK_ss62406952_rs41861475 SNP Uninformative 
ARK_ss62453938_rs41882274 SNP Uninformative 
ARK_ss62466877_rs41889047 SNP Uninformative 
ARK_ss62466880_rs41889048 SNP Uninformative 
ARK_ss62484289_rs41890230 SNP Uninformative 
ARK_ss62485711_rs41894194 SNP Uninformative 
ARK_ss62487088_rs41893053 SNP Uninformative 
ARK_ss62490142_rs41893757 SNP Uninformative 
ARK_ss62515930_rs41903052 SNP Uninformative 
ARK_ss62518402_rs41899079 SNP Uninformative 
ARK_ss62554507_rs41914650 SNP Uninformative 
ARK_ss62619747_rs41931155 SNP Uninformative 
ARK_ss62620131_rs41931981 SNP Uninformative 
ARK_ss62625066_rs41939013 SNP Uninformative 
ARK_ss62625201_rs41939858 SNP Uninformative 
ARK_ss62626533_rs41935901 SNP Uninformative 
ARK_ss62630137_rs41938903 SNP Uninformative 
ARK_ss62778762_rs41994846 SNP Uninformative 
ARK_ss62782137_rs41997469 SNP Uninformative 
ARK_ss62782146_rs41997472 SNP Uninformative 
ARK_ss62862759_rs42021824 SNP Uninformative 
ARK_ss62865288_rs42022558 SNP Uninformative 
ARK_ss62867832_rs42021406 SNP Uninformative 
ARK_ss62877153_rs42023980 SNP Uninformative 
ARK_ss62877252_rs42024011 SNP Uninformative 
ARK_ss62928531_rs42041883 SNP Uninformative 
ARK_ss62930439_rs42048416 SNP Uninformative 
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ARK_ss62935986_rs42045874 SNP Uninformative 
ARK_ss62980002_rs42057017 SNP Uninformative 
ARK_ss62980272_rs42057705 SNP Uninformative 
ARK_ss62987289_rs42061802 SNP Uninformative 
ARK_ss62988990_rs42058469 SNP Uninformative 
ARK_ss62989689_rs42060100 SNP Uninformative 
ARK_ss62997555_rs42074207 SNP Uninformative 
ARK_ss63007716_rs42068083 SNP Uninformative 
ARK_ss63528770_rs42263233 SNP Uninformative 
ARK_ss63611805_rs42288095 SNP Uninformative 
ARK_ss63648364_rs42300304 SNP Uninformative 
ARK_ss63819411_rs42368097 SNP Uninformative 
ARK_ss63888155_rs41811275 SNP Uninformative 
ARK_ss63953452_rs42399876 SNP Uninformative 
ARK_ss64036952_rs42441026 SNP Uninformative 
ARK_ss64217528_rs42534616 SNP Uninformative 
ARK_ss64314776_rs42573616 SNP Uninformative 
ARK_ss64361987_rs42601449 SNP Uninformative 
ARK_ss64487642_rs42661063 SNP Uninformative 
ARK_ss64491234_rs42661323 SNP Uninformative 
ARK_ss64578760_rs42710296 SNP Uninformative 
ARK_ss64654695_rs42755290 SNP Uninformative 
ARK_ss64722671_rs42820431 SNP Uninformative 
ARK_ss64723613_rs42819260 SNP Uninformative 
ARK_ss64751496_rs42852239 SNP Uninformative 
ARK_ss64839202_rs42931384 SNP Uninformative 
ARK_ss64960713_rs43049152 SNP Uninformative 
ARK_ss65009674_rs43099540 SNP Uninformative 
ARK_ss65056354_rs43144881 SNP Uninformative 
ARK_ss65062768_rs43158855 SNP Uninformative 
ARK_ss65201863_rs43284763 SNP Uninformative 
ARK_ss65202748_rs43283828 SNP Uninformative 
ARK_ss65203230_rs43287110 SNP Uninformative 
ARK_ss65203244_rs43287124 SNP Uninformative 
ARK_ss65203674_rs43287355 SNP Uninformative 
ARK_ss65206126_rs43291704 SNP Uninformative 
ARK_ss65210970_rs43293712 SNP Uninformative 
ARK_ss65221173_rs43306573 SNP Uninformative 
ARK_ss65293750_rs43379261 SNP Uninformative 
ARK_ss65368172_rs43451327 SNP Uninformative 
ARK_ss65370245_rs43457496 SNP Uninformative 
ARK_ss65371577_rs43457274 SNP Uninformative 
ARK_ss65371900_rs43455199 SNP Uninformative 
ARK_ss65377696_rs43457945 SNP Uninformative 
ARK_ss65466018_rs43551679 SNP Uninformative 
ARK_ss65612945_rs43695847 SNP Uninformative 
ARK_ss69357304_rs55617433 SNP Uninformative 
ARK_ss69357307_rs55617183 SNP Uninformative 
ARK_ss69357308_rs55617320 SNP Uninformative 
ARK_ss69357334_rs55617136 SNP Uninformative 
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ARK_ss73689451_rs55617251 SNP Uninformative 
ARK_ss73689452_rs55617270 SNP Uninformative 
ARK_ss95214860 SNP Uninformative 
ARK_ss95214864 SNP Uninformative 
ARK_ss95214867 SNP Uninformative 
ARK_ss95214874 SNP Uninformative 
ARK_ss95214878 SNP Uninformative 
ARK_rs17870216 SNP Fully Informative 
ARK_rs17870353 SNP Fully Informative 
ARK_rs17871880 SNP Fully Informative 
ARK_rs41255556 SNP Fully Informative 
ARK_rs41255662 SNP Fully Informative 
ARK_rs41257015 SNP Fully Informative 
ARK_rs41257112 SNP Fully Informative 
ARK_rs41587590 SNP Fully Informative 
ARK_rs41642092 SNP Fully Informative 
ARK_rs41718866 SNP Fully Informative 
ARK_rs41817317 SNP Fully Informative 
ARK_rs41843359 SNP Fully Informative 
ARK_rs41871255 SNP Fully Informative 
ARK_rs41915330 SNP Fully Informative 
ARK_rs41932920 SNP Fully Informative 
ARK_rs42027020 SNP Fully Informative 
ARK_rs42029586 SNP Fully Informative 
ARK_rs42053876 SNP Fully Informative 
ARK_rs42118884 SNP Fully Informative 
ARK_rs42155456 SNP Fully Informative 
ARK_rs42309927 SNP Fully Informative 
ARK_rs42312327 SNP Fully Informative 
ARK_rs42342962 SNP Fully Informative 
ARK_rs42502308 SNP Fully Informative 
ARK_rs42578633 SNP Fully Informative 
ARK_rs42688655 SNP Fully Informative 
ARK_rs42932713 SNP Fully Informative 
ARK_rs42978304 SNP Fully Informative 
ARK_rs43396806 SNP Fully Informative 
ARK_rs43397964 SNP Fully Informative 
ARK_rs43596425 SNP Fully Informative 
ARK_rs43703954 SNP Fully Informative 
ARK_rs8193049 SNP Fully Informative 
ARK_rs8193053 SNP Fully Informative 
ARK_rs8193055 SNP Fully Informative 
ARK_ss104796339 SNP Fully Informative 
ARK_ss104796341 SNP Fully Informative 
ARK_ss104796344 SNP Fully Informative 
ARK_ss104796352 SNP Fully Informative 
ARK_ss104796353 SNP Fully Informative 
ARK_ss38325445_rs29011157 SNP Fully Informative 
ARK_ss38326889_rs29015191 SNP Fully Informative 
ARK_ss38330080_rs29021595 SNP Fully Informative 
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ARK_ss38337238_rs29026551 SNP Fully Informative 
ARK_ss46526625_rs41257081 SNP Fully Informative 
ARK_ss62004026_rs41726305 SNP Fully Informative 
ARK_ss62488129_rs41895599 SNP Fully Informative 
ARK_ss62488138_rs41895602 SNP Fully Informative 
ARK_ss62491552_rs41897525 SNP Fully Informative 
ARK_ss62492737_rs41890820 SNP Fully Informative 
ARK_ss62530738_rs41910166 SNP Fully Informative 
ARK_ss62611859_rs41935052 SNP Fully Informative 
ARK_ss62625501_rs41940658 SNP Fully Informative 
ARK_ss62789190_rs41995914 SNP Fully Informative 
ARK_ss62789886_rs41998546 SNP Fully Informative 
ARK_ss62934126_rs42049356 SNP Fully Informative 
ARK_ss63007899_rs42068744 SNP Fully Informative 
ARK_ss63472982_rs42241895 SNP Fully Informative 
ARK_ss64413920_rs42628233 SNP Fully Informative 
ARK_ss64440170_rs42638947 SNP Fully Informative 
ARK_ss64882909_rs42976134 SNP Fully Informative 
ARK_ss64972149_rs43062765 SNP Fully Informative 
ARK_ss65184322_rs43766721 SNP Fully Informative 
ARK_ss65202157_rs43288056 SNP Fully Informative 
ARK_ss65239654_rs43329536 SNP Fully Informative 
ARK_ss65289507_rs43372164 SNP Fully Informative 
ARK_ss65290123_rs43376075 SNP Fully Informative 
ARK_ss65367880_rs43450138 SNP Fully Informative 
ARK_ss65382884_rs43465290 SNP Fully Informative 
ARK_ss65415824_rs43494261 SNP Fully Informative 
ARK_ss65420026_rs43502711 SNP Fully Informative 
ARK_ss65420027_rs43502712 SNP Fully Informative 
ARK_ss65420029_rs43502714 SNP Fully Informative 
ARK_ss65420031_rs43502716 SNP Fully Informative 
ARK_ss65624825_rs43702384 SNP Fully Informative 
ARK_ss69357306_rs55617309 SNP Fully Informative 
ARK_ss69357318_rs55617354 SNP Fully Informative 
ARK_ss69357319_rs55617174 SNP Fully Informative 
ARK_ss69357322_rs55617351 SNP Fully Informative 
ARK_ss69357324_rs55617390 SNP Fully Informative 
ARK_ss69357336_rs55617258 SNP Fully Informative 
ARK_ss73689408_rs55617385 SNP Fully Informative 
ARK_ss73689445_rs55617168 SNP Fully Informative 
ARK_ss73689467_rs55617437 SNP Fully Informative 
ARK_ss73689478_rs55617324 SNP Fully Informative 
ARK_ss73689479_rs55617311 SNP Fully Informative 
ARK_ss73689485_rs55617297 SNP Fully Informative 
ARK_ss95214857 SNP Fully Informative 
ARK_ss95214858 SNP Fully Informative 
ARK_ss95214863 SNP Fully Informative 
ARK_ss95214865 SNP Fully Informative 
ARK_ss95214869 SNP Fully Informative 
ARK_ss95214873 SNP Fully Informative 
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ARK_ss95214875 SNP Fully Informative 
ARK_rs17871955 Sample Clusters not as expected 
ARK_rs29015593 Sample Clusters not as expected 
ARK_rs29016829 Sample Clusters not as expected 
ARK_rs41255407 Sample Clusters not as expected 
ARK_rs41256961 Sample Clusters not as expected 
ARK_rs41971213 Sample Clusters not as expected 
ARK_rs42028267 Sample Clusters not as expected 
ARK_rs42028513 Sample Clusters not as expected 
ARK_rs42068459 Sample Clusters not as expected 
ARK_rs42102914 Sample Clusters not as expected 
ARK_rs42164128 Sample Clusters not as expected 
ARK_rs42371911 Sample Clusters not as expected 
ARK_rs42472240 Sample Clusters not as expected 
ARK_rs42544474 Sample Clusters not as expected 
ARK_rs42579977 Sample Clusters not as expected 
ARK_rs42690103 Sample Clusters not as expected 
ARK_rs42754503 Sample Clusters not as expected 
ARK_rs43380660 Sample Clusters not as expected 
ARK_rs43410172 Sample Clusters not as expected 
ARK_rs43455095 Sample Clusters not as expected 
ARK_rs43549594 Sample Clusters not as expected 
ARK_rs43572154 Sample Clusters not as expected 
ARK_rs43705168 Sample Clusters not as expected 
ARK_rs43707857 Sample Clusters not as expected 
ARK_rs43729240 Sample Clusters not as expected 
ARK_rs55617204 Sample Clusters not as expected 
ARK_rs55617272 Sample Clusters not as expected 
ARK_rs8193048 Sample Clusters not as expected 
ARK_ss104796338 Sample Clusters not as expected 
ARK_ss28451414_rs17871073 Sample Clusters not as expected 
ARK_ss62453668_rs41881585 Sample Clusters not as expected 
ARK_ss62463331_rs41883772 Sample Clusters not as expected 
ARK_ss62485393_rs41893490 Sample Clusters not as expected 
ARK_ss62485639_rs41894171 Sample Clusters not as expected 
ARK_ss62488132_rs41895600 Sample Clusters not as expected 
ARK_ss62488144_rs41895604 Sample Clusters not as expected 
ARK_ss62490139_rs41893756 Sample Clusters not as expected 
ARK_ss62537242_rs41909114 Sample Clusters not as expected 
ARK_ss62785710_rs42000457 Sample Clusters not as expected 
ARK_ss62789211_rs41995921 Sample Clusters not as expected 
ARK_ss62934615_rs42042620 Sample Clusters not as expected 
ARK_ss63011817_rs42070647 Sample Clusters not as expected 
ARK_ss63549708_rs42271298 Sample Clusters not as expected 
ARK_ss64261740_rs42555252 Sample Clusters not as expected 
ARK_ss64306304_rs42579196 Sample Clusters not as expected 
ARK_ss64430642_rs42633118 Sample Clusters not as expected 
ARK_ss64471540_rs42655015 Sample Clusters not as expected 
ARK_ss64672574_rs42765470 Sample Clusters not as expected 
ARK_ss64942091_rs43038502 Sample Clusters not as expected 
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ARK_ss65073178_rs43166805 Sample Clusters not as expected 
ARK_ss65201725_rs43282727 Sample Clusters not as expected 
ARK_ss65203854_rs43289334 Sample Clusters not as expected 
ARK_ss65212328_rs43297955 Sample Clusters not as expected 
ARK_ss65268174_rs43349824 Sample Clusters not as expected 
ARK_ss65291092_rs43380234 Sample Clusters not as expected 
ARK_ss65291390_rs43372439 Sample Clusters not as expected 
ARK_ss65521671_rs43608009 Sample Clusters not as expected 
ARK_ss73689448_rs55617330 Sample Clusters not as expected 
ARK_ss73689455_rs55617166 Sample Clusters not as expected 
ARK_ss73689477_rs55617197 Sample Clusters not as expected 
ARK_ss73689504_rs55617254 Sample Clusters not as expected 
ARK_ss95214855 Sample Clusters not as expected 
ARK_ss95214868 Sample Clusters not as expected 
ARK_rs41688025 Multiple Het clusters 
ARK_rs42852439 Multiple Het clusters 
ARK_rs43030763 Multiple Het clusters 
ARK_rs43073975 Multiple Het clusters 
ARK_ss104796340 Multiple Het clusters 
ARK_ss104796354 Multiple Het clusters 
ARK_ss62484286_rs41890229 Multiple Het clusters 
ARK_ss62721129_rs41977113 Multiple Het clusters 
ARK_ss63991193_rs42420659 Multiple Het clusters 
ARK_ss65203499_rs43289279 Multiple Het clusters 
ARK_ss65658944_rs41257282 Multiple Het clusters 
ARK_ss73689415_rs55617317 Multiple Het clusters 
ARK_ss73689416_rs55617267 Multiple Het clusters 
ARK_rs42029541 Was unable to call discrete clusters 
ARK_ss104796308 Was unable to call discrete clusters 
ARK_ss104796350 Was unable to call discrete clusters 
ARK_ss62067036_rs41743748 Was unable to call discrete clusters 
ARK_ss65624885_rs43702941 Was unable to call discrete clusters 
ARK_ss66538065_rs43708439 Was unable to call discrete clusters 
ARK_ss69357321_rs55617145 Was unable to call discrete clusters 
ARK_ss73689447_rs55617329 Was unable to call discrete clusters 
ARK_ss73689469_rs55617137 Was unable to call discrete clusters 
ARK_ss73689475_rs55617325 Was unable to call discrete clusters 
Genotyped SNP information 
This table contains the genotype information of each SNP. There are 6 classifications  
1. SNP failed 
2. SNP uninformative 
3. SNP fully informative 
4. Sample clusters not as expected 
5. Multiple Het clusters 
6. Unable to call discrete clusters 
 
